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LIST OF ABBREVATIONS
AaMΦ  Alternatively activated macrophage
ACR  American college of rheumatology
ADAM  A disintegrin and metalloprotease
APC  Antigen presenting cell
ApoB  Apolipoprotein B
BSA  Bovine serum albumin
CaMΦ  Classically activated macrophage
CCL  CC chemokine ligand
CCR  CC chemokine receptor
CD  Cluster of differentiation
CK   Chemokine
Ct   Cycle threshold 
CVD  Cardiovascular disease
CXCL  CXC chemokine ligand
CXCR  CXC chemokine receptor
DAS  Disease activity score
DC   Dendritic cell
dcSSc  Diffuse cutaneous systemic sclerosis
DM  Dermatomyositis
DMARD Disease modifying anti-rheumatic drug
dNTP  Deoxyribonucleotide triphosphate
ELISA   Enzyme linked immunosorbent assay
EULAR  European league against rheumatism
FACS  Fluorescence activated cell sorting
FcR  Fc receptor
FCS  Fetal calf serum
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GMCSF Granulocyte monocyte colony stimulating factor
iDC   Immature dendritic cell
IFN  Interferon
IL  Interleukin
7
8lcSSc  Limited cutaneous systemic sclerosis
LDL  Low density lipoprotein
MΦ   Macrophage
mDC   Mature dendritic cell
MHC  Major histocompatibility complex
MMP  Matrix metalloproteinases 
MoDC  Monocyte derived dendritic cell
NHS  Normal human serum
NSAID  Non-steroidal anti-inflammatory drug
OA  Osteoarthritis
oxLDL  Oxidized low density lipoprotein
p  Probability
PBS  Phosphate buffered saline
PBL  Peripheral blood lymphocytes 
PCR  Polymerase chain reaction
PI  Propidium iodide
PM  Polymyositis
PBGD  Porphobilinogeen deaminase 
RA  Rheumatoid arthritis
RIA  Radio immuno assay
RF  Rheumatoid factor
RT  Reverse transcriptase
SD  Standard deviation
SEM  Standard error of the mean
SF  Synovial fluid
SFMC  Synovial fluid mononuclear cells 
SJC  Swollen joint count
SLE   Systemic lupus erythematosus
Sqrt  Square Root
SSc  Systemic sclerosis
ST   Synovial tissue
TCR  T cell receptor
TJC  Tender joint count
TLR  Toll-like receptor
TNF  Tumor necrosis factor
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chapter 1
GENERAL INTRODUCTION

Auto-immunity
Inﬂ ammation is a key feature of a large variety of infectious and non-infectious disea-
ses. Normally, the immune system acts as our defence mechanism, by means of di-
recting an inﬂ ammatory response against foreign invaders, such as micro-organisms. 
Th erefore, the ability to distinguish self from non-self and to interpret whether a 
given situation inﬂ icts danger or not are key features of our immune system. When 
this mechanism fails, an inﬂ ammatory response to self antigens can occur, which is 
termed an auto-immune response. Th ese auto-immune responses can be local and 
mild, but can also result in severe systemic auto-immune diseases. Auto-immune 
diseases comprise a heterogeneous group of mostly chronic diseases, which are all 
characterized by an ongoing inﬂ ammatory response that is directed towards the bo-
dy’s own constituents. Th e aetiology of auto-immune diseases is largely unknown. 
Formation of so-called auto-antigens, for instance through mutations, might play a 
role in igniting auto-immune responses or even drive the whole chronic auto-immu-
ne process. However, the exact antigen(s) to which the immune response is directed 
is/are still unknown in most auto-immune diseases. Another hypothesis is that auto-
immune responses occur as a result of molecular structures of micro-organisms that 
resemble self molecules (“molecular mimicry”). Failure to down regulate immune 
responses during and aft er inﬂ ammation or inﬂ ammatory cascades running wild are 
alternative explanations that may, at least in part, contribute to auto-immunity. Alt-
hough each auto-immune disease is directed against speciﬁ c tissues and organs, signs 
and symptoms vary enormously among patients suﬀ ering from the same auto-im-
mune disease and overlap between diﬀ erent auto-immune diseases is common, ma-
king a diagnosis oft en diﬃ  cult. As the pathogenesis of most auto-immune diseases 
is largely unknown, their diagnosis is mostly based on a consensus of classiﬁ cation 
criteria, including a combination of clinical signs and symptoms and laboratory or 
radiological tests. 
Rheumathoid Arthritis
Rheumatoid arthritis (RA) is, along with Systemic Lupus Erythematosus (SLE) and 
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Multiple Sclerosis (MS), one of best known examples of an auto-immune disease. RA 
has a prevalence of approximately 1% worldwide and is therefore considered to be 
one of the most common autoimmune conditions. Th e hallmark of RA is chronic in
ﬂ ammation of the joints. Th e normal, healthy joint is formed by two bone structures, 
which are covered by a layer of cartilage to prevent direct bone to bone contact (ﬁ -
gure 1a). Th e space between the bony structures, which is called the synovial cavity, is 
surrounded by the joint capsule. Within the synovial cavity, a layer of synovial tissue 
(ST) forms the inner lining of the joint cavity. Th is ST is responsible for the produc-
12
Table 1 1987 ACR diagnostic criteria for rheumatoid arthritis
For classiﬁ cation purposes, a patient shall be said to have rheumatoid arthritis if he/she has satisﬁ ed at least 4 or 
these 7 criteria. Criteria 1 through 4 must have been present for at least 6 weeks. Patients with 2 clinical diagno-
ses are not excluded. Designation as classic, deﬁ nite, or probable rheumatoid arthritis is not to be made. 
tion of synovial ﬂ uid (SF), which is critical for a smooth movement of the joint. In 
addition, the ST contains blood vessels and a variety of leukocytes. Th ese leukocytes 
are critically involved in the eradication of apoptotic cells and cell debris, which ori-
ginate from joint damages, e.g. due to traumatic events. Th e upper layer of this tissue, 
oft en referred to as the synovial lining, is a one cell layer thick linage consisting of 
macrophage like cells and ﬁ broblast like cells. Th ese two cell types are therefore oft en 
referred to as macrophage-like synoviocytes (MLS) and ﬁ broblast-like synoviocytes 
(FLS). In inﬂ amed joints of RA patients the synovial lining is hypertrophic with a 
massive inﬂ ux of diﬀ erent leukocytes towards the sub-lining (ﬁ gure 1b). Next to MLS 
and FLS, the ST consists of B and T lymphocytes and dendritic cells (DC) 1-4. Inte-
restingly, the inﬂ amed ST in RA uniquely contains organized structures consisting of 
groups of B and T cells that mimic those found in activated secondary lymphoid or-
gans, 5, 6. Although their exact role is unknown, they might be involved in the chronic 
synovial inﬂ ammation which is characteristic for RA. In RA, this inﬂ ammation can 
eventually lead to cartilage damage and bone erosions (ﬁ gure 1b), potentially resul-
ting in severe disabilities for the patient. Next to pain relief, preventing bone erosions 
therefore is a major therapeutic goal in RA. 
Th e clinical diagnosis RA is set by a number of disease criteria which were deve-
loped by the American College of Rheumatology (ACR) 7, 8 (table 1). Th e current 
treatment of RA rests on three pillars. First, non-steroidal anti-inﬂ ammatory drugs 
(NSAIDs) are used for pain relief. Second, disease modifying anti-rheumatoid drugs 
(DMARDs) are used to suppress disease activity and to prevent joint damage. Fi-
nally, biologicals comprise a novel group of disease modifying anti-rheumatic drugs 
which are now widely used in daily clinical practice. Th ese agents speciﬁ cally target 
a certain inﬂ ammatory cell-surface molecule or soluble mediators such as cytokines. 
Th e best known example is targeting tumour necrosis factor alpha (TNF-α) with 
monoclonal antibodies (inﬂ iximab, adalimumab) 9-11 or soluble receptor fusion pro-
teins (etanercept) 12. Th ese agents, in combination with DMARDs, are now highly 
successful in the treatment of RA, resulting in a therapeutic response in about 70% 
of the patients 13. Th e eﬀ ect of treatment can be monitored with disease activity sco-
res, such as the DAS-28 score 14. Th is disease activity score evaluates 28 joints that 
are commonly involved in RA. Th e DAS-28 includes a visual analogue scale (VAS), 
the erythrocyte sedimentation rate (ESR) and the swollen and tender joint counts 
(SJC, TJC). As the DAS-28 is carefully validated in clinical practice, it allows tight 
monitoring of disease activity, which is a necessity when investigating potential novel 
therapeutic agents. Despite decades of intensive research, the exact pathogenesis of 
RA is still unknown. Although it is considered an auto-immune disease, no deﬁ ni-
tive human auto-antibody has been identiﬁ ed. Although rheumatoid factor (RF) was 
already discovered over 50 years ago 15-17 and is still used for diagnostic purposes, its 
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role in RA pathogenesis remains unknown, if at all present. More recently, antibodies 
against citrullinated peptides (anti-CCP’s) were identiﬁ ed as highly speciﬁ c for RA 
and therefore rapidly introduced as a novel diagnostic tool 18-20. As for RF, the role of 
these antibodies in the pathogenesis however is still unclear. Currently, various play-
ers in the pathogenesis of RA are being investigated for their therapeutic potential. 
Especially soluble mediators such as cytokines are being widely explored as potential 
therapeutic agents, mostly in terms of neutralizing their biologic activity. Some of 
these cytokines are already used in the clinic or are currently under investigation in 
clinical trials. Examples include IL-1β, IL-6, IL-15 and IL-17 21-33. Another approach 
that is being explored is blocking cell-surface molecules. Neutralizing B cell activity 
with anti-CD20 antibodies (Rituximab) 34-36 and blocking the T cell co-stimulation 
receptor CD28 with CTLA-4Ig (Abatacept) 37-40 are two examples of strategies that 
have already reached the clinic. However, the eﬃ  cacy of all these strategies varies 
tremendously, both among patients and during the disease course in individual pa-
tients. Th erefore, there is still a great need for novel therapeutic strategies against RA. 
Moreover, both traditional DMARDs and biologicals can have (severe) side eﬀ ects, 
which underscore the need for eﬀ ective, but also safer therapeutic intervention stra-
tegies. More insight in the pathogenesis of RA is therefore critical for the identiﬁ ca-
tion of such novel therapeutic targets. 
The APC-T cell interaction auto-immunity
As discussed above, failure of our immune system to distinguish self from non-self 
is the hallmark of auto-immunity. As diﬀ erent auto-immune diseases target diﬀ erent 
tissues and/or organs, the pathogenesis of a given auto-immune disease is characte-
rized by its own key players. Nonetheless, leukocytes that migrate towards the site 
of inﬂ ammation are generally accepted to play a role in all inﬂ ammatory conditi-
ons, including auto-immune diseases. Two critical types of leucocytes involved in 
normal inﬂ ammation and auto-immunity are T lymphocytes and antigen presenting 
cells (APC), such as DC and macrophages. As DC are perfectly equipped for antigen 
presentation, they are oft en regarded as “professional APC” 41-44. In their immature 
state, DC are specialized in taking up antigens. For this purpose, immature DC are 
active in macropinocytosis and express several diﬀ erent scavenger receptors on their 
surface, such as Fc gamma receptors (FcγR) and C-type-lectin receptors. In addition, 
DC express multiple receptors to interpret the local environment, including pattern 
recognition receptors, such as Toll-like receptors (TLR) and Nod-like receptors, to 
detect so called “danger signals”. Upon receiving a stimulus (“danger signal”), im-
mature DC lose their antigen uptake capacities and develop into mature DC. Classic 
examples of these maturation inducers are the TLR4 ligand lipopolysacharide (LPS) 
45, CD40 ligation 46 or stimulation with inﬂ ammatory cytokine cocktails 47. In turn, 
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these mature DC are ideally equipped for antigen presentation to T cells. DC are 
normally present in small amounts in the peripheral blood, which hampers large 
experiments with these cells. However, DC can be generated in vitro from blood 
monocytes by means of culturing these monocytes in the presence of IL-4 and GM-
CSF 48. Th e resulting monocyte derived DC (MoDC) functionally resemble blood 
DC in terms of antigen uptake and presentation capacities. A major task of APC is to 
present antigens taken up in the periphery in the context of major histocompatibility 
complexes (MHC) to T cells in the secondary lymphoid organs. For successful acti-
vation of naïve T cells at least three key signals are required (ﬁ gure 2). Recognition 
of the MHC-peptide complex on the APC surface by the T cell receptor (TCR) on 
the T cell is referred to as signal 1. Signal 2 consists of co-stimulatory signals that are 
provided by the APC, like the co-stimulatory molecules B7.1 and B7.2 (CD80 and 
CD86) that interact with CD28 on the T cell surface. Finally, a third cytokine signal 
is needed to direct T cells into a speciﬁ c diﬀ erentiation pathway. Next to DC, ma-
crophages and B cells also have antigen presenting capacities, although they are not 
as potent as DC. However, especially macrophages do have critical antigen uptake 
capacities and are therefore essential in the eradication of damaged leukocytes or 
other tissue components. Given the much higher numbers of these cells compared 
to DC, their cytokine secretion is responsible for a large proportion of local cytokine 
levels, which may subsequently inﬂ uence the nature of immune responses. Th e exact 
pattern of cytokine secretion by macrophages is largely depending on how they are 
stimulated. For instance, stimulation with the Th 1 cytokine IFN-γ (“classical activa-
tion”) results in a distinct type of macrophage, compared to macrophages which are 
stimulate with the Th 2 cytokines IL-4 or IL-13 (“alternative activation”) 49. T cells are 
the APC’s receiving partner in antigen presentation and comprise a heterogeneous 
group of lymphocytes that play a central role in adaptive immune responses. Upon 
maturation, APC home to lymph nodes or other lymphoid structures to interact with 
T lymphocytes. Upon the encounter of new antigens, these proteins are presented as 
peptides to naïve T cells (Th 0), which are T cells that have not yet encountered APC 
or diﬀ erentiation signals. As a result of this interaction, Th 0 cells are being directed 
into distinct types of T cells. T helper (Th ) cells comprise one of these subsets, which 
can be further divided into Th 1 and Th 2 cells, depending on their cytokine secretion 
pattern. More recently, Th 17 cells were described as a novel Th  subset 50, 51. In turn, Th  
cells activate B cells, which secrete immunoglobulins (Ig) upon diﬀ erentiation into 
plasma cells, resulting in a fully developed adaptive immune response. Next to acti-
vated Th  cells, Th 0 cells can also diﬀ erentiate into regulatory T cells (Tregs), which 
play a critical role in the inhibition of immune responses. In health, there is a tight 
balance between activated T cells and Tregs, designed to control immune responses. 
Th e potential eﬀ ect of a disturbance of this balance may be auto-immunity, which is 
illustrated by recent ﬁ ndings in patients with the rare syndrome of immune dysregu-
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lation, polyendocrinopathy, enteropathy, X-Linked (IPEX), who have been shown to 
have a mutation of the Treg marker FOXP3 52. Th us both APC and T cells play a key 
role in initiating and controlling adaptive immune responses. When a failure occurs 
anywhere in the cascade of antigen processing to T cell diﬀ erentiation, this might 
lead to unwanted immune responses. It is therefore not surprising that the role of 
APC and T cells is being thoroughly investigated in various auto-immune diseases. 
Currently, a substantial amount of evidence indicates that both T cells and APC are 
key players in a variety of auto-immune diseases.
Chemokines orchestrate leukocyte migration
Interaction and communication between distinct cells of the immune system is a key 
feature of any immune response. As discussed above, APC and T cells are two cell ty-
pes that drive immune responses upon their interaction, e.g. their cell-cell contact. In 
order to facilitate such an interaction, leukocytes secrete small chemotactic proteins 
which are termed chemokines. Chemokines comprise a large and ever growing fami-
ly of molecules that facilitate leukocyte migration 53, 54. To fulﬁ l this task, they bind to 
and signal through 7-transmembrane spanning chemokine receptors on the surface 
of their target cells. Chemokines are classiﬁ ed according to their cysteine structure 
16
Figure 1
The joint in health and RA. Adapted from M Koenders: 
“IL-17 and its relation to IL-1 and TNF in experimental arthritis”
and divided into four groups accordingly: CXC chemokines, CC chemokines, CXXC 
chemokines and C chemokines. Th e oﬃ  cial nomenclature for chemokines is also de-
rived from this classiﬁ cation, which made the chemokine system more transparent 55. 
Before, several chemokines had up to 5 diﬀ erent names, according to their discovery 
by independent research groups, making the chemokine system unnecessarily com-
plex. Next to the cysteine classiﬁ cation, another commonly used classiﬁ cation sepa-
rates chemokines into inﬂ ammatory and homeostatic chemokines. However, these 
two functions cannot always be separated easily, making this classiﬁ cation less useful. 
Th e chemokine family is notorious for its redundancy and promiscuity, as several 
chemokines act as ligands for the same receptor. Th e chemokines CCL19 and CCL21 
for instance both signal through chemokine receptor CCR7. In turn, this receptor 
is expressed on both mature DC and Th 0 cells, which makes CCL19 or CCL21 a li-
gand for multiple distinct cell types. Next to chemotactic capacities, numerous other 
functions have been addressed to several chemokines. Examples of this diversity in 
functions will be discussed below for two speciﬁ c chemokines, which form the key 
subject of investigation in this thesis. As described above, the interaction between 
APC and T cells largely determines the fate of the immune response. In order to faci-
litate this interaction, APC produce a speciﬁ c set of chemokines which preferentially 
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Figure 2
APC-T cell interaction
attract T lymphocytes. Within this group of T cell attracting chemokines, each che-
mokine attracts its own group of T cell subsets. However, this is not a matter of black 
or white, as there also exists also redundancy among the T cell attracting chemoki-
nes. Moreover, novel subsets of T cells are still being identiﬁ ed, which by deﬁ nition 
makes the picture incomplete. To date, a potential role for several T cell attracting 
chemokines has been suggested in the pathogenesis of chronic inﬂ ammatory and/or 
auto immune diseases. Examples include a potential role for CCL19, CCL21 in RA 6, 
56, 57, CCL17 in SLE 58, 59 and CXCL10 in MS 60-62. 
CC Chemokine Ligand 18 
CC chemokine ligand 18 (CCL18) is a chemokine that was discovered in the late 
90’s by a number of independent groups, resulting in a variety of diﬀ erent names 
for this chemokine. In 1997, Adema and co-workers described a chemokine ligand 
which preferentially attracted CD45RA+ Th 0 cells 63. As this chemokine was pre-
dominantly expressed on DC, it was named “dendritic cell derived CC-chemokine 
1” (DC-CK1). Interestingly, CCL18 was found to be expressed in germinal centres 
and T cell areas of secondary lymphoid organs, suggesting an important role in the 
18
Figure 3
CXCL16 structure and shedding (Adapted from R. vd Voort, “oral presentation 2005”)
interaction between DC and Th 0 cells. Almost simultaneously,  Hieshima and col-
leagues described a chemokine that was expressed at high levels in the lung, which 
they subsequently named “pulmonary and activation regulated chemokine” (PARC) 
64. Th ey found CCL18 mRNA to be expressed on alveolar macrophages, follicular 
DC and peripheral blood monocytes upon stimulation with LPS. In 1998, Kodelja 
and co-workers identiﬁ ed “alternative macrophage activation-associated CC-che-
mokine-1” (AMAC-1) 65, a chemokine that was expressed on mRNA level by alter-
natively activated macrophages 49, 66 in vitro and by alveolar macrophages in vivo. 
As MoDC expressed CCL18, it was intriguing that Langerhans cells, another well 
known DC-like cell, did not express CCL18 67. In addition, Wells and Peitsch and 
Guan et al reported a sequence that encoded for a novel CCL3-like chemokine with 
close homology to MIP-1α (SCYA3), which was named macrophage inﬂ ammatory 
protein 4 (MIP-4) (SCYA18) 68, 69. According the oﬃ  cial chemokine nomenclature, 
DC-CK1/PARC/AMAC-1/MIP-4 was renamed CCL18.
Th e CCL18 gene is located on chromosome 17q11.2, close to the location of most 
genes of the MIP family. Th e gene has a length of 7.2 kb, which is signiﬁ cantly longer 
than most other chemokine genes and encodes for a protein consisting of 69 amino-
acids with a weight of 7.8 kD. Th is CCL18 protein has a 64% homology with CCL3. 
To date, CCL18 is still regarded as an orphan chemokine, since none of the currently 
identiﬁ ed chemokine receptors acts as a high aﬃ  nity receptor for CCL18. However, 
it has been suggested that CCL18 may bind with low aﬃ  nity to some of the known 
chemokine receptors, although the functional importance of these interactions need 
to be established. Another feature of CCL18 that hampers research on its role in vivo
is the lack of a murine counterpart. Intriguingly however, it was recently claimed that 
recombinant human (Rh) and adenoviral (Ad) CCL18 were able to induce chemo-
taxis of murine lymphocytes 70.
Th e main function of CCL18 is (chemo) attraction of lymphocytes. CCL18  preferen-
tially attracts CD45RA+, Th 0 cells 63, but has also been reported to induce migration 
of activated CD3+ lymphocytes under speciﬁ c conditions 64. CCL18 mRNA is ex-
pressed in vitro by MoDC and alternatively activated macrophages while their pre-
cursors, peripheral blood monocytes, have been shown to express little or no CCL18 
mRNA 63, 71. In vivo, CCL18 is expressed on mRNA level by alveolar macrophages 64, 65
and germinal centre DC 63. Next to DC and macrophages, CCL18 was also expressed 
by mantle zone B cells 72. Th e exact regulation of CCL18 on myeloid cells is highly 
complex and still largely unknown, although CCL18 inducing eﬀ ects of Th 2 cytoki-
nes have been demonstrated on mRNA level 65. In previous studies, we found that DC 
maturation using the TLR4 ligand LPS strongly increased CCL18 mRNA expression 
57, which has been conﬁ rmed 71 and debated 65. However, little is known about CCL18 
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regulation on the protein level, which oﬀ  course is essential for a better understan-
ding of the role of this interesting chemokine in health and disease. As is the case for 
several chemokines, chemo-attraction is not the only function of CCL18. CCL18 was 
recently described to play a role in collagen synthesis by lung and dermal ﬁ broblasts, 
independently of ﬁ broblast proliferation 73, suggesting CCL18 may be involved in the 
process of ﬁ brosis. Interestingly, (pulmonary) ﬁ brosis is a feature that occurs in vari-
ous auto-immune diseases, which makes CCL18 an even more interesting subject of 
investigation in auto-immunity.
To date, a role for CCL18 has been suggested in a large variety of diseases, such as dif-
ferent forms of cancer 74-76, Gaucher’s disease 77, pulmonary diseases 78, 79 and inﬂ am-
matory/auto-immune conditions 57, 80. An intriguing feature of CCL18 is that its cir-
culating levels are relatively high, as most human studies so far describe as much as 
dozens of nanograms of CCL18 in serum or plasma of healthy individuals and even 
up to 1000 ng/ml in Gaucher’s disease 77. Th is allows it to be detected easily, making it 
a potentially interesting molecule as a prognostic marker for inﬂ ammatory diseases. 
Indeed, CCL18 has recently been put forward as a marker for Gaucher’s disease 77. 
CXC Chemokine ligand 16
CXC chemokine Ligand 16 (CXCL16) is one of the more recently identiﬁ ed members 
of the large and ever growing chemokine family and forms a unique chemokine-re-
ceptor couple with CXC Chemokine Receptor 6 (CXCR6). Remarkably, CXCL16 and 
CXCR6 were not initially linked to each other as a chemokine ligand and receptor 
pair. In 1997, Liao, Alkhatib and colleagues identiﬁ ed a novel gene encoding a che-
mokine receptor-like protein (STRL33) that acted as a co-receptor for HIV and the 
Simian Immunodeﬁ ciency Virus (SIV) 81, 82 on activated lymphocytes. Also in 1997, 
Deng and colleagues cloned two novel receptors that were used by SIV and HIV 83, 
one of which turned out to be the same molecule as STRL33, which later was oft en 
referred to as BONZO. In the same year, Loetscher and colleagues identiﬁ ed TYM-
STR, a chemokine receptor-like protein expressed in CD4(+) T lymphocytes and 
a potential function as a HIV co-receptor 84. A ligand for TYMSTR was not found 
among the already identiﬁ ed chemokines. Subsequent studies conﬁ rmed STRL33/
BONZO to be expressed on peripheral blood lymphocytes and to act as a viral co-
receptor in humans 85. Th e relevance of CXCR6 as a chemokine receptor was disco-
vered in 2000/2001, when Matloubian and Wilbanks identiﬁ ed a novel chemokine 
ligand named CXCL16 86, 87. Interestingly, the HIV co-receptor STRL33/BONZO/
TYMSTR was identiﬁ ed as the receptor for CXCL16 and re-named CXCR6. CXCL16 
was characterized as a trans-membrane chemokine consisting of diﬀ erent regions: 
an intracellular tail, a transmembrane part and an extracellular domain, consisting 
20
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of a mucin-like stalk and a chemokine domain (ﬁ gure 3). In the same year, Shimaoka 
and co-workers reported the isolation of a  cDNA clone from a library of stimulated 
THP-1 cells that encoded a 254 –amino acid protein of 30kD  88. Th e corresponding 
gene was shown to be located on chromosome 17p13. Th is molecule was able to bind 
and internalize oxidized LDL (oxLDL) and was therefore named Scavenger Recep-
tor that binds Phosphatidyl-Serine and Oxidized Lipoprotein (SR-PSOX) 88. OxLDL 
induces the transformation of macrophages into foam cells 89 and the proposed role 
of SR-PSOX as a scavenger receptor for oxLDL was in line with its expression in athe-
rosclerotic lesions and atheroma 90, 91. Intriguingly, SR-PSOX proved to be identical 
to CXCL16,  suggesting yet another chemokine with a dual role. Further insights in 
the regulation of CXCL16 revealed that membrane bound CXCL16 could be cleaved 
by A Disintegrin And Metalloprotase 10 (ADAM-10). Th is cleavage released the che-
mokine moiety of CXCL16 and allowed it to serve as a chemokine ligand 92, 93. Next 
to chemo attraction and oxLDL binding, CXCL16 was reported to mediate bacterial 
phagocytosis through its chemokine domain 94. Finally, CXCL16 was reported to not 
only attract leucocytes, but also to mediate adhesion of leucocytes 95.  
To date, CXCL16 expression and secretion has been described on a variety of dif-
ferent cells, such as APC, smooth muscle cells and ﬁ broblasts 88, 92, 96. Regarding the 
regulation of CXCL16, the Th 1 cytokine IFN-γ has been claimed to induce CXCL16 
production by myeloid cells under speciﬁ c circumstances 96, 97. Next to myeloid DC, 
CXCL16 expression has been reported on plasmacytoid dendritic cells (pDC)  98, but 
this ﬁ nding was not consistent in diﬀ erent studies 99. CXCL16 mRNA expression has 
been reported once on lymphocytes 100, but this ﬁ nding has not been conﬁ rmed and 
no functional attraction of CXCR6 positive cells has been shown so far. Th e CXCL16 
receptor CXCR6 is expressed mainly on activated T cells 85, 87. Given the expression 
proﬁ le of the CXCR6-CXCL16 couple, it is conceivable that CXCL16 and CXCR6 
are involved in facilitating APC-T cell interactions. However, in contrast to CCL18, 
CXCL16 recruits already activated T cells instead of Th 0 cells. Regarding CXCR6 
regulation, the cytokine IL-15 has been demonstrated to induce CXCR6 expression 
on lymphocytes 101, 102. Apart from these initial observations, still little is known re-
garding the regulation of the expression of CXCR6. Th erefore, it will be interesting 
to study the regulation and expression of CXCR6 and its ligand  CXCL16 in distinct 
pathological conditions, including RA.
CCL18 and CXCL16 in Rheumatoid Arthritis
As mentioned above, CCL18 has been suggested to play a role in the pathogenesis 
of several inﬂ ammatory diseases. As we are particularly interested in the APC-T cell 
interaction in RA, we evaluated the potential role of several T cell attracting chemo-
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kines in RA. For this purpose, we started oﬀ  with a large panel of chemokines secre-
ted by APC, of which CCL18 came out as a T cell attracting chemokine of particular 
interest 57. In line with this ﬁ nding, the presence of CCL18 in the ST of RA patients 
was described by us and others 57, 74. Interestingly, CCL18 co-localized with mature 
DC in secondary lymphoid follicles 57. To date, a substantial amount of data points 
toward the enrichment of DC and macrophages in the ST, which both may account 
for abundant CCL18 secretion in RA joints. Given its Th 0 cell attracting properties, 
its secretion by APC and its presence in RA joints, CCL18 is an interesting subject for 
further investigation in RA, both for its role in the pathogenesis and for its potential 
as a clinical marker, given its high circulating levels in vivo. 
As CXCL16 is well appreciated as a chemotactic factor for activated T cells that bear 
CXCR6, its role in inﬂ ammatory disease has been both been investigated and sug-
gested in a large variety of chronic inﬂ ammatory diseases, such as inﬂ ammatory di-
seases in the lung 102, 103. Th e ﬁ rst indication that CXCR6 might be of importance in 
RA came from the observation that CXCR6 was abundantly expressed on both CD4+ 
and CD8+ T cells in rheumatoid ST 104. Next to its chemotactic properties, the ability 
of membrane-bound CXCL16 to internalize oxLDL might be of interest in RA, as 
patients with RA have an increased morbidity and mortality due to cardio vascular 
disease, compared with the general population 105, that is accompanied by an increase 
in several cardiovascular risk factors 106-108.
Outline of this thesis
Th e chemokines CCL18 and CXCL16 are both T cell attracting chemokines which 
are expressed by APC. Moreover, there already is some initial evidence supporting a 
potential role for these chemokines in RA 57, 80, 104. Th e general aim of this thesis was 
therefore to further explore the potential role of CCL18 and CXCL16 in RA. For this 
purpose, we investigated the regulation of these chemokines in healthy donors and 
RA patients, their potential role in RA and whether their circulating levels in vivo 
correlated with clinical disease parameters. We recently demonstrated that CCL18 
mRNA production was signiﬁ cantly enhanced in mature DC derived from patients 
with RA 57. In chapter 2, we further investigated the level of CCL18 expression in 
RA DC and studied how neutralization of TNF-α, which is currently applied as a 
treatment for RA, would aﬀ ect CCL18 mRNA production by DC. In addition, we 
investigated whether TNF-α neutralization would aﬀ ect cytokine secretion of DC 
maturation in general. As little is known about the regulation of CCL18 at the pro-
tein level, we developed an ELISA and investigated the regulation of CCL18 protein 
expression in myeloid cells in chapter 3. As CCL18 expression was shown to be en-
hanced in RA ST, we additionally investigated the eﬀ ects of RA SF on CCL18 secre-
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tion by these myeloid cells. In chapter 4, we explored the expression and function 
of  the chemokine  CXCL16 in RA joints. As for CCL18, little was known about the 
regulation of CXCL16 by myeloid cells. We therefore aimed to investigate the regula-
tion of CXCL16 by monocytes, DC and macrophages in chapter 5. Both CCL18 and 
CXCL16 have relatively high circulating levels which makes them potentially inte-
resting as clinical markers. Moreover, circulating levels in the disease course of RA 
may provide important clues for the understanding of the role of these chemokines 
in the pathogenesis of RA. For this reason, we set out to investigate circulating levels 
of CCL18 and CXCL16 in a prospective cohort of RA patients and a cohort of RA 
patients that were treated with anti-TNF-α in chapter 6. CXCL16 has been proposed 
to act as a chemokine and as a receptor for oxLDL.  Th is might be of particular in-
terest in case of inﬂ ammatory disease like RA, in which cardiovascular morbidity is 
enhanced 105, 106. We therefore investigated the potential of soluble CXCL16 to bind 
oxLDL and its correlation with circulating markers of atherosclerosis in patients with 
RA in chapter 7. In the ﬁ nal chapter, chapter 8, the expression, secretion, regulation 
and circulating levels of the T cell attracting chemokines CCL18 and CXCL16 are 
discussed in the context of RA.
chapter 1     
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Abstract
Background: Dendritic cells orchestrate pivotal immunological processes mediated 
by the production of cytokines and chemokines. 
Objective: To assess whether neutralisation of tumour necrosis factor α (TNF-α) du-
ring maturation of dendritic cells aﬀ ects their phenotype and behaviour, which might 
explain the beneﬁ cial eﬀ ects of TNF-α neutralisation in rheumatoid arthritis.
Methods: Immature and fully matured dendritic cells were cultured from blood 
monocytes from patients with rheumatoid arthritis and healthy controls following 
standardised protocols. TNF-α was neutralised by addition of the p55 soluble TNF-α, 
PEGsTNF-RI. Th e eﬀ ect of TNF-α neutralisation on the phenotype (CD14, CD16, 
CD32, CD64, CD80, CD83, CD86 and MHC) of dendritic cells was investigated by 
ﬂ ow cytometry. Expression of chemokines (CCL17, CCL18, CCL19, CCL22, CCL3 
and CXCL8) and production of IL-1β and IL-6 were examined.
Results: Neutralisation of TNF-α during the diﬀ erentiation and/or maturation of DC 
did not result in an altered DC phenotype in the rheumatoid arthritis patients or 
the healthy controls. In contrast, the expression of CCL17, CCL18, CCL19, CCL22, 
CCL3 and CXCL8 by DC was signiﬁ cantly reduced when TNF-α activity was inhibi-
ted during lipopolysacharide triggered dendritic cell maturation. Th e production of 
IL-1β and IL-6 by matured dendritic cells was inhibited by PEGsTNF-RI. 
Conclusion: Inhibition of TNF-α activity during DC maturation lead to the develop-
ment of semi-mature cells. Th ese data suggest a novel pathway by which the neutra-
lisation of TNF-α might exert its therapeutic eﬀ ects. 
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Introduction
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterised by a sym-
metrical polyarthritis of the synovial joints leading to destruction of the cartilage 
and underlying bone. Although the exact mechanisms are still unclear, there is a 
large body of evidence suggesting a critical role for inﬂ ammatory mediators such 
as cytokines and chemokines 1-3. Pro- and anti-inﬂ ammatory cytokines, and more 
importantly the balance between these opposing groups, are likely to play a crucial 
role in the onset and perpetuation of RA 4-6. In this disease, interleukin 1β (IL-1β), 
interleukin 6 (IL-6) and tumour necrosis factor α (TNF-α) are thought to be the key 
mediators as concentrations of these cytokines are signiﬁ cantly elevated in the pe-
ripheral blood and the synovial compartment of RA patients and blockade of these 
mediators has proven to be a highly successful form of treatment 7-9. 
Chemokines are members of a superfamily of proteins that ensure that cell traﬃ  cking 
occurs in a proper temporal and spatial fashion 10. Th ere is evidence for an impor-
tant role for the chemokines interleukin 8 (IL-8; CXCL8), macrophage inﬂ ammatory 
protein α (MIP-1α; CCL3) and fractalkine (CX3CL1) in RA 11-13. Th e fact that the 
blocking of chemokine receptor 1 in RA patients results in a signiﬁ cant reduction 
in synovial cellularity further substantiates the important role of chemokines in sy-
novial inﬂ ammation 14. Previous work from our group demonstrated that DC from 
RA patients express signiﬁ cantly higher levels of the chemokines CCL17, CCL18, 
CCL19, CCL22, CCL3 and CXCL8 than those from healthy donors 15. In particular, 
chemokines CCL17, CCL18 and CCL19 were expressed at high levels, which is in-
triguing as these chemokines largely orchestrate the attraction of T cell subsets and 
might thus play an important role in RA pathology.  
In RA, both the synovial tissue and synovial ﬂ uid contain large numbers of  inﬂ am-
matory cells, including T cells, ﬁ broblasts, monocytes, macrophages and dendritic 
cells (DC) 16-18. DC are professional antigen presenting cells (APC) that are crucial 
in directing tolerance and immunity as well as the initiation of innate and adaptive 
immune responses 19, 20. Immature DC reside in the periphery and are specialised in 
uptake and processing of antigens. Maturation of these cells is triggered by a multi-
tude of pro-inﬂ ammatory stimuli and which coincides with major changes in DC 
phenotype and a loss of the ability to capture antigens 21. To date, a large body of 
evidence points to an important role for DC in synovial inﬂ ammation 22-26. 
For an optimal DC function the phenotypic characteristics (signals 1 and 2) are cru-
cial and are obligatory for T cell activation 27-29, while the capacity of mature DC to 
prime naive T cells and promote their diﬀ erentiation is attributed to their cytokine 
secretion pattern (signal 3) 30. While immature DC induce tolerance in the steady 
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state, mature DC induce antigen-speciﬁ c immunity 27, 31, 32. A disturbed balance of 
pro-inﬂ ammatory cytokines, which is undoubtedly present in RA, might therefore 
contribute to an enhanced DC maturation, culminating in a disturbed balance bet-
ween tolerance and (auto)immunity in RA. 
Th e potential role of TNF-α in DC biology, along with the clinical eﬀ ects of TNF-α 
blockade in RA, prompted us to investigate the eﬀ ects of TNF-α blockade on DC 
development. We hypothesised that the inhibition of TNF-α during DC development 
would interfere with DC maturation and the production of inﬂ ammatory mediators, 
so leading to restoration of immunological balance. We show here that neutralisation 
of TNF-α during DC maturation leads to the development of semi-mature DC. 
Methods
Patients
Eleven patients with active RA and 10 healthy volunteer controls were enrolled in the 
study. All patients fulﬁ lled the American College of Rheumatology (ACR) criteria for 
RA and gave informed consent for the study 33. We excluded patients who received 
therapy with systemic steroids or biological agents. All patients were treated with 
disease modifying anti rheumatic drugs alone or in combination with non-steroidal 
anti-inﬂ ammatory drugs. To assess disease activity, the DAS28 score was used 34. Th e 
Medical Ethics Committee of the University Medical Centre Nijmegen approved the 
study protocol.
Dendritic cell cultures
For cell cultures, 50 ml blood was taken from the RA patients and the controls intro 
10ml heparinised Vacutainer tubes. DC were cultured from peripheral blood mo-
nocytes using standardised protocols, essentially the same as previously described 
35. In brief, the procedures were as follows: Peripheral blood mononuclear cells were 
isolated by means of a Ficoll gradient centrifugation gradient (Ficoll Paque, Amers-
ham Biosciences, Uppsala, Sweden). Aft er several stringent wash steps, cells were 
incubated in six-well plates (Costar, Badhoevedorp, Th e Netherlands) for one hour 
at 37°C to allow adherence of monocytes. Th ereaft er, adherent cells were cultured in 
medium (RPMI-1640 (Dutch modiﬁ cation), Life Technologies, Grand Island, USA), 
supplemented with glutamine, antibiotics/antimycotics (both from Life Technolo-
gies, Grand Island, USA) and 10% fetal calf serum (FCS) for 6 days in presence of in-
terleukin 4 (IL-4) (500U/ml) and granulocyte macrophage colony stimulating factor 
(GM-CSF) (800U/ml) (Schering-Plough, Amstelveen, Th e Netherlands). On day 6, a 
proportion of the iDC was harvested for analysis of the immature state. To obtain full 
maturation, the remaining cells were cultured for two more consecutive days in the 
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presence of  2μg/ml E.coli lipopolysacharide (LPS) (Sigma-Aldrich, St. Louis, USA). 
On day 8, fully mature DC were harvested and studied.
Eﬀ ective blockade of TNF-α activity in DC cultures
For TNF-α blockade, we used a p55 soluble TNF-α receptor (PEGsTNF-RI), kindly 
gift ed to us by AMGEN®. To assess the amount of PEGsTNF-RI needed for full in-
hibition of TNF-α activity during the culture of DC, we determined the maximum 
production of TNF-α by matured DC originating from previous experiments from 
our group 35. To achieve eﬃ  cient neutralisation of TNF-α we added an 1000-fold 
excess of PEGsTNF-RI to the cultures. On day 0, 3 and 6 PEGsTNF-RI was added to 
the culture medium to examine its eﬀ ect on the diﬀ erentiation and maturation. As a 
control, carrier ﬂ uid that was provided by AMGEN®  was added to the cultures where 
appropriate.
To check whether a 1000-fold excess of PEGsTNF-RI was suﬃ  cient for maximum in-
hibition of TNF-α, we carried out a bio-assay using a 3T3 luciferase reporter cell line 
that is highly sensible for mediators that trigger NFκB signalling including TNF-α and 
IL-1β 36. As an initial step, we carried out a dose-response curve to test whether the 
PEGsTNF-RI was capable of the neutralisation of TNF-α and to study the value of our 
bio-assay for this purpose. Second, the supernatant obtained from the DC cultured 
with or without PEGsTNF-RI was added to the 3T3 cells and the luciferase response 
was studied. Another 1000-fold excess of PEGsTNF-RI was added to the system to test 
whether maximum inhibition of TNF-α was achieved in our experimental setup. 
Determination of DC phenotype using FACS techniques
Th e phenotype of DC was characterised using ﬂ owcytometry techniques (ﬂ uores-
cence activated cell sorting, FACS) (FACSCalibur®, Becton-Dickinson, San Jose, 
USA).  For this aim, DC were harvested and collected by centrifugation and further 
processed on melting ice. Cells were diluted in buﬀ er solution (phosphate buﬀ ered 
saline (PBS) with 1% bovine albumine, pH 7.4) in a concentration of 1x106  cells per 
ml and plated in v-shaped 96-wells plates (1x105 cells per plate). Cells were labelled 
with monoclonal mouse-anti human antibodies against the monocyte marker CD14, 
FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) (all from Dako, Glostrup, Den-
mark), DC-SIGN 37, the co-stimulatory molecules CD80 (Becton Dickinson, Moun-
tain View, USA) and CD86 (PharMingen, San Diego, USA), the mature DC mar-
ker CD83 (Beckman Coulter, Mijdrecht, Th e Netherlands), MHC-I (clone W6/32) 
and MHC-II (clone q1513), with mouse-isotype control and incubated at 4°C for 45 
minutes. Cells were then washed and labelled with goat anti-mouse FITC (Zymed 
Laboratories, South San Francisco, USA) as a secondary antibody. Aft er another 30 
minutes’ incubation at 4°C, cells were again washed, diluted in buﬀ er solution and 
transferred into FACS tubes. Cell phenotype was then analysed using FACS  .
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Radio Immuno Assay (RIA) for IL-1β production levels
When the DC were harvested, the supernatants were collected and stored for the 
measurement of cytokines. Polyclonal antibodies for IL-1β were kindly provided by 
Sclavo (Siena, Italy). Human recombinant IL-1β was radio-labeled by using the chlo-
ramine-T method 38. Brieﬂ y, all samples and standards were prepared and mixed with 
a standard buﬀ er which contains 13mM NA2 EDTA, 0.02% sodium azide, 0,25% 
bovine serum albumin (Boehring, Marburg, Germany) and inactivating units aproti-
nine, pH 7.4 (Bayer, Leverkussen, Germany). For measurement of IL-1β in superna-
tants, 10μl of sample or standard was added to the buﬀ er. Th e mixture was incubated 
for one day at room temperature. Aft er the addition of tracer (≈ 7,000 dpm/100μl) 
the incubation was continued for two more days. Separation of bound and free tra-
cer was achieved by the addition of 100 μl of a separation agent containing sheep 
anti-rabbit immunoglobulin G and 0.01% rabbit immunoglobulin G (Sigma). Aft er 
incubation for 30 minutes, the antibody complex was completely precipitated by the 
addition of 1 ml 7.5% polyethylene glycol 6000 (Merck, Darmstadt, Germany). Th e 
range of the standard curve was 20 to 3000 pg/ml with a sensitivity of 40 pg/ml. To 
minimise inter-assay variations, all samples from the same experiments were analy-
sed in the same run in duplicate. Th e inter-assay variation of our RIA is estimated at 
≤ 15%, whereas the intra-assay variation is ≤ 10%. 
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Table 1. Primers and TaqmanTM probes used for real-time quantitative PCR analysis 40
primer            probe
Chemokine        5’end                                        3’end     5’end      3’end
DK-CK1      CCTGGAGGCCACCTCTTCTAA            AGTCCCATCTGCTATGCCCAGCCAC
(CCL18)      TGCAGCTCAACAATAGAAATCAATT
ELC       CAGAGGACCTCAGCCAAGATG   CCTATGACCGTGCAGAGGGAGCCC
(CCL19)      TTCACAATGCTTGACTCGGACT
IL-8       AGAAGTTTTTGAAGAGGGCTGAGA   TCCAAGAATCAGTGAAGATGCCAGTGAAACTT
(CXCL8)      CAGACCCACACAATACATGAAGTG
MDC       GTCCTGTTCCCATCAGCGAT    CCATGACTCCCCACTGCCCTAAGCT
(CCL22)      CAGGCTGGAGAGAGAGATGGA
MIP 1α      TGTGTTTGTGATTGTTTGCTCTGA   CCTTCCCTCACACCGCGTCTGG
(CCL3)      TGGTGCCATGACTGCCTACA
TARC       GCAAAGCCTTGAGAGGTCTTGA   CCTCCTCACCCCAGACTCCTGACTGTC
(CCL17)      CGGTGGAGGTCCCAGGTSGT
GAPDH      GAAGGTGAAGGTCGGAGT    CAAGCTTCCCGTTCTCAGCC
       AGATGGTGATGGGATTTC
PBGD       GGCAATGCGGCTGCAA    CTCATCTTTGGGCTGTTTTCTTCCGCC 
       GGGTACCCACGCGAATCAC  
Enzyme Linked Immuno Sorbent Assay (ELISA) for IL-6 production levels
IL-6 was measured by using a commercially available enzyme linked immunosor-
bent assay (ELISA) (Pelikine CompactTM human IL-6 ELISA kit, CLB, Amsterdam, 
Th e Netherlands) according to the manufacturer’s instructions 39. 
Primers and probes for chemokine production measurements
Th e sequence of the primers (Life technologies) and TaqmanTM probes (PE Biosy-
stems, Branchburg, New Jersey) used in this study are given in table 1.  Th e chemo-
kine-speciﬁ c probes were labelled at the 5’ end with a FAM ﬂ uorescent group and at 
the 3’ end with a TAMRA quencher group. Th e probes speciﬁ c for the housekeeping 
genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and porphobilinogeen 
deaminase (PBGD) were labelled with a VIC ﬂ uorescent group at the 5’ end.
Real Time PCR for chemokine production levels
Expression levels of CCL17, CCL18, CCL19, CCL3, CCL22 and CXCL8 was measu-
red in six patients and six controls using real-time polymerase chain reaction (PCR) 
techniques. Aft er isolation of the DC, the cells were centrifuged and the pellet was 
solved in the Trizol reagent and stored at -70°C. Th ereaft er, RNA was extracted using 
reverse transcriptase polymerase chain reaction (RT-PCR) with 1 microgram of RNA. 
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OligoT primers were used for reversed transcription of mRNA. For PCR ampliﬁ ca-
tion, 5% of the cDNA was used. Th e standard PCR buﬀ er that was used, contained 
200μM dNTP’s, 0,1μM forward and reverse primer and 1 unit Taq polymerase. We 
followed TaqmanTM assay instructions for PCR procedures, with an end concentra-
tion of 175nM probe and 600nM primers. All PCR ampliﬁ cations were done on a 
ABI/PRISM 7700 sequence detector system. Th is system produces a real-time ampli-
ﬁ cation plot based upon the normalised ﬂ uorescence signal. Th e expression levels of 
the chemokines were related to the expression level of PBGD, a housekeeping gene 
with intermediate expression levels. Another housekeeping gene GAPDH was used 
as an internal control for the amount of cDNA in each individual.
Statistical analysis
Comparisons between groups were assessed using paired t tests or Wilcoxon’s signed 
rank test as appropriate. For statistical analysis, the GraphPad Prism® version 4 statis-
tical program was used. Probability (p) values  < 0.05 were considered signiﬁ cant.
Results
TNF-α activity inhibition
Th e maximum production of TNF-α by mature DC was around 5000 pg/ml, in line 
with a previous study 35. To determine the concentration of PEGsTNF-RI needed for 
an optimal TNF-α activity inhibition, we added diﬀ erent concentrations of the solu-
ble TNF-α receptor to 3T3 reporter cells which were stimulated with 1ng/ml TNF-
α (ﬁ gure 1a). A PEGsTNF-RI concentration of 100 ng/ml decreased the luciferase 
response with 56% (p < 0.001), while maximum (86%) inhibition of TNF-α activity 
was achieved by 1000 ng/ml PEGsTNF-R (a 1000-fold excess). A further increase of 
PEGsTNF-RI did not result in a greater inhibition of the luciferase response. In our 
supernatants obtained from fully matured DC, there was a 33% inhibition of the lu-
ciferase response aft er the addition of a 1000-fold excess (104 ng/ml) of PEGsTNF-RI 
(ﬁ gure 1b). A further increase of 1000-fold (104 μg/ml) in PEGsTNF-RI did not result 
in a further decrease in the luciferase response, indicating that a maximum neutrali-
sation of TNF-α in the supernatant had been achieved. Th e remaining luciferase res-
ponse is likely to  be caused by other NFκB activating cytokines in the supernatant.
Eﬀ ect of TNF-α blockade on dendritic cell diﬀ erentiation and maturation
We next investigated the eﬀ ect of TNF-α neutralisation during monocyte diﬀ eren-
tiation into immature DC. We added PEGsTNF-RI (1000-fold excess) to the mono-
cytes on day 0 and day 3 during DC development and compared the phenotype of 
the resulting immature DC with cells cultured under the same conditions but in the 
absence of PEGsTNF-RI. Both cell cultures expressed high levels of FcγRI, II and 
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III, intermediate levels of the markers CD80, CD86 and MHC-I&II and low levels 
of CD14 and CD83, typical phenotypical features of the immature DC 40, 41. In line 
with previous observations, the expression of FcγRII was higher on immature DC 
from RA patients (henceforth referred to as RADC) when compared with that of 
healthy controls (CDC) (table 2).  However, no diﬀ erences in DC phenotype were 
detected between cells cultured with and without PEGsTNF-RI, either in the rheu-
matoid group or in the control group, nor did the addition of PEGsTNF-RI aﬀ ect 
the phenotype aft er LPS mediated maturation in either group. In contrast, a clearly 
increased expression of co-stimulatory molecules and MHC was observed in both 
groups, whereas expression of FcγRs was down-regulated, resulting in a mature DC 
phenotype (table 2) even when TNF-α was inhibited to the maximum extend. 
40
Figure 1.
Inhibition of tumour necrosis factor (TNF�) activity by the addition of the p55 soluble TNF� receptor PEGsTNFRI. 
(A) Inhibition of 3T3 cells (luciferase response) stimulated by TNF-alpha (1 ng/ml) following the addition of various 
concentrations of PEGsTNFRI. (B) Neutralisation of TNF-alpha activity in the supernatant of mature dendritic cells by 
addition of PEGsTNFRI. A 1000-fold excess of PEGsTNFRI was sufﬁ cient to provide maximum inhibition of TNF-al-
pha activity, as a further 1000-fold excess did not cause any additional decrease in luciferase. (DC, dendritic cell).
Decreased expression of CCL17, CCL18, CCL19, CCL3, CCL22 and CXCL8 aft er TNF-
α neutralisation.
As we found previously that RADC expressed signiﬁ cantly higher levels of chemo-
kines and pro-inﬂ ammatory cytokines than DC from healthy controls, we examined 
whether this process is TNF-α driven. To do this, we investigated the eﬀ ect of TNF-α 
neutralisation on the expression of several DC-speciﬁ c and non-speciﬁ c chemokines 
during LPS triggered DC maturation. Fully matured RADC expressed signiﬁ cantly 
higher levels of the chemokines CCL17, CCL18, CCL19, CCL22, CCL3 and CXCL8 
than CDC (Figure 2). Intriguingly, the neutralisation of TNF-α during maturation 
of RADC resulted in a signiﬁ cantly decreased production of CCL18 (mean (SEM), 
pg/ml: 3514 (581) v 114 (27), p=0.002), CCL17 (7261 (935) v 424 (178), p=0.002), 
CCL22 (4636 (1278) v 405 (268), p=0.03), CCL19 (281 (35) v 15 (6), p<0.001), CCL3 
147 (66) v 1.5 (1.0), p=0.03) and CXCL8 (76 (10) v 7 (1), p<0.001). A similar trend 
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Decrease in chemokine expression by mature dendritic cells when TNF-alpha activity is inhibited. 
Expression of the chemokines CCL17, CCL18, CCL19, CCL22, CCL3 and CXCL8 by lipopolysacharide matured DC 
was measured using Real-Time PCR techniques. A clear decrease in chemokine expression was observed when TNF-
alpha activity was inhibited during the maturation process in both RA patients and healthy controls.
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was observed on chemokine expression by DC from healthy donors although this ef-
fect failed to reach statistical signiﬁ cance for CCL22 (p=0.09) and CXCL8 (p=0.06). 
Whereas inhibition of TNF-α activity in DC cultures from rheumatoid patients led 
to a signiﬁ cant decrease in chemokine expression, expression of CCL17, CCL18, 
CCL19, CXCL8 and CCL22 remained increased compared with healthy controls. 
Th is suggests that chemokine expression is not driven by TNF-α alone.
Decreased production of IL-1β and IL-6 by mature dendritic cells aft er TNF-α inhibition.
As IL-1 and IL-6 are deﬁ ned as key inﬂ ammatory mediators in RA, we investigated 
whether inhibition of TNF-α during DC culture inﬂ uenced the secretion of these 
mediators. As with the expression of chemokines, the secretion of both IL-1 (mean 
(SEM):108 (16) v 74 (10) pg/ml, p=0.02) and IL-6 (21282 (6543) v 13482 (5037) pg/
ml, p=0.007) decreased signiﬁ cantly when TNF-α was neutralised during maturation 
of RADC (ﬁ gure 3). Similarly, the addition of PEGsTNF-RI during maturation of 
CDC also resulted in a decreased production of IL-6 (10040 (3200) v 6970 (2100), 
p=0.005), although the decrease in IL-1 secretion was not signiﬁ cant (94 (10) v 78 
(8) pg/ml , p=0.08). 
Figure 3. 
Inhibition of TNF-alpha during DC maturation resulted in a decreased production of IL-1� and IL-6. 
(A) Production of IL-1�, (B) IL-6 secretion. Both pro-inﬂ ammatory mediators were signiﬁ cantly reduced when TNF-
alpha was neutralised during DC maturation triggered by the addition of LPS. Although the production of both IL-1 
and IL-6 was signiﬁ cantly greater by DC from RA patients, the decrease in production by blocking TNF-alpha was 
similar in both groups.
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Discussion
Our results show that the neutralisation of TNF-α during DC maturation does not 
inhibit DC maturation in terms of phenotype but does lead to a decreased produc-
tion of inﬂ ammatory mediators that reﬂ ects the development of the so called “semi-
mature” DC. Th e presence of these semi-mature DC might at least partially explain 
the therapeutic eﬀ ects of neutralisating TNF-α in vivo.
Autoimmunity is characterised by a loss of tolerance to the body’s own constituents 
that results in a destructive process directed to a speciﬁ c organ. Th e major goal in the 
treatment of autoimmune diseases would be the inhibition of APC function and the 
generation of tolerogenic DC 32. As RA is an autoimmune disease, DC are an attrac-
tive therapeutic target. Th eir importance in synovial inﬂ ammation was suggested by 
the fact that mature DC are present in synovial tissue of RA patients and are located 
strategically in well organised structures 22, 23, 26. Furthermore, DC are able to trigger 
and abrogate experimental arthritis, depending on the time of administration and 
the experimental set-up 24, 25. Modulation of DC in RA might therefore be used to 
combat autoimmunity as has already been achieved successfully in other autoim-
mune diseases 42. 
DC are professional antigen presenting cells that play a critical role in the ﬁ ne tuning 
of the balance between immunity versus tolerance. Whilst immature DC are perfect-
ly adepted for antigen uptake and processing, their maturation leads to functional 
changes that enhance their ability of DC to attract and activate T cells 31, 43. However, 
recent evidence has challenged this oversimpliﬁ ed model of immature and mature 
DC 44-46. Lutz and co-workers suggested that cytokines produced by fully matured 
DC are crucial for T cell immunity and proposed the theory of so called semi-ma-
ture DC, which resemble mature DC in terms of  their phenotype but produce low 
levels inﬂ ammatory mediators and are critical for induction of tolerance 45. However, 
the level of T cell stimulation remains strongly dependent on the signals mediated 
through various molecules expressed on the DC cell surface. Th e ﬁ rst signal accounts 
for the speciﬁ city of the immune response and involves the engagement of T cell 
receptors by an appropriate peptide-MHC complex. Second, interaction between co-
stimulatory molecules (signal 2) is required and determine the quality and fate of 
the immune response. Finally, pro-inﬂ ammatory mediators are thought to function 
as additional signals (third signal) which, direct T cells in harmony with signals re-
ceived through the TCR and co-stimulatory molecules 30. Th e type and quantity of 
these given signals is likely to determine the fate of the T cells. It is therefore tempting 
to speculate that these so called semi-mature DC drive the immune response toward 
the induction of T cell anergy. 
We have recently shown that DC obtained from RA patients produce higher levels 
of  pro-inﬂ ammatory mediators than those from healthy controls 35. Th is suggests 
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that in RA, DC possess a lower threshold for activation which, might lead to an al-
tered balance between tolerance and (auto)immunity. Th e fact that the production 
of inﬂ ammatory mediators by DC is at least partly inhibited by the neutralisation of 
TNF-α during DC maturation suggests that this might be one of explanation for the 
clinical success of TNF-α blockade. However, the production of inﬂ ammatory me-
diators by DC in RA remains higher despite the inhibition of TNF-α, which suggests 
the involvement of other pathways.
Th e exact mechanisms through which TNF-α inhibition has its beneﬁ cial eﬀ ects have 
not been deﬁ ned. Nevertheless, the critical role of TNF-α in DC development was 
recently shown in experimental models of arthritis and indicated that TNF-α has 
potential opposing eﬀ ects depending on the maturational stage of the DC. Another 
eﬀ ect of TNF-α blockade in RA might be the control of chemoattraction of inﬂ am-
matory cells into the synovial compartment. Th e decreased expression of chemo-
kines by DC aft er the inhibition of TNF-α in vitro suggests an important role for 
TNF-α in the control of cell inﬂ ux in vivo. In fact, a critical role for TNF-α in the ﬁ ne 
tuning of cell inﬂ ux was demonstrated recently in synovial sections of patients aft er 
the administration of anti-TNF-α 47. Besides the development of semi-mature DC 
and a diminished production of chemokines, our current study shows that other me-
chanisms might explain the beneﬁ cial eﬀ ects of TNF-α inhibition. One of these is the 
deceased production of IL-6, high levels of which are known to block the suppressive 
eﬀ ect of CD4+CD25+ T regulatory cells and skew the diﬀ erentiation of monocytes 
towards macrophages 48, 49. Th e inhibition of IL-6 secretion may thus potentially res-
tore the function of these regulatory T cells and lead to the development of immature 
DC designed to restore tolerance. Th e beneﬁ cial results derived from clinical trials ai-
ming for IL-6 blockade emphasise its potential role in RA 9. Although the inhibition 
of TNF-α sparked a revolution in the treatment of RA, the full inhibition of TNF-α 
does have side eﬀ ects like serious infections 50, SLE-like disease 51 and symptoms 
resembling multiple sclerosis (MS) 52. Detailed information regarding the actions of 
TNF-α and its inhibition in the modulation of the immune system would increase 
our understanding of these issues. 
Conclusions
We provide evidence for potential new mechanisms whereby neutralisation of TNF-α 
might achieve its beneﬁ cial eﬀ ects in clinical practice. Th ese mechanisms include the 
development of semi-mature DC and decreased chemoattraction following inhibiti-
on of chemokine production. Further research into the precise mechanisms of TNF-
α on DC mediated T cell polarisation and chemokine production is warranted. 
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Abstract
Background: Th e T cell attracting chemokine CCL18 is produced by antigen presen-
ting cells and a role for CCL18 has been suggested in the pathogenesis of a variety of 
diseases. Rheumatoid arthritis (RA) is one of these conditions, in which abundant 
CCL18 production is present. Although Th 2 cytokines and IL-10 are known to have 
an eﬀ ect on CCL18 production,  there are several gaps in our knowledge regarding 
the exact regulation of CCL18 secretion, both in general and in RA.  In this study 
we provide new insights in the regulation of CCL18 secretion by monocytes and 
dendritic cells.
Results: In contrast to a large panel of pro-inﬂ ammatory stimuli (IL-1β, TNF-α, IL-
10, IL-13, IL-15, IL-17, IL-18, IFN-γ), T cell mimicking molecules (RANKL, CD40L) 
or TLR driven maturation, the anti-inﬂ ammatory IL-10 strongly stimulated DC to 
secrete CCL18. On freshly isolated monocytes, CCL18 secretion was induced by IL-
4 and IL-13, in strong synergy with IL-10. Th is synergistic eﬀ ect could already be 
observed aft er only 24 hours, indicating that not only macrophages and dendritic 
cells, but also monocytes secrete CCL18 under these stimulatory conditions. A high 
CCL18 expression was detected in RA synovial tissue and incubation of monocytes 
with synovial ﬂ uid from RA patients clearly enhanced the eﬀ ects of IL-4, IL-13 and 
IL-10. Surprisingly, the eﬀ ect of synovial ﬂ uid was not driven by IL-10 of IL-13, sug-
gesting the presence of another CCL18 inducing factor in synovial ﬂ uid. 
Conclusion: In summary, IL-10 synergistically induces CCL18 secretion in combi-
nation with IL-4 of IL-13 on monocytes and monocyte derived cells. Th e eﬀ ects of 
IL-14, IL-13 and IL-10 are strongly enhanced by synovial ﬂ uid. Th is synergy may 
contribute to the high CCL18 expression in RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease that is mainly characte-
rized by inﬂ ammation of the synovial tissue (ST), leading to cartilage and bone des-
truction. Inﬂ ux of diﬀ erent inﬂ ammatory cells into the ST and enhanced production 
of cytokines and chemokines are all well known features of RA.  Chemokines are 
small proteins that act as key players in the chemo-attraction of diﬀ erent leucocytes 
and perform their chemo-attractive task through interaction with their receptor on 
the target cell. Several chemokines have been shown to be abundantly present in 
RA ST at highly strategic sites 1-3, which suggests a role for these chemokines in the 
pathogenesis of RA. In this respect, chemokines could be regarded as promising the-
rapeutic targets in RA. Th is concept has already been translated to the clinic, since 
the blockade of C Chemokine Receptor 1 (CCR1) has recently been shown to be 
clinically eﬀ ective in the treatment of RA 4.
Antigen presenting cells (APC), such as dendritic cells (DC) and macrophages (MΦ), 
are generally accepted as critical mediators in the complex pathogenesis of RA 5-7. 
APC produce a multitude of chemokines that attract speciﬁ c T cell subsets. Such 
chemokines are likely to play a critical role in the regulation of immune responses, 
since they orchestrate the spatial and temporal interaction between APC and T cells, 
which determines the fate and nature of the immune response. Evidence for this 
conceptual framework came recently from the observation that blocking APC-T cell 
interactions using CTLA4-Ig led to a signiﬁ cant reduction of disease activity in RA 8. 
Several chemokines orchestrate the attraction of T cells toward DC. It is tempting to 
speculate that interfering with these chemokines would lead to similar eﬀ ects on di-
sease activity as the direct blockade of T-cell DC interaction. Of this group of T- cell 
attracting chemokines, CCL18 and CXCL16 recently came out as potentially interes-
ting targets in RA from previous research by our group and others 9-13.
CC chemokine ligand 18 (CCL18, also DC-CK-1, PARC, AMAC-1) was ﬁ rst iden-
tiﬁ ed as a naïve T cell attracting chemokine 14-16.  Next to chemo-attraction, CCL18 
plays a role in stimulation of collagen production by ﬁ broblasts 17. Despite numerous 
attempts to identify its receptor, CCL18 is still an orphan chemokine. In vivo, CCL18 
expression was ﬁ rst found in high quantities in the lung, which is caused by the abun-
dant expression by alveolar MΦ 15. In vitro, DC and MΦ have been identiﬁ ed as 
CCL18 producers 14-16, 18, 19. To date, a substantial amount of data points toward the 
enrichment of DC and MΦ in the synovial tissue which likely to be responsible for 
the increased levels of CCL18 in RA synovial tissue and synovial ﬂ uid (SF) compared 
with that from healthy individuals 18, 20. In this line, CCL18 has been identiﬁ ed as a 
clinical marker in Gaucher’s disease, a condition in which MΦ activation is likely to 
play a role in the pathogenesis 21, 22. In addition, a role for CCL18 has been suggested 
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in a large variety of diseases, such as systemic sclerosis and acute lymphoblastic leu-
kaemia 23, 24. In RA, we recently found that circulating CCL18 levels are elevated com-
pared with controls and correlated with disease activity 25. Moreover, CCL18 mRNA 
expression by DC from RA patients was shown to be higher than by DC from healthy 
controls, which could be inﬂ uenced by blockade of TNF-α 10, 13. Th e exact regulation 
of CCL18 protein secretion however is complicated and the studies published thus far 
have led to controversial results 18, 19, 26-28, as elegantly reviewed by Schutyser et al 29.
In order to clarify the mechanism of CCL18 expression and secretion in RA, we in-
vestigated the role of a large panel of inﬂ ammatory mediators known to play a role 
in the disease process on CCL18 secretion. Here, we show that CCL18 secretion by 
monocytes and DC is regulated by synergistic eﬀ ects between IL-4/IL-13, IL-10 and 
RA SF, whereas pro-inﬂ ammatory cytokines and Toll-like receptor (TLR) ligands did 
not have any inﬂ uence on CCL18 secretion. Th ese data add novel information to the 
puzzle of increased CCL18 expression in RA. 
Methods
Patients and samples
For cell culture experiments, 50ml peripheral blood was taken from healthy volun-
teers and RA patients aft er receiving informed consent in 10ml lithium heparine 
(Vacutainer, USA) tubes. Synovial biopsies from RA patients were taken with small 
needle arthroscopy (Storz, Tutlingen, Germany). Synovial ﬂ uid from RA patients was 
obtained during arthroscopy. For our experiments in which monocytes were stimu-
lated with SF, a pool of SF from 10 diﬀ erent RA patients was used. Synovial samples 
from healthy controls were taken during scheduled arthroscopic procedures by or-
thopedic surgeons in patients with traumatic knee injuries. Th e Nijmegen medical 
ethics committee (MEC) approved these studies.
Recombinant proteins and antibodies
For stimulation of iDC, we used 20 ng/ml recombinant (rh) IL-1β, rhTNF-α, rhIL-
10, rhIL-13, rhIL-15, rhIL-17, rhIL18, 10 ng/ml IFN-γ (all R&D systems, Minnea-
polis, USA), or 20 ng/ml RANKL and CD40L (Pepro Tech, Rocky Hill, USA). DCs 
were cultured with 500 U/ml IL-4 and 800 U/ml GM-CSF. Th e same IL-4 concen-
tration was used for monocyte stimulations. For Toll-like receptor stimulation, 10 
μg/ml pam3cys (TLR2), 25 μg/ml poly (i:c) (TLR3),  2 μg/ml lipopolysacharide (LPS) 
(TLR4), or 1 μg/ml R848 (TLR7/8) was used 30. Blockade of IL-10 (Ebioscience, San 
Diego, USA) and blockade of IL-13 (Diaclone, Becanson, France) was achieved with 
a 1000x excess of a neutralizing antibody. For FACS analysis, we used mouse-anti hu-
man antibodies against CD14, (Dako, Glostrup, Denmark), CD83 (Beckman Coul-
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ter, Mijdrecht, Th e Netherlands), IL-4Rα (Santa Cruz, California USA), IL-13RαII 
(R&D systems, Minneapolis, USA) and IL-10Rα (R&D systems, Minneapolis, USA) 
or mouse-isotype control (goat IgG for IL-13RαII). For ELISA, mouse anti-human 
and biotynilated goat anti-human CCL18 were used as capture and detection anti-
body (R&D systems, Minneapolis, USA). A standard curve was made with rhCCL18 
(R&D systems, Minneapolis, USA). Immuno histochemistry for CCL18 was perfor-
med with AZN-CK18B 18 as a primary antibody. 
Monocyte/macrophage and MoDC isolation and culture
MoDC were cultured using essentially the same protocol as described previously 13, 
31. In brief, peripheral blood mononuclear cells were isolated from venous blood by 
density gradient centrifugation over Ficoll-Hypaque (Amersham Biosciences, Roo-
sendaal, Th e Netherlands). Th e interphase was collected and washed with citrated 
phosphate buﬀ ered saline, and the cells were allowed to adhere for 1 hour at 37°C 
in RPMI-1640 (Life Technologies, Breda, Th e Netherlands) supplemented with 2% 
human serum in culture plates (Costar, Badhoeverdorp, Th e Netherlands). Adherent 
cells were cultured in RPMI-1640 Dutch modiﬁ cation supplemented with 10% fetal 
calf serum L-glutamine  (Life Technologies, Breda, Th e Netherlands) and antibiotic-
antimycotic agents (Life Technologies, Breda, Th e Netherlands) (culture medium) in 
the presence of IL-4 (500 U/ml; Strathmann Biotech, Hamburg Germany) and gra-
nulocyte monocyte-colony stimulating factor (GM-CSF) (800 U/ml; R&D systems, 
Minneapolis USA) for 6 days. Fresh culture medium with the same supplements was 
added at day 3, and then iDC were harvested at day 6. To generate mature DC, im-
mature DC were re-suspended in a concentration of 0.5x106/ml in fresh IL-4 and 
GM-CSF containing culture medium. Immature DC were then stimulated with cyto-
kines or maturation stimuli in the presence of IL-4 and GM-CSF. DC were harvested 
aft er another 48 hours of culture. For CCL18 measurements in supernatant of cells 
stimulated with TLR ligands, aliquoted culture supernatant from previous experi-
ments was used 30. 
For the culture of monocytes/macrophages, CD14+ cells were isolated with magnetic 
cell sorting and separation (MACS). In brief, mononuclear cells were labelled with 
anti CD14 microbeads (Miltenyi Biotec, Amsterdam, the Netherlands) and incubated 
for 30 minutes at 4°C. CD14 positive cells were then separated from the other cells 
using a MACS column (Miltenyi Biotec, Amsterdam, the Netherlands) according 
to the manufacturers instructions. CD14+ cells were cultured in a concentration of 
0.5x106 cells/ml in culture medium for up to 6 days. Where appropriate, fresh culture 
medium was added on day 3. Aft er 6 days, supernatant was collected for ELISA and 
cells were prepared for FACS analysis. In some additional experiments, monocytes/
macrophages were cultured for three days in the same concentration and in the same 
54
media in teﬂ on bags 32 or in rotation discs (Cellon, Luxembourg) 33 to prevent adhe-
rence of the cells. In experiments in which monocytes/macrophages were stimulated 
with RA SF, the cells were cultured for three days in the presence of 100 μl RA SF. 
Cells were then harvested and re-suspended in fresh culture medium without SF, but 
with the cytokines that were present in the ﬁ rst three days. Anti-IL-10 or anti-IL-13 
neutralizing antibodies were only present during the ﬁ rst three days.
Immuno histochemistry
For immuno histochemistry, frozen ST was cut into 7 μm sections and mounted on 
slides, air-dried, and stored at -80°C. Before staining, the cryosections were air-dried, 
ﬁ xed in acetone for 10 min and air-dried again. Th e sections were then stained with 
5μg/ml mouse anti human CCL18 or isotype control at 37°C for 1 hour at room 
temperature (RT) and washed in PBS. Endogenous peroxidase was blocked with 
0.3% H2O2/methanol. Aft er another wash-step, the sections were incubated with 
a biotin-conjugated horse anti-mouse antibody at RT for 30 min. Next, the samples 
were washed and incubated with avidin-biotin-HRP complex (Vector, Burlingham, 
UK) at RT for 20 min. Next, the section were stained with diaminodenzidine (DAB) 
(Sigma, Zwijndrecht, the Netherlands). Finally, sections were then counterstained 
with hematoxylin, rehydrated and mounted in to allow microscopic evaluation of 
the samples.
Fluorescence-Activated Cell Sorter (FACS) analysis
Th e phenotype of cells was characterized by using ﬂ ow cytometry techniques (FACS). 
For this aim, cells were harvested and collected by means of centrifugation and further 
processed on melting ice. Cells were diluted in buﬀ er solution (PBS with 1% bovine 
albumine, pH 7.4) in a concentration of 1106  cells/ml and plated in v-shaped 96 wells 
plates (1105 cells per plate). Cells were labeled with monoclonal mouse- or goat anti 
human antibodies or mouse-isotype control (goat IgG for IL-13RαII) and incubated 
at a temperature of 4°C for  45 minutes. Cells were then washed and labeled with 
goat-anti-mouse (or rabbit anti-goat when appropriate) FITC (Zymed Laboratories, 
South San Francisco, USA) as a secondary antibody. Aft er another 30 minute in-
cubation at 4°C, cells were again washed, diluted in buﬀ er solution and transferred 
into FACS tubes. Cells were gated according to their forward and side scatters and 
ﬂ uorescence was measured with a FACSCalibur® (Becton-Dickinson, San Jose, USA) 
and Cellquest® soft ware.
Enzyme Linked Immuno Sorbent Assay (ELISA)
For the detection of CCL18 protein levels of CCL18 in supernatant, a sandwich 
ELISA was performed as described previously 18, 34. In brief, maxisorb ELISA plates 
(Nunc, Roskilde, Denmark) were coated overnight with 50 μl/well 1 μg/ml capture 
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antibody in PBS. Next, the plates were washed 3 times with PBS and blocked with 300 
μl 1% Bovine Albumin (Sigma, Zwijndrecht, the Netherlands) in PBS for a minimum 
of 1h at RT. Aft er washing 3 times with ELISA wash buﬀ er (PBS containing 0.05% 
Tween-20), the plates were incubated with 50 μl/well of serial dilutions of the sample 
for 2 hrs at RT. Serial dilutions of rhCCL18 were used to obtain a standard curve. Af-
ter washing 3 times with ELISA wash buﬀ er, the plates were incubated with 50 μl/well 
of 0.05 μg/ml secondary antibody at RT for 1 hr. Th ereaft er, the plates were washed 3 
times with ELISA wash buﬀ er, and incubated with 50μl /well of streptavidin conjuga-
ted to Poly-Horse Radish Peroxidase (CLB, Amsterdam) for 20 minutes at RT. Aft er 
washing 3 times with ELISA wash buﬀ er, the presence of HRP was detected using 
50 μl/well 3,3’,5,5-tetramethylbenzidine (TMB) (Biomerieux, Marcy l’Etoile, France) 
diluted in peroxide buﬀ er (UP) (Biomerieux, Marcy l’Etoile, France). Th e reaction 
was stopped with 50 μl/well 2,5M H
2
SO
4
. Absorbance was measured at 450 nm using 
a Magellan Tracker V4.XX (Tecan Austria GMBH). As an internal control for inter-
assay variability, a sample of pooled normal human serum (n=300) was taken along 
in all assays. Th e maximal accepted inter-assay variability is 10%. Th e detection limit 
of the ELISA is 100 pg/ml.
Statistical analysis
CCL18 production levels by monocyte derived cells upon diﬀ erent stimulations were 
compared with a Wilcoxon Signed Rank test.  p-values < 0.05 were considered sig-
niﬁ cant.
Results
IL-10 strongly enhances CCL18 production by MoDC while maturation and pro-in-
ﬂ ammatory mediators do not.
First we investigated whether several mediators that are known to be important in 
RA were able to enhance CCL18 production by MoDC. In line with previous studies, 
unstimulated immature DC (iDC) produced signiﬁ cant amounts of CCL18 19. Inte-
restingly, incubation with TNF-α, IL-1β, IL-13, IL-15, IL-17, IL-18 and IFN-γ did not 
stimulate CCL18 secretion when added to day 6 iDC (n=6). In contrast, the anti-in-
ﬂ ammatory IL-10 strongly induced CCL18 production by iDC (p=0.03) (ﬁ gure 1a). 
Next we tested whether factors well known to induce maturation or T cell mimicking 
could induce CCL18 production. Th ese experiments demonstrated that LPS, CD40L 
and RANKL did not enhance CCL18 production (n=3) (ﬁ gure 1b). Recent studies 
demonstrated that other TLR pathways than TLR4 are all capable of inducing DC 
maturation, but have diﬀ erent eﬀ ects on cytokine production 30, 35, 36. However, stimu-
lation of TLR2 (pam3cys), TLR3 (poly (i:c)), TLR4 (LPS) or TLR7/8 (R848) did not 
sort any eﬀ ect on CCL18 secretion (n=6) (ﬁ gure 1c), whereas they did elicit a potent 
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cytokine response 30. Since IL-13 is more abundantly present in RA than IL-4 and 
since some conﬂ icting results have been published on CCL18 production induced by 
LPS when DC were cultured with IL-13 vs. IL-4, we compared these culture methods 
(n=6). In both the IL-4 and IL-13 cultures, IL-10 strongly induced CCL18 (p=0.03 
for both IL-4 and IL-13 culture), while LPS again did not (ﬁ gure 2). In addition, IL-
10 in combination with LPS was not signiﬁ cantly diﬀ erent from IL-10 alone (ﬁ gure 
2). Also co-stimulation with LPS and the cytokines tested (as in ﬁ gure 1) did not sort 
any eﬀ ect on CCL18 secretion (data not shown).
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Figure 1. 
IL-10 induces CCL18 secretion by monocyte derived dendritic cells.
Panel A depicts CCL18 secretion by MoDC (cultured with IL-4 and GM-CSF) upon stimulation with TNF-alpha�, 
IL-1beta� , IL-10 , IL-13 , IL-15 , IL-17 , IL-18 (all 20 ng/ml) and IFN-gamma� (10 ng/ml) (n=6). Panel B depicts 
CCL18 secretion by MoDC upon stimulation with  LPS (2µg/ml), CD40L or RANKL (20 ng/ml) (n=3). Panel C depicts 
CCL18 secretion upon stimulation upon TLR2 (pam3cys, 10 µg/ml), TLR3 (poly (i:c), 25 µg/ml), TLR4 (LPS,  2 µg/
ml) or TLR7/8 (R848, 1 µg/ml) mediated stimulation (n=5)  In all experiments, a direct comparison was made with 
unstimulated cells. The bars represent the mean (±SEM) CCL18 secretion in pg/ml . 
* represents a p-value of <0,05 (Wilcoxon Signed Rank test)
IL-10 acts in synergy with IL-4 /L-13 in promoting CCL18 production by monocytes.
MoDC and alternatively activated MΦ (AaMΦ) 37, 38 are known to produce CCL18. 
Both these cell types originate from CD14+ monocytes and depend on IL-4 or IL-13 
(in combination with GM-CSF for MoDC) for their diﬀ erentiation. To determine 
whether CCL18 secretion by myeloid cells is dependent on these cytokines, mono-
cytes were freshly isolated and stimulated with GM-CSF, IL-4, IL-13 and IL-10 alone 
or in combinations (n=6). Even aft er 6 days, unstimulated and GM-CSF treated mo-
nocytes/macrophages did not secrete CCL18, whereas both IL-4 and IL-13 stimula-
tion resulted in a clear secretion of CCL18, which is in line with previous ﬁ ndings 
on AaMΦ 16. Interestingly, stimulation with IL-10 alone only had a minimal eﬀ ect 
on CCL18 production by these monocytes/macrophages. When IL-10 was provided 
together with IL-4 or IL-13, this resulted in 3- and 2-fold increase in CCL18 secre-
tion respectively (ﬁ gure 3). Interestingly, already in low concentrations, IL-10 had 
its synergistic eﬀ ect with IL-4 (ﬁ gure 4a). In order to rule out eﬀ ects of adherence, 
we cultured CD14+ monocytes/macrophages for three days in teﬂ on bags 32 and in 
rotation discs 33. Th e morphology of these cells was comparable with freshly isolated 
monocytes according to their forward/side scatter pattern (data not shown). In both 
cultures, IL-4 did still induce CCL18 production in the same way as the cultures in 
24-wells plates (ﬁ gure 4b). As a proof of principle, we next tested whether the sy-
nergy between IL-4/IL-13 and IL-10 could already be observed aft er only 24 hours. 
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Figure 2. 
Similar pattern of CCL18 production by IL-4 vs. IL-13 cultured monocyte derived dendritic cells.
Immature MoDC were initially cultured with either IL-4 or IL-13, in combination with GM-CSF.  On day 6, these im-
mature DC were stimulated for 48 hours with IL-10 (20 ng/ml), LPS (2µg/ml) or both. The bars represent the mean 
(±SEM) CCL18 (pg/ml) production/ml of 6 individual experiments.
* represents a p-value of <0,05 (Wilcoxon Signed Rank test)
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Intriguingly, we could indeed observe a clear CCL18 secretion aft er 24 hours upon 
stimulation of freshly isolated monocytes with IL-4/IL-13 and IL-10, whereas stimu-
lation with IL-4, IL-13 or IL-10 alone did only result in a minor or even undetectable 
CCL18 secretion (n=3) (ﬁ gure 4c). Since IL-10 appeared to synergize with IL-4 and 
IL-13, we investigated whether these cytokines could up-regulate each other’s recep-
tors, possibly resulting in enhanced signaling. Th is was not the case; IL-10 did not up 
regulate either the IL-4/IL-13 common receptor IL-4Rα1 or the speciﬁ c IL-13Rα2. 
Furthermore, IL-4 had no eﬀ ects on IL-10Rα (data not shown). 
RA synovial ﬂ uid enhances CCL18 secretion independently of IL-10 and IL-13.
We and others demonstrated CCL18 expression in RA ST in the lining and the peri-
vascular regions 10, 20. In ﬁ gure 5, we show a high CCL18 expression in RA synovial 
tissue (ﬁ gure 5a,b,c), which was preferentially located in both the synovial lining lay-
er and the peri-vascular regions. Intriguingly, CCL18 was also expressed in control 
synovial tissue, although not as abundant as in RA ST (ﬁ gure 5d,e,f). Notably, some 
parts of the sections were even negative for CCL18, which is in sharp contrast with 
RA. In order to explain the abundant CCL18 expression in RA, we tested whether in-
cubation with RA SF could induce CCL18 production on monocytes/macrophages. 
Since RA SF itself contains CCL18 18, 20, we cultured freshly isolated monocytes for 3 
days in the presence of SF, washed the cells and cultured on for another 3 days in the 
absence of RA SF (n=6). Firstly, this pre-incubation with RA SF resulted in marked 
CCL18 production (mean 676 (±151) pg/ml) (ﬁ gure 6b). Secondly, culture of freshly 
isolated monocytes in the presence of RA SF,  resulted in a 9- and 10-fold increase in 
CCL18 secretion upon stimulation with IL4/IL-13 respectively and a 22-fold increase 
compared with IL-10 alone (ﬁ gure 6a). Intriguingly, this synergistic eﬀ ect with IL-4, 
IL-13 and IL-10 could still be observed aft er 3 days of culture in the complete absence 
of RA SF (ﬁ gure 6b), indicating that the cell does not require a continuous stimula-
tion in order to secrete CCL18. To exclude intrinsic diﬀ erences between monocytes/
macrophages from RA patients and controls may contribute to the eﬀ ects on CCL18 
secretion, we tested whether monocytes/macrophages from RA patients (n=3) res-
ponded diﬀ erently to combinations of IL-4, IL-13, IL-10 and SF. No diﬀ erence in the 
CCL18 secretion pattern was observed between monocytes/macrophages of healthy 
controls and RA patients upon these stimuli (data not shown), ruling out intrinsic 
diﬀ erences in monocytes in RA that aﬀ ect CCL18 secretion.
Since the synergy caused by RA SF appeared similar to the synergy between cyto-
kines we already observed (ﬁ gure 4), we tested whether IL-10 and/or IL-13, both 
present in RA SF, were responsible for this phenomenon by blocking these cytokines 
with neutralizing antibodies. Th e potency of these antibodies was ﬁ rst tested by de-
termining their ability to inhibit the synergistic CCL18 secretion upon stimulation 
with a combination of IL-10 and IL-4/IL-13. Addition of anti-IL-10 resulted in a 73 % 
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inhibition of the synergy between IL-4 and IL-10 and anti IL-13 completely abroga-
ted the synergistic eﬀ ect of IL-13 with IL-10 (ﬁ gure 6c). Unexpectedly however, bloc-
kade of IL-10 or IL-13 in SF in the presence of IL-4 or IL-13 and IL-10 respectively 
did not inhibit the synergy between these cytokines and SF (ﬁ gure 6a&b), suggesting 
that SF contains a yet unidentiﬁ ed factor that triggers CCL18 secretion.
Discussion
In this study, we add new pieces to the complicated puzzle of CCL18 regulation in 
RA. Firstly, we demonstrate that CCL18 production can be induced by IL-4, IL-13 
and IL-10 in monocyte derived cells. Secondly, we show that a large panel of pro- in-
ﬂ ammatory stimuli and TLR mediated signals leading to DC maturation are of no in-
ﬂ uence on CCL18 production. Th irdly, IL-10 only induces a minor CCL18 secretion, 
but acts in synergy with both IL-4 and IL-13 on monocytes and monocyte derived 
cells. Finally, we provide evidence that RA SF is able to induce CCL18 secretion in 
strong synergy with IL-4, IL-13 and IL-10, which could not be inhibited by a bloc-
kade of IL-10 and IL-13. 
Figure 3. 
Synergistic effect on CCL18 secretion by monocytes upon stimulation with IL-4/IL-13 in combination with IL-10. 
MACS isolated monocytes were cultured for 6 days and stimulated on day 1 with IL-4 (500U/ml), IL-13 (20 ng/ml), 
IL-10 (20 ng/ml) or a combination of the cytokines. The bars represent the mean (±SEM) CCL18 (pg/ml) of 6 indivi-
dual experiments. In all experiments, a direct comparison was made with unstimulated cells. ND= not detectable
* represents a p-value of <0,05 (Wilcoxon Signed Rank test)
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CCL18 can be produced by MoDC as well as by certain types of MΦ. Oft en these 
cell types are considered to be totally diﬀ erent cells. However, the diﬀ erences bet-
ween MoDC and AaMΦ are not that large, since monocyte derived macrophages 
are cultured in the presence of GM-CSF by some groups 39 and both cells require the 
presence of IL-4 or IL-13. Penna and co workers demonstrated that several in vivo 
DC subtypes were not able to produce CCL18 40, which is in contrast with previous 
ﬁ ndings, where CCL18 mRNA expression was found on CD11c+ myeloid blood DC 
28. Moreover, in vitro cultured MoDC have been identiﬁ ed as potent CCL18 produ-
cers 18, 19. Th ese data suggest that a CD14+ monocyte origin in combination with a 
stimulation by IL-4/IL-13 is critical for CCL18 secretion. Th is hypothesis is streng-
thened our data, demonstrating that non-adherent monocytes /macrophages were 
able to produce CCL18 under the inﬂ uence of IL-4. In addition, the synergistic ef-
fects of IL-4/IL-13 and IL-10 on CCL18 secretion by freshly isolated monocytes were 
already clearly visible aft er 24 hours. Th is indicates that a full diﬀ erentiation into DC 
or MΦ is not essential for CCL18 production as has been suggested previously for 
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Figure 4. 
Synergistic CCL18 production by monocytes upon stimulation with IL-4 and IL-10 can be induced rapidly and by 
low concentrations of IL-10
Panel A depicts CCL18 secretion by monocytes upon stimulation with different doses of IL-10 in the presence of IL-
4. Panel B represents CCL18 secretion by monocytes that were cultured for three days in the presence or absence of 
IL-4 in teﬂ on bags or rotation discs to prevent adherence. Panel C depicts CCL18 secretion by monocytes that were 
cultured for 24 hours with no stimulation or in the presence of IL-4, IL-13, IL-10 or a combination of IL-4/IL-13 with 
IL-10. The bars in panel A and B represent the mean CCL18 (pg/ml) of duplicates of 1 individual experiment and 
panel C shows the mean (±SEM) of 3 separate experiments. ND= not detectable
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CCL18 mRNA expression 16. Th us monocytes rapidly secrete CCL18 upon triggering 
with the right stimuli. 
In the literature there is still some controversy regarding the eﬀ ect of DC maturation 
on CCL18 production. Vulcano and co workers suggested that DC down regulate 
their CCL18 secretion upon maturation 19. Th is is in contrast with results from other 
studies, where maturation caused an increased mRNA expression 10, 27, 28. A simi-
lar contrast between protein and mRNA was found on blood DC 28, 40. Th e reason 
for these diﬀ erences between mRNA expression and protein secretion patterns still 
needs to be investigated in detail. Recently, we already provided evidence that DC 
maturation does not inﬂ uence CCL18 protein secretion 18, which is further streng-
thened by the data from the present study, in which diﬀ erent TLR stimulatory pa-
thways did not induce CCL18 production, whereas full DC maturation was achieved 
30. Also TNF-α and CD40L, both well appreciated inducers of DC maturation 41, 42, 
did not enhance CCL18 production. Perhaps the discrepancy between the diﬀ erent 
Figure 5 
CCL18 expression in normal and RA synovial tissue.
Panel A and B depict 2 sections of control synovium, where CCL18 expression is expressed in parts of the lining and 
some perivascular regions. Panel D and E depict 2 representative synovial sections from RA where CCL18 is present 
in the lining and perivascular regions. Panel C and F represent isotype controls on RA synovium and that from healthy 
individuals  respectively.
reports is hidden in subtle diﬀ erences in culture conditions, which are diﬃ  cult to 
trace in the published data. Intriguingly, stimulation with IL-10 alone only lead to a 
marginal induction of CCL18 secretion by monocytes/macrophages, but did act in 
a strong synergy with IL-4 or IL-13.  Th e latter is not caused by an up regulation of 
the receptors IL-10Rα, IL-4Rα or IL-13Rα2 (data not shown). Probably intracellular 
pathways direct the synergy between these cytokines, which is an interesting topic 
that warrants further investigation. 
We showed that RA SF  induces CCL18 production and strongly synergizes with IL-
4, IL-13 and IL-10. Blocking studies revealed that neither IL-10 nor IL-13 in SF were 
responsible for this eﬀ ect. Th is suggests the presence of another, yet unidentiﬁ ed 
CCL18 inducing factor in RA SF. Another explanation for this fact might be the pre-
sence of inhibiting factors in SF that counter-regulate the eﬀ ects of IL-10 and IL-13. 
Th e identiﬁ cation of the factor in SF that drives the eﬀ ects on CCL18 secretion may 
provide important new insights to the pro- vs. anti inﬂ ammatory balance in RA. In 
order to ﬁ nd this factor in a complex ﬂ uid like SF, more knowledge on the pathways 
of CCL18 regulation is critical. Another intriguing observation from our study is the 
ﬁ nding that pre-incubation with SF lead to a sustained synergistic CCL18 secretion 
upon stimulation with IL-4, IL-13 and IL-10. Th is could be regarded as an “imprin-
ting eﬀ ect”, meaning that the cell’s previous environment determines the nature of 
response to stimuli, even when the cell is no longer in such an environment. Results 
from previous studies, in which we showed that MoDC from RA patients diﬀ er in 
phenotype and cytokine response from control DC aft er 6 days in culture might also 
be explained by such a phenomenon 31, 43. 
Upon the encounter of an antigen, DC normally mature and migrate to lymphoid tis-
sues in order to perform their task of antigen presentation to T cells. Immature DC 
or MΦ can also encounter naïve T cells in the periphery, which subsequently might 
result in tolerance 44. Th is peripheral tolerance is a critical mechanism to prevent auto-
immunity. A role for CCL18 in this part might explain the high expression of CCL18 
by alveolar MΦ 15, 16, which are located at a site where the maintenance of tolerance to 
non-pathogenic antigens, that are constantly present, is crucial. Also the synergistic 
eﬀ ect on CCL18 secretion that we found with IL-10, a cytokine that is well appreciated 
as a pivotal regulator of the immune system, ﬁ ts in this picture. Th e synovial lining 
in the joints has similarities with the alveolar lining in the lung. Th ey both consist 
of MΦ-like cells and both form a barrier to a site in which self- and non-pathogenic 
antigens are constantly present. Th e disease process in RA is considered to be driven 
by pro inﬂ ammatory cytokines such as IL-1β, TNF-α, IL-17 and IL-18 45-50, whereas 
CCL18 is regulated by IL-10, IL-4 and IL-13. It is therefore tempting to speculate that 
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Figure 6
CCL18 production by monocytes upon stimulation with RA synovial ﬂ uid
Panel A. Monocytes/macrophages were cultured for three days. A part of the cells were incubated with IL-10, IL-4 
or IL-13 alone (left side of the ﬁ gure) and another part was incubated with these cytokines in the presence of RA SF 
(right side of the ﬁ gure). Half of the latter were also incubated with neutralizing antibodies against IL-10 and IL-13 
or both, which is shown by the white, gray and checked bars respectively in panel A. The bars represent the mean 
CCL18 pg/ml from 6 separate experiments. ND= not detectable
Panel B. The cells were then washed and only the cytokines were added again to the fresh medium. After another 3 
days, supernatant was measured again. The left side of the ﬁ gure shows the CCL18 production upon stimulation with 
IL-4, IL-13 and IL-10. The right side shows the production upon stimulation with these cytokines by cells that have 
been pre-incubated with SF for three days, in the presence or absence of anti IL-10, anti IL-13 or both (white, gray 
and checked bars respectively). ND= not detectable
* represents a p-value of <0,05 (Wilcoxon Signed Rank test)
Panel C. The potency of neutralizing antibodies against IL-13 and IL-10 was tested by investigating their ability 
to inhibit the synergy between IL-13 and IL-10 and IL-4 and IL-10. The bars represent the mean (±SEM) CCL18 
secretion (pg/ml).
the high CCL18 expression in RA is designed to uphold peripheral tolerance, which 
however seems to fail. Th is failure might be explained in two ways. Th e ﬁ rst explana-
tion might be that the skewing in the balance towards Th 1 is still present despite the 
upregulation of anti inﬂ ammatory mediators. Secondly, mature DC are present in the 
synovial tissue in perivascular regions and secondary lymphoid organs 3, 51, which is in 
sharp contrast with healthy synovial tissue. Th erefore an explanation for the ongoing 
immune process might be that these mature DC direct naïve T cells towards a pheno-
type that drives the pro-inﬂ ammatory immune response in the synovial tissue.  
Conclusions
In summary, we provide evidence that monocyte derived cells produce CCL18 under 
the inﬂ uence of IL-4 and IL-13. IL-10 acts in strong synergy with IL-4 and IL-13 as a 
key regulator of CCL18 production by monocytes, which indicates that CCL18 secre-
tion is not conﬁ ned to fully developed DC and MΦ. In addition, the eﬀ ects of IL-4, 
IL-13 and IL-10 are strongly enhanced by RASF, which is due to yet unidentiﬁ ed fac-
tors. Both the in vivo expression pattern and the contributing factors to its regulation 
in vitro are suggestive for a role for CCL18 in the regulation of the immune system, 
both in health and auto-immune diseases such as RA.  
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Abstract
Objective: Directional migration of leukocytes is orchestrated by the regulated ex-
pression of chemokine receptors and their ligands. Th e receptor CXCR6 is abun-
dantly expressed by Th 1-polarized eﬀ ector/memory lymphocytes accumulating at 
inﬂ ammatory sites. Th is study was undertaken to examine the presence of CXCR6+ 
T cells and of CXCL16, the only ligand for CXCR6, in the joints of patients with 
rheumatoid arthritis (RA). 
Methods: Flow cytometry analysis was used to examine the expression of CXCR6 by 
peripheral blood and synovial ﬂ uid (SF) T cells. In addition, by performing conven-
tional and real-time RT-PCR, immunohistochemistry and ELISA we determined the 
expression of CXCL16 and its protease ADAM-10 within synovium and by cultured 
macrophages. SF T cell migration was studied with the Transwell system.
Results: Accumulation of CXCR6+ T cells within RA SF coincided with highly eleva-
ted levels of CXCL16+ macrophages. In vitro studies revealed that monocytes start to 
express CXCL16 upon diﬀ erentiation into macrophages and that RA SF and tumor 
necrosis factor (TNF) enhanced CXCL16 expression. Moreover, RA patients respon-
ding to anti-TNF therapy show a strongly decreased CXCL16 expression, whereas 
non-responding patients did not. Interestingly, ADAM-10, a recently identiﬁ ed pro-
tease of CXCL16, was abundantly expressed by CXCL16+ macrophages in vitro and 
in RA in vivo, resulting in increased levels of cleaved CXCL16 in RA SF relative to 
controls. Finally, CXCR6+ T cells from RA SF are attracted by CXCL16. 
Conclusion: Th ese data provide evidence that enhanced production of CXCL16 in RA 
synovia leads to recruitment of CXCR6+ memory T cells, thereby contributing to the 
inﬂ ammatory cascade associated with RA pathology.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune which is characterized by a 
chronic inﬂ ammation of multiple synovial joints. Large numbers of leukocytes inﬁ l-
trate and accumulate within the synovial tissue (ST) and synovial ﬂ uid (SF) 1-3. Th ese 
leukocytes include T cells, especially CXCR6+ memory T cells, monocytes, plasma 
cells and granulocytes. While in most patients these cells are dispersed throughout 
the synovium, in other patients highly organized lymphoid structures resembling 
germinal centers can be found 4. Although the cause of RA is still unknown, the 
recruitment and cytokine-induced activation of inﬂ ammatory cells is thought to be 
essential in perpetuation of the inﬂ ammatory response and, ultimately, in cartilage 
and bone destruction 5-7.
Th e traﬃ  cking of leukocytes is regulated through selective expression of an array of 
chemokines, adhesion molecules and their corresponding receptors. Chemokines are 
secreted proteins that attract leukocytes via activation of 7-transmembrane-domain 
G-protein-coupled receptors 8, 9. Adhesion molecules provide adhesive capacity du-
ring cell-extracellular matrix or cell-cell contact, e.g., when leukocytes transmigrate 
the endothelium 10, 11. In this respect CXCL16 is an exceptional chemokine, because it 
has the potential to function as a chemoattractant and as an adhesion molecule. While 
classical chemokines are expressed as small soluble proteins, CXCL16 is ﬁ rst synthe-
sized as a transmembrane protein expressed by macrophages (MΦ), dendritic cells 
(DC) and endothelial cells 12-14. Data from Shimaoka et al 15 have recently suggested 
that cell-surface-expressed CXCL16 can indeed function as an adhesion molecule. 
However, upon cleavage by proteases the extracellular domain is released as a soluble 
chemokine that attracts eﬀ ector/memory T cells that express CXCR6, the receptor 
for CXCL16 12, 14. Furthermore, CXCL16 also acts as a scavenger receptor for oxidized 
LDL and bacteria 13, 16, 17, conﬁ rming that CXCL16 is a multifunctional protein. Con-
cerning structure and mechanism of action CXCL16 resembles the other transmem-
brane chemokine: fractalkine. Also fractalkine has been shown to mediate adhesion 
in its transmembrane form, and to mediate chemotaxis as a cleaved protein 18-20.
Kim and colleagues recently reported the accumulation CXCR6+ T cells  in SF of a 
small number of RA patients 21. As yet, however, nothing is known about the expres-
sion of CXCL16, the only known ligand for CXCR6, in RA joints. Th erefore, we ana-
lyzed the expression of CXCL16, its recently characterized protease ADAM-10, and 
CXCR6 in vitro and in vivo within healthy joints and in the joints of RA patients. Our 
data demonstrate that expression of CXCL16 and ADAM-10 is strongly enhanced in 
RA synovial, resulting in the recruitment and accumulation of CXCR6+ memory T 
cells in RA joints. Th ese data imply an important role for CXCL16-CXCR6 in syno-
vial inﬂ ammation that is strongly associated with RA pathogenesis.
72
Patients and methods
Patients and samples
ST, SF and peripheral blood were obtained from a total of 43 RA patients attending 
either the Department of Rheumatology or the outpatient clinics of the University 
Medical Center (UMC) Nijmegen. All patients fulﬁ lled the American College of 
Rheumatology criteria for RA 22 and gave informed consent for the study. Th e di-
sease activity was assessed using the disease activity score for 28 joints (DAS28) 23. 
For the present study, ST, obtained from RA patients (n=13) scored as having very 
active RA (DAS28 > 5.1), was compared with that from healthy individuals (n=5). In 
addition, SF was obtained from 17 RA patients with active disease, 5 osteoarthritis 
(OA) patients and 2 controls with trauma injury. Th erapeutic regimens of all RA 
patients were recorded before blood sampling. Patients receiving either prednisolone 
or biologic therapies, such as anti tumor necrosis factor (anti-TNF) or interleukin 
1 (IL-1) receptor antagonist, within 6 weeks prior to the study were not included 
in the current analysis. For immunohistochemical analysis, synovial biopsies from 
RA patients (n=13) were obtained using small needle arthroscopy. An average of 
20 biopsy samples was obtained from the medial and lateral suprapattelar pouch on 
each occasion. For comparison, ST from healthy controls (n=5) was obtained during 
arthroscopic procedures performed by orthopedic surgeons. During these procedu-
res, SF was isolated and collected when possible. In addition, we isolated peripheral 
blood mononuclear cells (PBMC) from a total of 18 healthy individuals. To analyze 
the eﬀ ect of TNF blocking therapy, ST was isolated from RA patients (n=6) before 
and 6 weeks aft er treatment with the human anti-TNF monoclonal antibody (ada-
limumab; 40 mg subcutaneously every other week). Th is study was approved by the 
Ethics Committee of the UMC Nijmegen.
Isolation of synovial ﬂ uid mononuclear cells
Synovial ﬂ uid mononuclear cells (SFMC) from resuspended RA SF were obtained 
by density gradient centrifugation over Lymphoprep (Axis-Shield, Oslo, Norway). 
SFMC in the interphase were collected, washed extensively with citrated phosphate 
buﬀ ered saline (PBS), and used immediately for ﬂ uorescence activated cells sorting 
(FACS) analyses and/or migration assays.
Generation of monocyte-derived macrophages
To generate MΦ, PBMC were isolated from buﬀ y coats by density gradient centri-
fugation over Lymphoprep (Axis-Shield). PBMC in the interphase were collected, 
washed extensively with citrated PBS, and allowed to adhere to plastic for 1 hour. 
Next, the peripheral blood lymphocytes (PBL) were washed away and the adhering 
monocytes were diﬀ erentiated into MΦ by culturing in RPMI 1640 (“Dutch mo-
diﬁ cation”) supplemented with L-glutamine and antibiotic-antimycotic (both from 
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Invitrogen, Breda, Th e Netherlands) plus 5% human serum (HS) (Sigma, Steinheim, 
Germany) for up to 10 days. Culture medium was refreshed every 3 days. Analysis by 
ﬂ ow cytometry demonstrated that these MΦ express high levels of CD14 and CD11c, 
intermediate levels of MHC class II and CD86, and no CD80 and CD209/DC-SIGN 
(data not shown). During some experiments, either freshly isolated monocytes or 
day 3 MΦ were cultured in the presence of RA SF or recombinant human TNF (Pe-
proTech, London, UK) for 2 days.
RNA isolation, RT-PCR, and real-time PCR
Total RNA was isolated from synovial biopsies or tonsil tissue sections using Trizol 
(Invitrogen) according to manufacturers description. Aft er treatment with DNase 
I (Roche Applied Science, Almere, Th e Netherlands), ﬁ rst-strand cDNA synthesis 
was performed by a standard reverse transcription reaction, using Moloney Murine 
Leukemia Virus reverse transcriptase (Invitrogen) and pd(N)6 random hexamers 
(Amersham Biosciences, Freiburg, Germany). Synthesis was performed at 20°C for 10 
min, 42°C for 45 min, 95°C for 10 min, followed by cooling-down at 4°C. As a negative 
control, the reaction was also performed in the absence of reverse transcriptase. PCR 
was performed with AmpliTaq DNA Polymerase (Applied Biosystems, Niewerkerk 
a/d IJssel, Th e Netherlands), 100 ng primer, 200 μM dNTPs (both from Amersham 
Biosciences) and 1.5 mM MgCl
2
 in PCR Buﬀ er (both from Applied Biosystems). Th e 
primers used for CXCL16 ampliﬁ cation were 5’-CCCGCCATCGGTTCAGTTCA-3’ 
and 5’-GTGGACTGCAAGGTGGACAG-3’, for ADAM-10 were 5’-CGGAACAC-
GAGAAGCTGTGA-3’ and 5’-AAGTCTGTGGTCTGGTAAATT GTATCA-3’, and 
for actin were 5’-GCTACGAGCTGCCTGACGG-3’ and 5’-GAGGCC AGGATG-
GAGCC-3’. PCR was started with a 5 min denaturation step at 95°C, aft er which am-
pliﬁ cation was performed in 30 cycles of denaturation at 95°C for 30 sec, annealing 
at 58°C for 30 sec, and elongation at 72°C for 30 sec. Aft er a ﬁ nal elongation step for 
10 min at 72°C, samples were cooled to 4°C and analyzed by electrophoresis in a 2% 
agarose gel containing ethidium bromide.
Quantitative real-time PCR was essentially performed as described previously 24. 
Brieﬂ y, ampliﬁ cations were performed with SYBR Green Master Mix on an ABI/
PRISM 7000 sequence detector system (both Applied Biosystems). Quantiﬁ cation of 
the PCR signals was performed by comparing the cycle threshold (Ct) value in dupli-
cate, of the gene of interest of each sample with the Ct values of the reference house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Furthermore, 
the housekeeping gene porphobillinogen deaminase (PBGD) was used as an internal 
control for the amount of cDNA in every individual. Th e primers (Eurogentec, Maas-
tricht, Th e Netherlands) used for CXCL16 real-time PCR were 5’-CTTCATTTTT-
TGCTGA TGGTTCC-3’ and 5’-GTCCCAGCACGGCACCT-3’, for GAPDH were 
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5’-GAAGGTGAAGGTCGGAGT-3’ and 5’-AGATGGTGATGGGATTTC-3’, and 
for PBGD were 5’-GGCAATGCGGCTGCAA-3’ and 5’-GGGTACCCACGCGAAT-
CAC-3’.
Antibodies
Next to the isotype controls mIgG1, mIgG2a, mIgG2b, (all from BD Biosciences, 
Alphen aan den Rijn, Th e Netherlands), rbIgG (Jackson ImmunoResearch Labo-
ratories, West Grove, PA), and gIgG (R&D Systems, Abingdon, UK), the following 
mAb were used (clone name given in parentheses): anti-human CXCR6 (56811.111) 
(R&D Systems), PE-conjugated anti-human CD3 (HIT3a) (BD Biosciences), anti-
human CD14 (RM052), PE-conjugated anti-human CD14 (RM052), anti-CD208/
DC-LAMP (104.G4) (all from Beckman Coulter, Mijdrecht, Th e Netherlands), 
anti-human CD31 (JC70A) (DAKO Cytomation, Glostrup, Denmark), anti-human 
CD45RO (UCHL-1) (BD Biosciences), and anti-human CD68 (EBM11) (DAKO Cy-
tomation). In addition, we used goat anti-human CXCL16 (R&D Systems), biotinyla-
ted rabbit anti-human CXCL16 (PeproTech), rabbit anti-human ADAM-10 (Serotec, 
Oxford, UK), biotinylated horse anti-mouse, biotinylated rabbit anti-rat, biotinyla-
ted horse anti-goat; biotinylated goat anti-rabbit (all from Vector, Burlingame, CA), 
FITC-conjugated goat anti-mouse (Zymed, South San Francisco, CA), PE-conjuga-
ted goat anti-rabbit (Caltag Laboratories, Burlingame, CA), AlexaFluor 647-conjuga-
ted donkey anti-goat, and AlexaFluor 647-conjugated goat anti-mIgG2b (both from 
Molecular Probes, Leiden, Th e Netherlands).
Immunohistochemistry
For immunohistochemistry frozen ST was cut into 7 μm sections, mounted on slides 
(SuperFrost; Fisher Scientiﬁ c, Pittsburgh, PA), air-dried, and stored at -80°C. Before 
staining cryosections were air-dried, ﬁ xed in cold acetone for 10 min, air-dried again, 
and washed with PBS. Endogenous peroxidase was blocked with 1% H
2
O
2
 plus 0.2% 
NaN
3
 in PBS at room temperature  for 10 min. Aft er washing with 0.5% BSA plus 0.01% 
NaN3 in PBS, sections were then stained with primary Abs at 37°C for 1 hour, followed 
by incubation with biotin-conjugated secondary Abs at room temperature for 30 min. 
Next, the samples were incubated with avidin-biotin-HRP complex (Vector) at room 
temperature for 45 min. Color was then developed with amino ethyl carbazole (Zymed, 
San Francisco, CA). Sections were counterstained with hematoxylin and mounted in 
Kaiser’s glycerin-gelatin solution (Merck, Darmstadt, Germany). ST sections were ana-
lyzed with a DM LB microscope (Leica, Wetzlar, Germany), and photographed using a 
DC300 camera and Twain Driver-soft ware (IM500) (both from Leica). All immunohis-
tochemical stainings were accompanied by appropriate isotype-matched controls. Per 
antibody staining at least 2 tissue sections per patient were microscopicaly examined by 
2 independent observers who were unaware of the patient’s identity and state.
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Flow cytometry
Staining of cell-surface proteins was essentially performed as described previously 
25. Brieﬂ y, cells were incubated with the primary Ab at 4°C for 30 min. Aft er wa-
shing, the cells were stained with ﬂ uorescently-labeled secondary Ab 4°C for 30 min. 
Propidium iodide was added to exclude dead cells. Flow cytometric analyses were 
performed on either a FACSCalibur or a FACScan with CellQuest soft ware (all from 
BD Biosciences).
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Figure 1
Expression of CXCR6 on T cells from patients with RA. A. FACS results: While a small percentage of peripheral blood 
T cells from RA patients (RA blood) express CXCR6, this chemokine receptor is widely expressed by RA SF T cells. T 
cells were stained for CXCR6 and CD3. The quadrants indicate the expression above the background. Dead cells were 
excluded by gating on propidium iodide-negative cells. Representative examples are shown. B: Percentage CXCR6+ T 
cells in control blood (C blood) (n=10), RA blood (n=4), and RA SF (n=6). Values are the maean and SD. ** = p<0.01. 
C: Expression of CXCL16 mRNA in control (C) ST and in synovia from RA patients (RA) was determined by RT-PCR 
using speciﬁ c primers. Tonsil mRNA (T) and water (W) were used as positive and negative controls, respectively. Re-
sults shown are representative of control synovial and RA synovia. D: Quantiﬁ cation of CXCL16 mRNA demonstrated 
a signiﬁ cantly enhanced expression in RA synovia (RA, n=6) compared with control synovia (C, n=4). Expression was 
determined by quantitative real-time PCR. CXCL16 levels were normalized to the levels of the house-keeping gene 
GAPDH. * = a p<0.05 versus controls.
CXCL16 sandwich ELISA
For the detection of soluble CXCL16 in serum, SF or culture supernatant, a sandwich 
ELISA was set up. Maxisorb ELISA plates (Nunc, Roskilde, Denmark) were coated 
overnight with 50μl/well of 1 μg/ml goat anti-human CXCL16 (R&D Systems) in 
PBS at 4°C. Next, the plates were washed 3x with PBS and blocked with 100 μl of 1% 
BSA in PBS for 1 h at 37°C. Aft er washing 3x with PBS containing 0.05% Tween-20 
(ELISA buﬀ er), the plates were incubated with serial dilutions of the samples (50 μl /
well) for 1 h at 37°C. Serial dilutions of recombinant human CXCL16 (R&D Systems) 
were used to obtain a standard curve. Samples and recombinant protein were diluted 
in 1% BSA in PBS. Aft er washing 3x with ELISA buﬀ er, the plates were incubated 
with 50 μl/well of 0.5 μg/ml biotinylated rabbit anti-human CXCL16 (PeproTech) in 
ELISA buﬀ er for 30 min at RT. Next, the plates were washed 3x with ELISA buﬀ er, 
and incubated with 50 μl/well of HRP-conjugated avidin-biotin complex (Vector) in 
ELISA buﬀ er for 30 min at RT. Aft er washing 3x with ELISA buﬀ er, and 1x with PBS, 
the presence of HRP was detected using 100 μl/well of 100 μg/ml 3,3’,5,5’-tetrame-
thylbenzidine (Sigma) in DMSO (ﬁ nal percentage 1%) diluted in 100 mM NaAc (pH 
4.5) buﬀ er. Th e reaction was stopped with 100 μl/well 800 mM H2SO4. Absorbance 
was measured at 450 nm using a 3550-UV Microplate Reader (BioRad, Hercules, 
CA). Th e detection limit of this ELISA is ~100 pg/ml.
Migration assays
Migratory responses of SF T cells were evaluated by using Transwell polycarbona-
te inserts (6.5 mm diameter) with 5 μm pores (Costar Corning, Cambridge, MA). 
SFMC were resuspended in RPMI 1640 (Invitrogen) containing 0.5% BSA (migrati-
on medium) and injected (250 X 103/100 μl) in the upper compartment of the Trans-
well. Serial dilutions of recombinant human CXCL16 (R&D Systems) were made in 
migration medium and added to the lower compartment (600 μl/Transwell). SFMC 
were allowed to migrate at 37°C in air with 5% CO
2
 for 90 min. Next, the inserts 
were discarded and 20% of the SFMC that had migrated were counted using a ﬂ ow 
cytometer as described previously 26. Th e remaining SFMC were stained for CD3 to 
determine the percentage of T cells by ﬂ ow cytometric analysis.
Statistical analysis
For statistical analyses we ﬁ rst logarithmically transformed the values from groups 
with a skewed distribution. Next, diﬀ erences between groups were calculated by 
using the two sample t test. p-values of less than 0.05 were considered signiﬁ cant.
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Results
SF from RA patients contains increased numbers of CXCR6+ memory T cells
Recent data demonstrated that the chemokine receptor CXCR6 is preferentially ex-
pressed by T eﬀ ector/memory cells involved in Th 1 responses and that CXCR6+ T 
Figure 2
Enhanced expression of CXCL16 protein within RA synovia. CXCL16 was expressed in the thin synovial lining (ar-
rowhead) of healthy synovia (A), but was much more pronounced by the hyperthrophic lining of RA synovia (B). Many 
cells present within the sub-lining of RA synovia express high levels of CXCL16 (B and C). Note that (cleaved) CXCL16 
was also associated with ﬁ laments of the extracellular matrix (B). Staining of serial sections indicated that expression 
of CXCL16 (E) correlated with the presence of CD68+ synovial macrophages�(F). We also detected CXCL16 within 
some vessels (G). Staining serial sections for CD31 conﬁ rmed that these cells were endothelial cells (H). In addition, 
many lymphocyte aggregates contain CXCL16+ cells (I). Analysis of stained serial sections suggested that these 
CXCL16+ cells were CD68+ macrophages (J) amidst CD45RO+ memory lymphocytes (K). Cryo-sections were stained 
for CXCL16 (A-C, E, G and I), CD68 (F and J), CD31 (H), or CD45RO (K), or matched control antibodies (D and I). 
All sections were counterstained with hematoxylin. Sections shown are representative for ST from 10 RA patients and 
5 controls. (Original magniﬁ cations x 400 in A-F, and I-L; x 630 in G and H).
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cells were enriched at sites of inﬂ ammation 21. Th erefore, we analyzed CXCR6 expres-
sion on T cells isolated from blood and SF of RA patients and healthy individuals. 
As shown in ﬁ gure 1a and 1b, both control PBMC (mean 8%) and RA PBMC (mean 
5%) contain only small numbers of CXCR6+ T cells. In contrast, up to 80% of the 
T cells within RA SF expressed CXCR6 (mean 32%), whereas little or no leukocytes 
could be detected in SF of controls (ﬁ gure 1a and b, and data not shown). RT-PCR 
analysis further conﬁ rmed that CXCR6 mRNA is indeed expressed by RA SF cells 
(data not shown). In two patients analyzed, the CXCR6+ T cells displayed a memory 
phenotype (CD3+CD45RO+) and about 52% of them was CD4+ and 48% CD8+ 
(data not shown). Th ese results thus conﬁ rm and extend the data reported by Kim et 
al. 21, and demonstrate that high numbers of CXCR6+ T cells speciﬁ cally accumulate 
in SF of RA patients.
Increased CXCL16 expression by RA synovial macrophages and endothelial cells
As yet, nothing is known about the expression of CXCL16, CXCR6’s only known 
ligand, in ST or SF. Th erefore, we ﬁ rst determined the expression of CXCL16 mRNA 
in RA ST or control ST by RT-PCR. RNA from a tonsil was included as a positive 
control. As shown in ﬁ gure 1c, a CXCL16 PCR product of the expected size was rea-
dily detected in both control synovia (n=3) and RA synovia (n=7), as well as in tonsil. 
Subsequent quantitative analysis demonstrated that CXCL16 RNA levels were signi-
ﬁ cantly increased in RA synovia (n=6) as compared to control ST (n=4) (ﬁ gure 1d). 
Next, we analyzed the expression of CXCL16 in situ by applying immunohistoche-
mistry on tissue sections from 10 RA and 5 control synovia. Th e results demonstrated 
that in control synovia the expression of CXCL16 was conﬁ ned to the single layer of 
synovial lining MΦ (ﬁ gure 2a). Synovial tissue from RA patients, however, showed a 
strong increase in the number of CXCL16+ cells that was most predominant in the 
thickened synovial lining and sub-lining (ﬁ gure 2b and c). Th e number of CXCL16-
expressing cells was directly related to the degree of cellularity of the ST (data not 
shown). Th e overlapping expression patterns of CXCL16 and the MΦ marker CD68 
conﬁ rmed that the CXCL16+ cells in the synovial lining were CD68+ MΦ (ﬁ gure 2e 
and f). Interestingly, while essentially all blood vessels in control synovia appeared 
CXCL16 negative (data not shown), some CD31+ blood vessels in RA-synovium 
expressed signiﬁ cant levels of CXCL16 (ﬁ gure 2g and h). In addition, CXCL16-ex-
pressing cells were also detected within perivascular lymphoid aggregates (Figure 2i). 
Staining of serial sections suggested that also the CXCL16+ cells that are surrounded 
by CD45RO+ memory lymphocytes are CD68+ MΦ (ﬁ gure 2i-k). Th ese results de-
monstrate that, due to increased numbers of MΦ and activated endothelial cells, the 
expression of the chemokine CXCL16 is highly increased in RA synovia compared 
with control synovia.
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Enhancement of CXC16 expression in macrophages by addition of RA SF or TNF
Next, we investigated the expression of CXCL16 by blood-derived monocytes and 
MΦ. Whereas freshly isolated monocytes did not express CXCL16 on their cell-
surface, upon diﬀ erentiation into MΦ, they rapidly began to express transmembrane 
CXCL16 and remained CXCL16+ for at least 10 days of culture (ﬁ gure 3a and b). 
Intriguingly, addition of RA SF to freshly isolated monocytes resulted in a signiﬁ cant 
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Figure 3
Strongly increased expression of CXCL16 by macrophages after exposure to RA SF or TNF. A: Peripheral blood 
monocytes were differentiated into macrophages and analyzed by ﬂ ow cytometry. CD14+ monocytes/ macrophages 
were gated and stained with anti-CXCL16 (bold lines) or isotype-matched control antibodies (thin lines). Dead cells 
were excluded by gating on propidium iodide-negative cells. B: Diagram showing the mean percentages of CXCL16+ 
macrophages at the time points indicated. C: Increasing levels of transmembrane CXCL16 on macrophages, with 
addition of increasing concentrations of RA SF or TNF to freshly isolated monocytes. At day 2, the percentage of 
CXCL16+CD14+ macrophages was determined by ﬂ ow cytometry. The mean and SD percentages from 2 donors 
are shown. Dead cells were excluded by gating on propidium iodide-negative cells. D: Signiﬁ cant levels of cleaved 
CXCL16 released by cultured  macrophages. By sandwich ELISA the supernatants of macrophages (MAC) or pe-
ripheral blood lymphocytes (PBL) cultured for 1, 2 or 3 days were analyzed for the presence of cleaved CXCL16. E: 
TNF induced expression of cleaved CXCL16. Culture supernatants of day 2 macrophages were analyzed by sandwich 
ELISA. Representative results out of 2-5 experiments are shown. * p<0.05, ** p<0.01, *** p<0.001 versus the 
unstimulated group. See ﬁ gure 1 for other deﬁ nitions.
and concentration-dependent increase in cell-surface-expressed CXCL16 (ﬁ gure 3c). 
Also TNF, one of the constituents of RA SF and a key protein in RA, was suﬃ  cient to 
increase the expression of transmembrane CXCL16. 
Because cleavage of CXCL16 is required to exert its chemotactic activity towards 
CXCR6-expressing lymphocytes, we also analyzed the MΦ culture supernatants for 
the presence of cleaved CXCL16. As shown in ﬁ gure 3d, while PBL cultures were 
essentially negative, signiﬁ cant amounts of cleaved CXCL16 were readily detected 
in the culture supernatant of day 1-3 MΦ. Moreover, mimicking the RA inﬂ amma-
tory environment through the addition of TNF, further signiﬁ cantly increased the 
amount of cleaved CXCL16 in the culture supernatant (ﬁ gure 3e). Because RA SF 
contains cleaved CXCL16 itself (see below) we did not measure soluble CXCL16 in 
the supernatant of RA SF-treated MΦ. 
To investigate the eﬀ ect of TNF on the expression of CXCL16 in vivo, we determined 
the CXCL16 expression in synovia of 3 RA patients who responded to the treatment 
and 3 non-responders. Th e synovial lining and sub-lining of all patients contained large 
amounts of CXCL16+ synovial MΦ within prior to treatment (ﬁ gure 4a and c). Intri-
guingly, CXCL16 expression was severely reduced in the clinically responding patients 
(compare ﬁ gure 4a with 4b) but not in the non-responding patients (compare ﬁ gure 4c 
with 4d). Taken together, these data demonstrate that TNF and RA SF, stimuli associated 
with synovial inﬂ ammation, increase the expression of CXCL16 in vitro and in vivo.
ADAM-10 expression in RA synovia coincides with the presence of cleaved CXCL16 in 
RA SF.
ADAM-10 has very recently been implicated in the cleavage of CXCL16 27, 28. Analy-
sis of monocytes and monocyte-derived  MΦ revealed  that transmembrane ADAM-
10, like CXCL16, was induced on day 2 MΦ  and is further upregulated by addition 
of RA SF (ﬁ gure 5a and b). Moreover, analysis of serial sections from RA ST showed 
that expression of the protease ADAM-10 overlapped completely with the CXCL16-
expressing MΦ in the hypercellular synovial lining (ﬁ gure 5f and g). RT-PCR analysis 
further conﬁ rmed that ADAM-10 mRNA was expressed by RA ST (data not shown). 
In control ST, ADAM-10 staining was limited to the thin synovial lining but still 
overlapped with the CXCL16 staining (ﬁ gure 5c and d).
To investigate whether the enhanced expression of both CXCL16 and ADAM-10 by 
synovial MΦ of RA patients results in elevated levels of cleaved CXCL16, we per-
formed ELISA on serum and SF from controls or patients with either OA or RA. 
Although cleaved CXCL16 was readily detectable in serum, we did not observe sig-
niﬁ cant diﬀ erences between sera from RA patients and healthy controls (data not 
shown). In contrast, analysis of SF demonstrated that RA SF contains signiﬁ cantly 
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more cleaved CXCL16 than SF from controls (ﬁ gure 6a). Interestingly, also SF from 
patients with the milder inﬂ ammatory disease OA contained less cleaved CXCL16 
than RA SF, although this diﬀ erence was not signiﬁ cant. Th ese data strongly suggest 
that the increase in CXCL16 and ADAM10 expressing MΦ  in RA ST also results in 
the release of high amounts of cleaved CXCL16 into the SF in vivo.
Cleaved CXCL16 attracts memory T cells from RA SF
Finally, we determined whether the large numbers of CXCR6+ T cells observed in 
RA SF were indeed functionally capable of responding to cleaved CXCL16. As shown 
in ﬁ gure 6b, RA SF derived T cells rapidly lose their CXCR6 expression upon incuba-
tion with increasing concentrations of cleaved CXCL16. Th ese data indicate that the 
CXCR6+ T cells derived from RA SF internalized CXCR6 upon binding of cleaved 
CXCL16 and thus are able to respond to CXCL16. Subsequent migration experi-
ments further conﬁ rmed that cleaved CXCL16 attracted RA SF T cells in a concen-
tration dependent manner (ﬁ gure 6c). Th ese results indicate that large numbers of 
RA SF T cells express functional CXCR6 allowing migration towards strong CXCL16 
sources like RA SF.
Discussion
Inﬂ ux of leukocytes, including CXCR6+ leukocytes, into both ST and SF contributes 
to the pathogenesis of RA. Here, we report that the chemokine CXCL16, the ligand 
for CXCR6, is normally expressed by MΦ in the thin lining of healthy synovia. In 
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Figure 4
Reduced CXCL16 expression upon successful anti-TNF treatment of RA patients. Before anti-TNF treatment, CXCL16 
is strongly expressed within RA synovia (A and C). Expression of CXCL16 is severely reduced in clinically responding 
patients (B), but not in non-responding patients (D). Synovia were isolated before (A and C) and after (B and D) anti-
TNF treatment. All cryo-sections were stained for CXCL16 and counterstained with hematoxylin. Control stainings were 
negative. Results are representative of 3 responding and 3 non-responding patients. (Original magniﬁ cations x 100). 
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RA synovia, CXCL16 expression is elevated and strongly increased due to the pre-
sence of large numbers of synovial MΦ. In addition, we show that these CXCL16+ 
MΦ strongly express the recently identiﬁ ed CXCL16 protease ADAM-10 in situ. In 
vitro studies demonstrated that monocyte-derived MΦ express both transmembrane 
and cleaved CXCL16 and that the expression is enhanced by RA SF and the pro-
inﬂ ammatory stimulus TNF. Moreover, only successful anti-TNF therapy is associ-
ated with decreased CXCL16 expression in situ. Finally, elevated expression of both 
CXCL16 and ADAM-10 by RA ST MΦ in situ is associated with high amounts of 
cleaved CXCL16 in RA SF and with the presence of signiﬁ cantly increased numbers 
of CXCR6+ T cells in this SF.
CXCL16 is a recently identiﬁ ed transmembrane chemokine expressed by MΦ and 
DC 12-14. Upon proteolytic cleavage, the NH2-terminal part of CXCL16 is released 
and functions as a soluble chemoattractant for CXCR6+ T cells and plasma cells 12, 
14. Interestingly, Kim et al reported that CXCR6+ is a marker for eﬀ ector/memory 
T cells and that large numbers of CXCR6+ T cells were detected in SF from 3 RA 
patients 21. Here, we extended these observations and added novel data concerning 
the expression and function of CXCR6’s only ligand CXCL16. First, we demonstrated 
that fresh control or RA PBMC contain only small numbers of CXCR6+ T cells (ﬁ -
gure 1a and b). In contrast, up to 80% of the T cells within RA SF expressed CXCR6. 
Immunohistochemical staining of RA ST for CXCR6 revealed no signiﬁ cant staining 
of T cells (data not shown). However, PCR analysis demonstrated that low levels of 
CXCR6 mRNA are also present within ST from RA patients (data not shown). Since 
chemokine receptors are generally expressed at relatively low levels, and we demon-
strated that CXCR6 is rapidly down regulated upon CXCL16 binding (ﬁ gure 6b), 
these data suggest that CXCR6 is diﬃ  cult to detect by immunohistochemistry. 
Quantitative analysis demonstrated that the expression of CXCL16 mRNA is incre-
ased in RA ST as compared to control ST (ﬁ gure 1d). Immunostaining revealed that 
in healthy individuals, CXCL16 is expressed by the single layer of cells that make up 
the synovial lining (ﬁ gure 2). In RA patients however, elevated expression of CXCL16 
is detected in the hypercellular synovial lining, while additional CXCL16+ cells are 
now detected in the sub-lining and within perivascular lymphocyte aggregates. 
Overall, CXCL16 expression correlated with increased cellularity of the RA synovia. 
Based on CD68/CXCL16 staining of serial sections and morphology, the CXCL16+ 
cells in the lining, sub-lining and lymphocyte aggregates mainly represent MΦ. Alt-
hough we did not observe co-localization of CXCL16 with the DC-marker CD208/
DC-LAMP (data not shown), we cannot exclude that some DC or follicular dendritic 
cells also express CXCL16. Finally, CD31/CXCL16 staining of serial sections implied 
that some endothelial cells express CXCL16 (ﬁ gure 2g and h). Th ese data are in line 
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with previous results demonstrating that cardiac and umbilical endothelial cells can 
express CXCL16 29, 30.
Furthermore, our in vitro studies show that a signiﬁ cantly larger population of MΦ 
expressed transmembrane CXCL16 upon addition of RA SF, or TNF, one of the major 
cytokines in RA SF, than controls (ﬁ gure 3). Moreover, TNF-treated MΦ also released 
increased amounts of cleaved CXCL16. Th is could be of signiﬁ cant importance, since 
TNF is strongly expressed in RA joints and is considered to be a key player in RA 
Figure 5
Enhanced expression of CXCL16 protease ADAM-10 by RA synovial macrophages. ADAM-10 negative peripheral 
blood monocytes were differentiated into macrophages and analyzed by ﬂ ow cytometry. A: CD14+ monocytes/ ma-
crophages were gated and stained with anti-ADAM-10 (bold lines) or isotype-matched control antibodies (thin lines). 
Dead cells were excluded by gating on propidium iodide-negative cells. Addition of RA SF to macrophages (day 3) 
increases their expression of ADAM-10 (B). After 2 days the percentage of ADAM-10+CD14+ macrophages was deter-
mined by ﬂ ow cytometry. The mean and SD percentages from 2 donors are shown. Dead cells were excluded by gating 
on propidium iodide-negative cells. * = p<0.05 versus controls. ST from controls showed expression of both CXCL16 
(C) and its protease ADAM10 (D) in the thin synovial lining. In contrast, expression of both CXCL16 (F) and ADAM10 
(G) was highly enhanced in the hypercellular synovial lining of RA ST. Frozen sections were stained for CXCL16 (C 
and F), ADAM-10 (D and G), or a matched control antibody (E), and counterstained with hematoxylin. Representative 
stainings are shown. See ﬁ gure 1 for other deﬁ nitions (Original magniﬁ cations x 400).
chapter 4    
85
pathogenesis 31. In fact, anti-TNF treatment is eﬀ ectively used in clinics worldwide 
to treat RA  32-34. Interestingly, we observed a severely reduced CXCL16 expression 
in synovial tissue from RA patients responding to anti-TNF treatment, but not in 
non-responding patients (ﬁ gure 4). Th ese data suggest that not only in vitro, but also 
in vivo the expression of CXCL16 is controlled by TNF. We are currently extending 
these studies with a larger cohort of RA patients receiving anti-TNF therapy.
Interestingly, highly elevated levels of cleaved CXCL16 were present in SF from RA 
patients, and this coincided with large numbers of ADAM-10+ MΦ  (Figures 5 and 
6). ADAM-10 has recently been described to be a major protease involved in the 
cleavage and release of CXCL16 27, 28. Th erefore, our data suggest that in RA, ADAM10 
expression by the thick layer of synovial lining MΦ is involved in the release of large 
amounts cleaved CXCL16 in the SF. We note that also signiﬁ cant amounts of CXCL16 
are detected in serum of healthy individuals, suggesting that cleavage of CXCL16 also 
occurs in steady-state conditions. Th is reasoning is in accordance with our observa-
tion that the synovial lining of healthy individuals does express low levels of both 
CXCL16 and ADAM-10. Since CXCL16 has been suggested to contain multiple res-
triction sites for proteases 12, 14, also other proteases, e.g. matrix metalloproteinases 
(MMP) or TNF converting enzyme (TACE), are likely to be involved in the cleavage 
of CXCL16. With respect to cleavage of CXCL16 in synovium, MMP-1 could be an 
interesting candidate since we have recently shown that this protease is abundantly 
expressed by RA synovial MΦ 35, 36.
Finally, we demonstrate that cleaved CXCL16 indeed activates CXCR6 expressed by 
RA SF T cells (ﬁ gure 6). First, addition of cleaved CXCL16 to these T cells leads to the 
loss of cell-surface CXCR6 suggesting CXCL16-mediated CXCR6 internalization. 
Ligand-induced activation and subsequent internalization is a common feature of 
chemokine receptors 37. Aft er being internalized some chemokine receptors recycle 
back to the cell membrane while others are degraded in the lysosomal compartment. 
As yet, it is not known how CXCR6 behaves aft er being internalized. However, we 
do demonstrate that CXCR6+ T cells isolated from RA SF are capable to migrate in 
response to CXCL16 in vitro (ﬁ gure 6c). Th erefore, our data imply that CXCL16 and 
CXCR6 play an important role in the recruitment of activated T cells into RA joints.
Several mouse studies have conﬁ rmed the importance of chemokines in RA develop-
ment in vivo. Administration of a CCL2/MCP-1 antagonist prevented the onset of ar-
thritis in the MRL-LPS arthritis model 38 and neutralizing CXCL10/IP-10 antibodies 
prevented adjuvant-induced arthritis 39. Also in RA patients, adhesion molecules and 
chemokines play important roles in synovial inﬁ ltration and RA pathogenesis. For 
instance, enhanced expression of adhesion molecules, e.g. E-selectin, VCAM-1 and 
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ICAM-1 33, 40, and various chemokines, including CCL2/MCP-1, CCL5/RANTES, 
CCL18/DC-CK1 and CXCL8/IL-8, have been detected in RA tissue and/or synovial 
ﬂ uid 41-48. Interestingly, therapy with a CCR1 antagonist has recently been shown to 
be beneﬁ cial in RA 49. Oral administration of this antagonist signiﬁ cantly reduced the 
number of ST macrophages and T cells, and this was correlated with a trend toward 
clinical improvement as compared to placebo-treated controls. Despite the apparent 
redundancy in the chemokine system, evidence is accumulating that chemokine and 
chemokine receptor antagonists have strong potential as therapeutic agents for pa-
tients with autoimmune disease 37, 50. Our data suggest that the use of either CXCR6 
antagonists or protease inhibitors acting on CXCL16 cleavage could be additional 
novel approaches to treat patients with RA.
Based on the results of this study, the following model for the role of CXCL16 – 
CXCR6 in RA pathogenesis can be envisaged. During inﬂ ammation of the joint, lo-
cally activated endothelial cells express increased levels of adhesion molecules and 
chemokines, resulting in enhanced immigration of monocytes. Within the synovial 
tissue these monocytes now become attracted by chemokines released by the synovial 
lining, and diﬀ erentiate into MΦ. Diﬀ erentiating MΦ start to express both CXCL16 
and ADAM-10, expression of which is further enhanced by SF from the synovial 
cavity, and/or by TNF released by the MΦ themselves. At the now thickened syno-
Figure 6
Cleaved CXCL16 is overexpression in RA synovial ﬂ uid and attraction of SF T cells. A: Expression of cleaved CXCL16 
in RA SF (n=17) was compared with that in SF from controls (n=2), or from patients with OA (n=5). CXCL16 con-
centrations were measured by sandwich ELISA. Values are the mean and SD. * = p < 0.02. B: Loss of cell-surface-
expressed CXCR6 on RA SF T cells induced by activation by cleaved CXCL16. The level of CXCR6 expressed by 
unstimulated T cells was set at 100%. C: SF T cells from RA patients are attracted by soluble CXCL16. Migration 
was concentration-dependent and reached an optimum at 10 ng/ml. Migration of RA SF T cells was determined in a 
Transwell migration assay. Migrating cells were counted and stained for CD3 and CXCR6. Representative results from 
3 experiments are shown. Values are the mean and SD. See ﬁ gure 1 for other deﬁ nitions.
vial lining, ADAM-10 cleaves transmembrane CXCL16 resulting in elevated concen-
trations of cleaved CXCL16 in the SF. Cleaved CXCL16  attracts large numbers of 
CXCR6+ memory T cells into the RA joint. Th ese memory T cells release cytokines 
like TNF that can now activate MΦ  and other resident cells, thus sustaining the in-
ﬂ ammatory cascade contributing to RA pathogenesis.
In conclusion, our data suggest that over-expression of CXCL16 targets CXCR6+ 
memory T cells to synovia from RA patients. Th erefore, CXCL16 and CXCR6 could 
be intrinsically involved in the inﬂ ammation associated with RA pathology. 
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Abtract
Objective: Th e chemokine CXCL16 is secreted by macrophages and dendritic cells 
to attract memory type T cells. CXCL16 expression is increased in arthritic joints of 
patients with rheumatoid arthritis (RA) and a role for CXCL16 has been suggested 
in the pathogenesis of RA. To date, little is known about the regulation of CXCL16 
on monocytes/macrophages and DC. Th e aim of this study was to elucidate how 
CXCL16 expression is regulated in healthy donors and patients with RA.
Methods: CD14+ cells were isolated from the peripheral blood or synovial ﬂ uid of 
RA patients and healthy controls, diﬀ erentiated into diﬀ erent types of dendritic cells 
or macrophages and stimulated with various cytokines or LPS. Cell surface proteins, 
including surface CXCL16,  were measured by ﬂ owcytometry and soluble CXCL16 
was measured by ELISA.
Results: Distinct types of dendritic cells constitutively express and secrete CXCL16, 
which is not aﬀ ected by maturation. Monocytes rapidly upregulate membrane-bound 
CXCL16 expression and release soluble CXCL16 upon culture. CXCL16 expression 
by monocytes is transiently inhibited by the TLR4 ligand LPS. Th 2 type cytokines 
inhibit soluble CXCL16, whereas Th 1 stimuli enhance its release. In RA monocytes/
macrophages, neither CXCL16 expression, nor CXCL16 regulation is diﬀ erent from 
healthy controls.
Conclusions: Culture of monocytes is the main trigger for CXCL16 surface expres-
sion in vitro, which is not altered in RA. Together our data suggest that the increased 
CXCL16 expression in patients with RA is likely to be caused by increased inﬂ ux of 
monocytes rather than intrinsic diﬀ erences in CXCL16 regulation. 
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Introduction
Rheumatoid arthritis (RA) is a chronic auto-immune disease, characterized by in-
ﬂ ammation of the joints, which eventually leads to cartilage and bone destruction. 
One of the hallmarks of the inﬂ ammatory process in RA is the migration of a variety 
of leukocytes towards the synovial tissue (ST).  Among these leukocytes, both anti-
gen presenting cells (APC) and T cells are regarded as important players in RA 1-3. T 
cells constitute a large group of lymphocytes that can be divided in an ever growing 
number of subsets. To date, it is still unclear which exact T cell subsets are most im-
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Figure 1:
CXCL16 expression and secretion by MoDC
Panel A shows surface expression of CXCL16 (shaded) vs. goat IgG (dotted) for immature DC (left side) and mature DC 
matured with 2 µg/ml LPS (right side) at day 8. One representative ﬁ gure of 10 individual experiments is shown. The 
accompanying Mean Fluorescence Intensity (MFI) is shown in de ﬁ gure. Panel B shows the mean (±SEM) CXCL16 
secretion of 6 individual cultures upon maturation with LPS for 48 hours. The mean (±SEM) CXCL16 secretion of 6 
individual experiments is shown.
portant in RA. However, the abundance of CD45RO+ lymphocytes in RA synovial 
ﬂ uid (SF) 4 suggests that activated, memory type T cells might play a signiﬁ cant role 
in RA. Th e nature of T cell mediated immune responses is largely orchestrated by 
their interaction with APC, such as dendritic cells (DC) and macrophages. Recently, 
we and others demonstrated the presence of DC, the most potent APC, in RA syno-
vial tissue 5-7.  Interestingly, DC derived from RA patients have an altered behaviour 
and phenotype 6, 8, 9, indicating a potential role in RA. Th e fact that the APC-T cell 
interaction is nowadays successfully being targeted in a RA patients with CTLA-4Ig 
10 strengthens the hypothesis that both DC and T cells play are key players in RA. 
In order to attract and interact with other leukocytes, APC produce a variety of che-
mokines. Chemokines are small secreted proteins which act as chemotactic ligands 
through interaction with 7-membrane spanning chemokine receptors. CXC chemo-
kine Ligand 16 (CXCL16) is a chemokine that exhibits chemotactic properties to-
wards leukocytes expressing CXC chemokine receptor 6 (CXCR6). Th is receptor is 
predominantly expressed on activated, memory type T cells 11, 12, but expression has 
also been demonstrated on NKT cells and plasma cells 13, 14. Similar to fractalkine, but 
in contrast to all other chemokines, CXCL16 exists as a trans-membrane protein and 
a soluble chemo-attractant. CXCL16 is expressed on the surface of macrophages, DC, 
ﬁ broblasts and smooth muscle cells 12, 15-17. To exert its chemotactic activity,  CXCL16 
is shed from the cell surface, a process that can be mediated by the protease ADAM-
10 18, 19.  In addition to its role as a chemokine ligand, CXCL16 (alternatively named 
SR-PSOX) acts as a scavenger receptor for oxidized LDL in its membrane-bound 
form 20 and might therefore play a role in the transformation of activated macropha-
ges into cholesterol loaded foam cells. Interestingly, membrane-bound CXCL16 has 
been proposed to mediate adhesion to CXCR6+ cells 21, suggesting that it does not 
only attract T cells, but supports a prolonged interaction between APC and  activated 
T cells as well.
Based on its potential to attract memory T cells, the CXCL16-CXCR6 pathway has 
been suggested to play an important role in the pathogenesis of several inﬂ ammatory 
diseases 12, 22-25. We recently showed that CXCL16 is abundantly expressed in RA ST 
12, which was conﬁ rmed by others 15, 25. In addition, CXCL16 can be found in high 
amounts in the SF of RA patients 12, 15. Interestingly, neutralization of CXCL16 recent-
ly proved to be beneﬁ cial in collagen induced arthritis, substantiating its potential as 
a therapeutic target 25. Despite the large body of evidence for a role of CXCL16 in a 
variety of inﬂ ammatory diseases, little is known on the regulation of CXCL16 expres-
sion. However, cells originating from monocyte precursors are held responsible for 
a large part of the CXCL16 expression in the synovial cavity 12. In this light, insight 
in CXCL16 regulation by these cells might help to explain the abundant expression 
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in this particular site. Th e aim of this study was therefore to elucidate the factors that 
regulate CXCL16 expression and release by monocytes and DC both in healthy indi-
viduals and in RA patients. Here, we provide novel data that contribute to the under-
standing of the complex regulation of CXCL16 in these cells. Th is regulation however 
is not altered in RA, suggesting that the increased CXCL16 expression in RA joints is 
predominantly caused by an increased inﬂ ux of CXCL16 producing cells.
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Figure 2: 
CXCL16 expression and secretion by IFN-�DC and IL-15DC
Panel A shows expression of CD80 and CD86 (shaded) vs. mouse IgG1 (dotted) by DC cultured with IL-15 (100 
ng/ml) or IFN-alpha 500 U/ml) in combination with GM-CSF (500 U/ml) for 6 days and another 48 hours in the 
presence or absence of 2 µg/ml LPS. Representative data of 8 individual experiments are shown. Panel B shows 
representative CXCL16 membrane expression on day 8 with and without stimulation with 2 µg/ml of three individual 
experiments. Panel C shows mean soluble CXCL16 (±SEM) from day 6 to day 8 of 3 individual experiments. The 
accompanying Mean Fluorescence Intensity (MFI) is shown in de ﬁ gure.
Methods
Patients and samples
For all blood cell cultures, 50 ml heparinized venous blood was taken from healthy vo-
lunteers and RA patients. SF was obtained from RA patients with an active local inﬂ am-
mation by means of puncture or during small needle arthroscopic procedures. All RA 
patients fulﬁ lled the ACR criteria for RA 26 and for experiments with RA monocytes, 
only patients with an active disease (DAS-28 > 5.1) were included 27. Th ese patients were 
treated with NSAIDs and methotrexate and/or sulphasalazine and had not received tre-
atment with biologicals. Th e study was approved by the local ethics committee. Infor-
med consent was recorded from all patients who participated in the study.
Recombinant proteins and antibodies
For the generation of MoDC, the following recombinant human (Rh) proteins were 
used: GM-CSF (Strathmann Biotech, Hamburg Germany),  IL-4 (Strathmann Bio-
tec), IL-15 and IFN-αA2 (Ropheron A, Roche). For stimulating monocytes/macro-
phages, we used Rh IL-10, IL-13, IL-15, IL-18, TNF-α and IFN-γ (all R&D Systems, 
Abingdon, UK). For FACS analysis, goat anti-human CXCL16 (R&D Systems, Abin-
gdon, UK) and mouse anti-human CD14 (Immunotech), CD80 (Becton Dickinson), 
CD86 (Pharmigen), CD83 (Beckman Coulter, Mijdrecht, Th e Netherlands), MHC-
I (clone W6/32) and MHC-II (clone q1513) were used. As control antibodies for 
FACS,  mIgG1, mIgG2a, mIgG2b, (all from BD Biosciences, Alphen ad Rijn, Th e Ne-
therlands) and goat IgG (R&D Systems, Abingdon, UK) were used. Donkey anti-goat 
AlexaFluor 647 (Molecular Probes, Leiden, Th e Netherlands) and goat anti-mouse 
FITC (Zymed South San Francisco, CA, USA) were used as secondary antibodies. 
Th e goat anti-human CXCL16 antibody was also used as a detection antibody for 
ELISA. For the standard curve, RhCXCL16 (R&D Systems, Abingdon, UK) was used 
and biotinylated rabbit anti-human CXCL16 (Pepro Tech, Rocky Hill, USA) was 
used as a detection antibody. 
Isolation of monocytes and generation of monocyte derived dendritic cells and mono-
cytes/ macrophages
MoDC were cultured as described previously 28, 29. In brief, mononuclear cells were 
isolated with a density gradient over Lymphoprep (Axis-Shield, Oslo, Norway). Mo-
nonuclear cells were isolated by adherence and were cultured in medium enriched 
with 10% FCS (Greiner), 500 U/ml GM-CSF and 350 U/ml IL-4, 100 ng/ml IL-15 or 
500 U/ml IFN-α. For maturation, cells were cultured for another 2 days in the pre-
sence of cytokines and 2 μg/ml LPS. For experiments with monocytes/macrophages, 
CD14+ cells were isolated by means of magnetic cell separation (MACS) (Miltenyi 
Biotec). Cells were stimulated with 350 U/ml IL-4, 20 ng/ml IL-10, 20 ng/ml IL-13, 
20 ng/ml IL-15, 20 ng/ml IL-18, 20 ng/ml TNF-α  or 10 ng/ml IFN-γ as indicated. 
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Synovial Fluid cell isolation
Synovial ﬂ uid samples were centrifuged and cells were extensively washed in PBS. 
Synovial ﬂ uid mononuclear cells (SFMC) from RA SF were obtained by density gra-
dient centrifugation over Lymphoprep. SFMC were washed with PBS, and either 
used immediately for FACS analyses or prepared for CD14+ MACS isolation. SFMC 
and CD14+ SF cells were either directly prepared for FACS analysis or cultured for 
24 hours where indicated.
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Figure 3: 
CXCL16 expression and secretion by monocytes/macrophages
Panel A shows increasing CXCL16 expression (shaded) vs. goat IgG (dotted) on freshly isolated monocytes that were 
cultured for 48 hours. The accompanying Mean Fluorescence Intensity (MFI) is shown in de ﬁ gure. Panel B shows 
cumulative CXCL16 release over the ﬁ rst 48 hours. The ﬁ gure is representative for 5 individual experiments. 
Fluorescent Activated Cell Sorting (FACS)
For FACS analysis, cells were prepared as described previously 28. In brief, cells were 
incubated with primary antibody or matched isotype control (normal goat IgG for 
CXCL16) for 30 minutes on melting ice. Cells were washed and incubated with a se-
condary antibody for another 30 minutes. Aft er a ﬁ nal wash step, cells were transfer-
red into FACS tubes and analyzed on a FACS Calibur (Becton Dickinson).
Enzyme Linked Immuno Sorbent Assay (ELISA)
CXCL16 detection in cell supernatant was performed with a sandwich ELISA as des-
cribed previously 30. Samples were measured in duplicate or triplicate and pooled 
normal human serum was taken along as an internal control on every plate. Th e 
detection limit of our ELISA is 100 pg/ml.
Statistical Analysis
Diﬀ erences between soluble CXCL16 secretion levels between diﬀ erent stimulati-
ons were tested for signiﬁ cance with a Wilcoxon’s signed rank test or a paired t test 
when appropriate (ﬁ gure 2c). Diﬀ erences in CXCL16 surface expression between RA 
monocytes and SF CD14+ cells were tested for statistical signiﬁ cance using a Mann 
Whitney U test. P-values <0.05 were considered signiﬁ cant.
Results
CXCL16 is expressed and secreted  by monocyte derived dendritic cells 
To study CXCL16 expression by MoDC, adherent monocytes from 10 healthy indi-
viduals were cultured in the presence of IL-4 and GM-CSF for 6 days, resulting in 
MoDC with an immature phenotype (data not shown). Upon additional stimulation 
with LPS for 2 days, immature DC developed a mature phenotype with up-regulation 
of co-stimulatory molecules (CD80 and CD86), the mature DC marker CD83 and 
MHC molecules (data not shown). Interestingly, we found that  CXCL16 surface ex-
pression  was comparable for mature and immature MoDC (n=10, ﬁ gure 1a). In line 
with our FACS results, CXCL16 secretion by DC matured with LPS was not diﬀ erent 
from CXCL16 release by immature DC (n=6, ﬁ gure 1b), which is in contrast to the 
increased secretion observed for many other chemokines and cytokines 9, 28, 31. 
In RA, monocytes encounter a large variety of cytokines, potentially skewing their 
diﬀ erentiation towards a DC phenotype. In addition, culturing with IL-4 may in-
troduce an in vitro bias with regard to CXCL16 expression by MoDC. Th erefore we 
examined CXCL16 expression and secretion by MoDC cultured from 3 healthy in-
dividuals in the presence of IFN-α or IL-15 32, 33, both of which have been suggested 
to play a role in the pathogenesis of RA 34, 35. We will refer to these cells as IFN-αDC 
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and IL-15DC throughout the manuscript. Both these DC types express low levels 
of the co-stimulatory molecules CD80 and CD86.  Upon stimulation with LPS, DC 
exhibit a clearly increased surface expression of CD80 and CD86 (ﬁ gure 2a). With 
regard to CXCL16 expression, we did not observe signiﬁ cant diﬀ erences between IL-
15DC, IFN-αDC and DC cultured with IL-4 (ﬁ gure 2b), although IL-15DC exhibi-
ted somewhat higher CXCL16 expression in an occasional donor. Similarly, CXCL16 
secretion by IL-15DC was somewhat higher than CXCL16 secretion by IL-4DC or 
IFN-αDC, but this diﬀ erence was not statistically signiﬁ cant (n=3, ﬁ gure 2c). In line 
with MoDC cultured with IL-4, stimulating IFN-αDC and IL-15DC with LPS for 2 
days did not result in consistent eﬀ ects on CXCL16 expression or secretion (ﬁ gure 
2b,c), indicating that CXCL16 expression and secretion is similar on immature and 
mature MoDC generated at diﬀ erent conditions. 
Rapid increase of CXCL16 expression and secretion by cultured  monocytes
Since CXCL16 expression was comparable on distinct MoDC, we next investigated 
how trans-membrane and soluble CXCL16 is regulated on their predecessors. Fresh-
ly isolated monocytes weakly expressed CXCL16 on their cell surface. Interestingly, a 
clear up-regulation of CXCL16 surface expression could already be observed within 
4 hours of culture in medium without cytokines, resulting in a full blown expres-
sion in as little as 12 hours. Th is expression was consistent over time and the level 
of expression resembled CXCL16 expression on MoDC (n=5, ﬁ gure 3a). Th is upre-
gulation of CXCL16 expression was closely followed by CXCL16 protein release, as 
we could detect signiﬁ cant amounts of CXCL16 aft er as little as 4-6 hours, with a 
clear cumulative eﬀ ect over time (ﬁ gure 3b). In line with our previous ﬁ ndings 12, the 
protease ADAM-10 could not be detected on the surface of monocytes/macrophages 
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Figure 4: 
Th2 cytokines inhibit CXCL16 secretion by monocytes/macrophages
The ﬁ gure depicts mean (±SEM) (n=8) secreted CXCL16 levels (ng/ml) of monocytes that were cultured for 36 hours 
in medium and stimulated with IL-4 (300 U/ml), IL-10 (20 ng/ml), IL-13 (20ng/ml), IL-15 (20 ng/ml), IL-18 (20ng/
ml), TNF-alpha (20ng/ml) or IFN-gamma (10 ng/ml). *= p<0.05, **= P<0.01. 
using ﬂ owcytometry within the ﬁ rst 48 hours of culture (data not shown), suggesting 
that other pathways of CXCL16 shedding must be involved. Th e rapid increase in 
CXCL16 expression and secretion was not due to culture eﬀ ects, as adherent mo-
nocytes, monocytes isolated with negative selection or exchanging FCS for human 
serum had a similar CXCL16 expression pattern and kinetics (data not shown). In 
order to examine the possibility that CXCL16 protein is already stored intracellularly 
by monocytes, we performed an intracellular FACS staining on fresh PBMC’s that 
were gated on CD14 expression. Interestingly, the intracellular expression was simi-
lar to membrane expression (data not shown), suggesting that CXCL16 protein is not 
stored in large amounts to be transported to the membrane but is actually produced 
de novo upon culture of monocytes.
Inhibition of CXCL16 secretion by Th 2/anti-inﬂ ammatory cytokines and stimulation 
by the Th 1 cytokine IFN-γ
To date, little is known on the eﬀ ects of cytokines on CXCL16 expression and release 
by human monocytes/macrophages. Moreover, no data are available on the ﬁ rst 48 
hours, where the most profound up-regulation takes place (ﬁ gure 3). Th erefore we 
investigated the eﬀ ect of pro- and anti-inﬂ ammatory cytokines on trans-membrane 
and soluble CXCL16 levels. In the supernatant of 36 hour monocytes/macrophages 
(n=8), we measured a CXCL16 release of 3.0 ±0.4 ng/ml (mean ±SEM). Interestingly, 
the Th 2 cytokines IL-4 and IL-13 inhibited CXCL16 release with 43% (1.7 ±0.3 ng/
ml, p=0.008) and 38% (1.9 ±0.3 ng/ml, p=0.008)  respectively (ﬁ gure 4). Further-
more, the anti-inﬂ ammatory/regulatory cytokine IL-10 inhibited soluble CXCL16 
release on developing monocytes/macrophages with 26% (2.2 ±0.2 ng/ml, p=0.008). 
In contrast, stimulation with the Th 1 cytokine IFN-γ resulted in an increase of 13% 
(3.4 ±0.5 ng/ml, p=0.02) compared with medium alone (ﬁ gure 4). Th is eﬀ ect could 
not be observed for the pro-inﬂ ammatory cytokines TNF-α, IL-15 and IL-18, indica-
ting that soluble CXCL16 release is uniquely upregulated by IFN-γ. Using ﬂ owcyto-
metry, a maximal CXCL16 membrane expression could be observed on monocytes/
macrophages at 36 hours, irrespective of stimulation with pro- or anti-inﬂ ammatory 
cytokines (data not shown).
LPS inhibits CXCL16 expression and secretion by monocytes
To further investigate the eﬀ ects of monocyte activation on CXCL16 expression, we 
incubated freshly isolated monocytes with the TLR4 ligand LPS. Intriguingly, LPS 
clearly delayed the upregulation of CXCL16 expression within the ﬁ rst 48 hours 
(n=3, ﬁ gure 5a). Th e inhibition of surface expression however was transient, as the 
expression aft er 48 hours was comparable to the expression on unstimulated mo-
nocytes/macrophages. When measured at 36 hours in 12 healthy individuals, LPS 
resulted in a signiﬁ cant inhibition of (mean ±SEM) CXCL16 release (1.9 ±0.3 ng/ml) 
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compared to unstimulated monoctyes (3.4 ±0.4 ng/ml) (p=0.001) (ﬁ gure 5b). In a 
concentration/time-course experiment, stimulation with 1 ng/ml LPS resulted in the 
same eﬀ ects as stimulation with 1000 ng/ml on both CXCL16 membrane expression 
(n=3, ﬁ gure 5c) and secretion (n=3, ﬁ gure 5d), indicating that an initial stimulation 
with a relatively low concentration of LPS is suﬃ  cient to delay trans-membrane ex-
pression and soluble CXCL16 release by cultured monocytes.
CXCL16 expression and secretion is not altered in RA 
In order to explain the increased CXCL16 expression in RA 12, we tested whether 
CXCL16 was diﬀ erentially regulated on blood monocytes from RA patients compa-
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Figure 5:  
LPS inhibits CXCL16 expression and secretion
Panel A depicts CXCL16 surface expression (shaded) vs. goat IgG (dotted) of monocytes/macrophages that were cul-
ture for 48 hours in the presence (bottom) or absence (top) of LPS (100 ng/ml). Representative result of 3 individual 
experiments is shown. Panel B shows CXCL16 secretion (ng/ml) by monocytes/macrophages cultured for 36 hours in 
the presence or absence of 100 ng/ml LPS (n=12) ) **p<0.01. Panel C depicts mean ﬂ uorescence intensity (MFI) of 
monocytes/macrophages cultured for 48 hours in the presence of LPS in increasing concentrations (0-1000 ng/ml). 
Mean (±SEM) values of 3 individual experiments are shown. Panel D depicts soluble CXCL16 (ng/ml) released by 
monocytes/macrophages cultured for 48 hours in the presence of LPS in increasing concentrations (0-1000 ng/ml). 
Mean (±SEM) values of 3 individual experiments are shown. The accompanying Mean Fluorescence Intensity (MFI) 
is shown in de ﬁ gure.
red to healthy controls. Freshly isolated monocytes from 3 RA patients with active 
disease showed a similar low surface expression of CXCL16 as monocytes from 3 
healthy controls (ﬁ gure 6a). Furthermore, CXCL16 expression followed similar kine-
tics in RA monocyes as in monocytes from healthy controls (ﬁ gure 6a). Interestingly, 
CD14+ cells isolated from RA synovial ﬂ uid (n=5) had a CXCL16 expression level 
(median (range)) that was slightly but signiﬁ cantly higher than the expression level 
on peripheral blood monocytes  (5.0 (4.5-7.0) vs. 10.0 (8.0-15.0) (p=0.03)) (ﬁ gure 6a 
and 6b), but clearly lower than cultured macrophages beyond 12 hours. Upon culture 
for 24 hours, SF CD14+ cells further upregulated CXCL16 surface expression in a 
similar way as peripheral blood monocytes (ﬁ gure 6b). In contrast, SF lymphocytes 
did not express CXCL16 (data not shown), which is in line with peripheral blood 
lymphocytes 12. As stimulation with LPS resulted in the clearest eﬀ ects on CXCL16 
expression and secretion, we stimulated RA monocytes with LPS. Comparable to 
monocytes from healthy controls, the normal increase in CXCL16 expression and 
release by RA monocytes (n=3) was delayed by LPS (ﬁ gure 6c&d).
Discussion
CXCL16 is expressed by myeloid cells and is abundant in RA joints 12, 15, 25. In the 
present study, we provide novel data that contribute to the understanding of CXCL16 
regulation in RA patients and healthy controls. First, we show that CXCL16 expres-
sion and release is conserved on distinct myeloid DC and not aﬀ ected by maturation. 
Second, we demonstrate that monocytes rapidly upregulate CXCL16 expression and 
release when brought into culture, which is transiently abrogated by LPS. Th ird, we 
show that Th 2 cytokines suppress CXCL16 secretion while the Th 1 cytokine IFN-γ 
enhances CXCL16 secretion by monocytes/macrophages. Finally, we demonstrate 
that RA monocytes express similar levels of CXCL16 compared to monocytes from 
healthy controls and that CXCL16 regulation is not altered in RA monocytes compa-
red to monocytes of healthy controls.
Monocytes diﬀ erentiate into macrophages or DC upon leaving the bloodstream and 
entering the tissues. Culturing monocytes/macrophages in vitro is considered to mi-
mic this monocyte to macrophage development in vivo 36, 37. In our experiments, this 
model for monocyte activation was the strongest trigger for upregulation of CXCL16 
surface expression. Maximal CXCL16 surface expression was observed aft er as little as 
12 hours and expression was highly stable and conserved on distinct monocyte derived 
cells, e.g. independent of DC or macrophage diﬀ erentiation. Th is suggests that diﬀ e-
rentiation of monocytes, which also occurs by entering the tissues, is the main trigger 
for upregulation of CXCL16 expression, which may explain the abundant CXCL16 
expression in various tissues 24, 38, both in health and disease. Th e exact mechanism of 
chapter 5   
103
this increase remains to be elucidated, but our results suggest that rapid de novo pro-
duction rather than stored intracellular CXCL16 protein is responsible for the increase 
of CXCL16 expression upon culturing monocytes. Interestingly, CD14+ cells isolated 
from RA SF had a CXCL16 expression that was slightly higher than blood monocytes 
but lower than cultured macrophages, which might be explained by a certain state of 
activation of CD14+ cells in RA SF. In our experiments, we detected large amounts of 
soluble CXCL16, while we could not detect ADAM-10 expression within the ﬁ rst 48 
hours of culture. Th is may indicate that other pathways, for example alternative splicing 
or other proteases, contribute to the release of the extracellular CXCL16 domain.
To date, little is known about CXCL16 regulation on myeloid cells. In our study, 
we observed a small but signiﬁ cant increase in CXCL16 secretion upon stimulation 
Figure 6: 
CXCL16 regulation is not altered in RA
Panel A depicts CXCL16 expression (shaded) vs. goat IgG (dotted) on monocytes/ macrophages from RA patients 
that were cultured for 48 hours. Representative ﬁ gure of 3 individual experiments is shown. Panel B shows CXCL16 
expression on freshly isolated SF CD14+ cells (left) and SF CD14+ cells cultured for 24 hours (right). Representa-
tive ﬁ gure of 5 experiments is shown. *Difference between blood CD14+ cells (ﬁ gure 6A, ﬁ rst plot) and SF CD14+ 
cells (ﬁ gure 6B, ﬁ rst plot) is signiﬁ cant (p=0.03). Panel C depicts CXCL16 mean ﬂ uorescence intensity (MFI) of RA 
monocytes/macrophages that were cultured in the presence of 100 ng/ml LPS (0-1000 ng/ml) for 48 hours. Mean 
(±SEM) values of 3 individual experiments are shown. Panel D  depicts soluble CXCL16 (ng/ml) released by RA 
monocytes/macrophages that were cultured in the presence of 100 ng/ml LPS (0-1000 ng/ml) for 48 hours. Mean 
(±SEM) values of 3 individual experiments are shown
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with IFN-γ, suggesting that this Th 1 cytokine does have some stimulatory eﬀ ect on 
CXCL16 levels. However, this eﬀ ect on monocytes is only small compared to the 
eﬀ ect of merely culturing monocytes. Interestingly, we observed an inhibition of 
CXCL16 release by the Th 2 cytokines IL-4 and IL-13 and the anti-inﬂ ammatory cy-
tokine IL-10. Th is indicates that Th 1 vs. Th 2 polarisation can enhance or inhibit solu-
ble CXCL16 to some extend, which may aﬀ ect local CXCL16 levels. Stimulation with 
TNF-α, IL-15, IL-18 or IFN-α, which all have been suggested to play a signiﬁ cant role 
in RA 34, 35, 39-43, had little or no eﬀ ect on CXCL16 expression or secretion. Th e lack of 
CXCL16 inducing eﬀ ect of TNF-α seems in contrast with our previous ﬁ ndings. Ho-
wever, this apparent inconsistence can be explained by temporal factors, as CXCL16 
expression did not increase upon stimulation with TNF-α, but decreased without 
additional cytokine stimulation aft er 48 hours, with a both a CXCL16 positive and 
negative fraction 12. Th is CXCL16 negative fraction of unstimulated monocytes lost 
viability beyond 48-72 hours, which could be prevented by stimulation with TNF-α 
but also growth factors such as (G)M-CSF (data not shown). Th us TNF-α does not 
exert a direct CXCL16 inducing eﬀ ect on cultured monocytes/macrophages.
While the Th 2/anti inﬂ ammatory cytokines IL-4/IL-13/IL-10 inhibited soluble 
CXCL16 secretion by monocytes to some extend, the TLR4 ligand LPS clearly delay-
ed CXCL16 expression and secretion. Considering the data from the present study, 
it cannot be excluded that this eﬀ ect is indirectly caused by cytokines such as IL-10. 
Alternatively, one can speculate that LPS, as a strong initiator of innate immunity, 
delays upregulation of CXCL16 expression and secretion to allow optimal orchestra-
tion of an innate immune response. On DC, we did not detect signiﬁ cant eﬀ ects on 
CXCL16 upon maturation with LPS. Th is is likely to be explained by a ceiling eﬀ ect, 
as CXCL16 expression already is maximal on these cells. In addition, we did not ob-
serve signiﬁ cant diﬀ erences between mature and immature DC on soluble CXCL16 
levels, indicating that DC maturation does not inﬂ uence CXCL16 expression or se-
cretion in any way. 
In previous studies, it was shown that circulating CXCL16 serum levels are not al-
tered in patients with active RA compared to healthy controls 15, 30. In contrast, lo-
cal expression in the ST is increased 12, as is the expression of  the receptor CXCR6 
in the SF 12. Th e data of the present study provide no evidence for deregulation of 
CXCL16 expression in RA monocytes. Given these data, it is conceivable that in-
creased CXCL16 expression in RA joints is caused by inﬂ ux of monocytes rather 
than enhanced production per cell. Th e observation that RA patients responding to 
anti-TNF-α treatment did have a decreased CXCL16 expression in the ST compared 
to non-responders 12 may be caused by a diﬀ erence in monocyte numbers, either by 
decreases in inﬂ ux or enhanced apoptosis. Further studies using synovial biopsies 
105
chapter 5   
during DMARD or anti-TNF-α treatment need to be performed to conﬁ rm this re-
lationship and to value the potency of targeting CXCL16 or its receptor CXCR6 as a 
future therapy for RA.
In summary, we provide evidence suggesting that monocytes rapidly upregulate 
CXCL16 upon diﬀ erentiation into macrophage or DC, which can be transiently inhibi-
ted by mimicking innate immune activation using LPS. Soluble CXCL16 release is in-
hibited by Th 2/anti inﬂ ammatory cytokines and stimulated by the Th 1 cytokine IFN-γ 
to some extend. Together our data suggest that the abundant expression of CXCL16 in 
RA joints might be the result of abundance of inﬁ ltrating monocytes/macrophages in 
the synovial tissue, as no evidence for deregulation of CXCL16 in RA was observed. 
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Abstract
Background: Antigen presenting cells (APC) and T cells are considered to play a sig-
niﬁ cant role in the pathogenesis of rheumatoid arthritis (RA). CCL18 and CXCL16 
are two chemokines that facilitate T cell attraction by APC, of which a role in the 
pathogenesis of RA has been suggested.
Objective: To compare the circulating levels of CXCL16 and CCL18 in RA with con-
trols and to investigate the relation of CXCL16 and CCL18 with RA disease activity 
and joint damage.
Methods: Circulating CCL18 and CXCL16 levels were determined in 61 RA patients 
with a follow-up of 6 years and a group of 41 healthy controls with ELISA. Chemo-
kine levels were correlated with demographical data, disease activity (DAS28) and 
joint damage (modiﬁ ed Sharp score). In addition, serum CCL18 and CXCL16 levels 
from a cohort of 44 RA patients treated with anti TNF-α were correlated with disease 
activity.
Results: CCL18 levels in serum were signiﬁ cantly elevated in RA patients compared 
to controls, while serum CXCL16 levels were not. In contrast to CXCL16, serum 
CCL18 was positively correlated with disease activity. Both CCL18 and CXCL16 le-
vels decreased upon treatment with anti TNF-α.  Neither CCL18 nor CXCL16 cor-
related with joint damage and progression.
Conclusion: Here, we show, for the ﬁ rst time, that circulating CCL18 and not CXCL16 
levels are elevated in RA patients as compared with controls and correlate with di-
sease activity in RA. More knowledge regarding the regulation and function of both 
CCL18 and CXCL16 is essential to value their role in RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic auto-immune disease, characterized by an in-
ﬂ ammation of the synovial joints that eventually leads to cartilage damage and bone 
destruction. Despite extensive research, the exact pathogenesis of RA is still unclear. 
Nowadays, there is substantial evidence supporting a role for antigen presenting cells 
(APC), such as dendritic cells (DC) and macrophages (MФ) in RA 1-3. Th ese APC ac-
tivate T cells and subsequently play a pivotal role in orchestrating immune responses 
4. In addition, upon stimulation by T cells, APC act as downstream players in RA and 
secrete cytokines such as TNF-α and IL-1β, which are now successfully targeted in 
the clinic 5, 6. In order to direct T cell responses, APC ﬁ rst need to attract diﬀ erent T 
cell subsets. Th is chemo-attraction is mediated by chemokines (CK). CK constitute a 
large family of proteins that all possess chemo-attractive capacities towards leucocy-
tes. A subset of the CK family preferentially attracts T cells and is therefore critical in 
the direction of T cell-driven immune responses.
Recently, we started investigating the role of DC and a large panel of T cell attrac-
ting chemokines secreted by those DC in RA, of which CXC chemokine ligand 16 
(CXCL16) and CC Chemokine ligand 18 (CCL18) were identiﬁ ed as particularly 
interesting subjects 7-11. CXCL16 is a unique trans-membrane CK exists in both a 
membrane bound and soluble form. Membrane bound CXCL16 is a scavenger recep-
tor for oxidized low density lipoproteins (LDL) 12, can facilitate cell adhesion 13 and 
mediates phagocytosis of bacterial fragments 14. Th is membrane-bound CXCL16 is 
expressed on APC 9, 15, 16 and can be cleaved by proteases such as ADAM-10 17, 18
to serve as a chemo-attractant for CXCR6+ cells in its soluble form 16, 19. Th e receptor 
CXCR6 is present on activated, memory type T cells, plasma cells and NKT cells 19-21. 
We recently demonstrated the abundant expression of CXCL16 and CXCR6 in RA 
synovial tissue and ﬂ uid, as well as its regulation by synovial ﬂ uid and TNF-α 9. In ad-
dition, we found high levels of cleaved CXCL16 in the synovial ﬂ uid of RA patients. 
Recently, additional evidence for a role for CXCL16 in RA was provided as CXCL16 
was suggested as a potentially novel therapeutic target in RA as blockade of CXCL16 
resulted in a decrease in arthritis in murine collagen induced arthritis 22.
CCL18 (DC-CK1, PARC, AMAC-1) is a another T cell attracting CK that was ﬁ rst 
identiﬁ ed as a chemo attractant for naïve T cells and is produced by DC and alter-
natively activated MФ 23-26.  CCL18 was initially found in high quantities in the lung 
(alveolar MФ) in health and disease 24. Interestingly, a high CCL18 expression was 
found in synovial tissue of patients with RA 7, 27, which suggested that CCL18 might 
play a role in the pathogenesis of RA. In addition, CCL18 can also act as a pro-ﬁ bro-
tic factor in the lung 28, indicating that T cell attraction is not the only function of 
CCL18. Circulating CCL18 has been shown to be useful as a biomarker for Gaucher’s 
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disease 29. Moreover, associations with circulating CCL18 levels have been suggested 
in a large variety of diseases, including lymphoblastic leukemia 30, atopic dermatitis 
31, ovarian carcinomas 32 and allergic asthma 33.
Sensitive biomarkers for disease activity and progression in RA are currently still lac-
king. Th e demand for such markers, however, is increasing, since novel therapeutic 
strategies are very expensive, have serious side eﬀ ects and vary in eﬃ  cacy between 
individual patients. Th is, in combination with the suggested roles of CXCL16 and 
CCL18 in RA pathogenesis prompted us to investigate their circulating levels in RA 
and their potential correlation with clinical disease parameters. In the present study, 
we show that serum levels CCL18 are elevated in RA and signiﬁ cantly correlate with 
disease activity parameters in two independent cohorts, whereas CXCL16 did not 
show any correlation with disease activity. Neither of the two CK correlated with 
radiological progression. Th ese results suggest that serum CCL18 but not CXCL16 
might reﬂ ect the disease course of RA.
Methods
Patients
Patient serum samples were repetitively taken from 61 patients enrolled in the RA in-
ception cohort of the Radboud University Nijmegen Medical Centre. All patients ful-
ﬁ lled the ACR criteria for the diagnosis RA 34. Th e ﬁ rst sample was taken at the time of 
diagnosis, prior to the initiation of treatment with disease modifying anti rheumatic 
drugs (DMARDs), and is referred to as baseline sample throughout the manuscript. 
None of the patients had been treated with anti TNF-α during the period of follow-up 
we analyzed in our study. Patients were seen on a regular basis and data were col-
lected every 3 months during the ﬁ rst two years and every 6 months thereaft er. In 
this cohort, serum samples can be correlated with  clinical data from the same day of 
the blood sample, such as disease activity (DAS-28 score 35), joint damage (modiﬁ ed 
Sharp score 36) and laboratory values. Serum samples of healthy volunteers (n=41) 
were used as controls to compare CK levels with RA serum levels. In addition, serum 
samples were taken from 44 patients who where treated with anti-TNF-α (inﬂ iximab) 
in the St. Maartenshospital. Th e ﬁ rst sample was taken before the ﬁ rst infusion and the 
next samples were taken aft er 2, 6 and 14 weeks. Th e ESR was measured on the same 
time points, as were the joint scores and VAS for the DAS-28 score.
Enzyme Linked Immuno Sorbent Assay (ELISA)
For the detection of chemokine protein levels of CXCL16 and CCL18 in serum, sand-
wich ELISA’s were performed as described previously 9, 37. As an internal control for 
inter-assay variability, a sample of pooled normal human serum (n=300) was taken 
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Figure 1: 
Serum chemokine levels in RA vs. controls
Serum chemokine levels were measured in RA patients prior to DMARD treatment and in healthy controls. Panel A 
depicts CCL18 levels and panel B depicts CXCL16 levels in serum from RA patients (n=61) and controls (n=41). 
Box & whiskers plots show median levels with interquartile range and full range. Levels were compared with a Mann 
Whitney U test Exact p-values are provided in the ﬁ gure.
Figure 2: 
Serum chemokine levels during anti TNF-alpha treatment
Chemokine levels were measured before and during treatment with inﬂ iximab. Panel A & B depict serum CCL18 and 
CXCL16 at baseline vs. week 2 and panels C & D depict serum CCL18 and CXCL16 levels at baseline vs. week 14. 
Levels were compared with a Wilcoxon’s signed rank test. Exact p-values are provided in the ﬁ gure.
along in all assays.  Th e detection limits for the ELISA’s is 100 pg/ml for both CCL18 
and CXCL16. Th e maximum inter-assay variability is estimated at 10%. In order to 
minimize eﬀ ects of this variability, samples that were directly compared were measu-
red in the same assay.
Statistical analysis
In order to evaluate whether circulating chemokine levels were diﬀ erent in RA pa-
tients prior to DMARD treatment compared to healthy controls, baseline serum 
samples from patients were compared with control serum samples with a Mann 
Whitney U test. When examining the relation between circulating chemokine levels 
with disease activity and joint damage, correlations between chemokine levels and 
clinical data were determined with Pearson’s  correlation. CCL18 and modiﬁ ed Sharp 
scores were root transformed. To asses diﬀ erences between chemokine levels at dif-
ferent time-points in our cohort of patients treated with anti-TNF-α,  comparison 
between baseline and follow-up data was done with a Wilcoxon’s signed rank test. 
Th e correlation between changes in DAS-28 and changes in CCL18 or CXCL16 levels 
was done with a Spearman’s correlation test. 
Results
Circulating  CCL18 but not CXCL16 levels are elevated in RA
CCL18 and CXCL16 levels prior to DMARD treatment were measured in serum 
of 61 patients and compared with serum of healthy controls (n=41). At baseline, 
CCL18 levels were signiﬁ cantly higher in RA patients (median (interquartile range) 
49.0 ng/ml (31.5-71.0))  compared to CCL18 levels in controls (28.6 ng/ml (15.8-
35.7)) (p=0.0004) (ﬁ gure 1a). In contrast, CXCL16 levels were not signiﬁ cantly ele-
vated in RA patients (6.0 (4.0-7.3) ng/ml) compared to healthy controls (6.3 (5.2-7.7) 
ng/ml) (p=0.14) (ﬁ gure 1b). Neither CCL18 nor CXCL16 levels were associated with 
demographic or patient characteristics, including rheumatoid factor positivity, age at 
disease onset and gender as calculated by univariate analysis (data not shown). 
CCL18 but not CXCL16 correlates with the disease activity score (DAS-28)
Since we were interested in the relation with disease severity and potential suitability 
of CCL18 and/or CXCL16 as a biomarker for disease severity in RA, we investigated 
whether circulating levels of these CK correlated with clinical parameters at baseline 
and over 3 and 6 years. In table 1, patient and disease characteristics are shown at 
baseline and over time for progression of joint damage. 
SqrtCCL18 at baseline was positively correlated with the DAS-28 score (R=+0.38 (p 
=0.003)) and ESR (+0.39 (p =0.003)) (upper panel of table 2). In contrast, baseline 
serum CXCL16  levels did not correlate with disease activity. As could be expected 
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considering their regulation, CCL18 and CXCL16 were inversely correlated but this 
correlation did not reach statistical signiﬁ cance (R=-0.22 (p=0.10)). 
Over time, a trend towards a positive correlation between mean serum CCL18 and 
mean DAS-28 could be observed, although its was less strong compared to baseline 
(R=+0.21 (p= 0.10) over 3 years (R=+0.23  (p =0.07) over 6 years) (upper panel of 
table 3). As for baseline, mean CXCL16 over time did not correlate with mean DAS-
28 (R=+0.06 (p=0.63) and +0.02 (p= 0.86)  over 3 and 6 years respectively). Mean 
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CXCL16 and mean CCL18 again showed a trend towards an inverse correlation (R=-
0.21 (p =0.10) and -0. 20   (p=0.12) over 3 and 6 years, respectively). 
Serum chemokine levels do not correlate with joint damage and progression              
Cartilage and bone damage are important clinical outcomes in the chronic process 
of RA.  In order to investigate whether serum CK levels could predict joint damage, 
we correlated CK levels at baseline and during the follow-up period with modiﬁ ed 
Sharp-scores and progression. In the literature, female gender and rheumatoid fac-
tor are known for their positive relation with progression of joint damage in RA 36 
and might therefore act as confounding factors. However, the levels of CCL18 and 
CXCL16 were not related to gender or rheumatoid factor in our study population 
(data not shown). In these patients, neither CCL18 nor CXCL16 correlated signi-
ﬁ cantly with Sharp score at baseline (lower panel of table 2). For comparison, the 
correlation of baseline DAS28 with progression in Sharp score between 0-3 years and 
0-6 years was R=0.36 (p=0.005) and R=0.39 (p=0.002), respectively. Also, the CK 
levels over time, averaged over 3 years and 6 years, did not correlate with progression 
of joint damage over the same time period, in contrast to the DAS28 (lower panel of 
table 3).
CCL18 decreases upon anti TNF-α treatment and correlates with DAS-28
Anti-TNF-α treatment is known for its strong and rapid eﬀ ects on disease activity 
in RA. Furthermore, TNF-α has been suggested to play a role in the regulation of 
expression of both CCL18 10 and CXCL16 9, 17. To investigate the relation between 
chemokine levels and disease activity during treatment with anti TNF-α, we measu-
red these parameters in a group of RA patients that were treated with inﬂ iximab 
(n=44). Interestingly, in 95% of the patients (35/37, for 7 patients week 2 serum was 
not available), CCL18 levels dropped signiﬁ cantly (p<0.0001) aft er the initiation of 
anti TNF-α treatment (ﬁ gure 2a). In this period, the change in CCL18 was positively 
correlated with the change in DAS-28 (R=+0.38  (p=0.04)). CXCL16 levels were also 
signiﬁ cantly lower (p=0.04) at week 2, but the diﬀ erence was small (median 4118 
pg/ml vs. 3928 pg/ml). Moreover, CXCL16 dropped in only 65% (24/37) patients 
aft er initiation of treatment and increased in 13 patients (ﬁ gure 2b) and a correlation 
with DAS-28 did not reach statistical signiﬁ cance (R=+0.38 (p=0.07)). Th e CCL18 
changes over the ﬁ rst two weeks of treatment did not evolve in a common pattern 
that could be observed throughout the whole follow-up. Aft er 14 weeks of treatment, 
CCL18 and CXCL16 levels were still signiﬁ cantly lower than baseline CCL18 levels 
(ﬁ gure 2c&d). However, the change in CCL18 aft er 14 weeks did not correlate signi-
ﬁ cantly with a change in DAS-28 (R=0.15 (p=0.5)). As for CCL18, CXCL16 levels at 
week 14 did also not correlate signiﬁ cantly with DAS-28 (R= -0.03  p=0.8). 
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Discussion
In the present study, we show that circulating CCL18 but not CXCL16 levels are 
elevated in RA patients compared with controls and correlate with disease activity. 
In addition, neither CXCL16 nor CCL18 correlated with the level of joint damage or, 
more importantly, the progression of such damage.
Th e correlation between CCL18 and disease activity might reﬂ ect a role for CCL18 
in the pathogenesis of RA. Th e interpretation of this observation however is diﬃ  cult 
and hampered by the lack of knowledge on the exact role of CCL18 in the immune 
system, which might be either pro- or anti- inﬂ ammatory. It is tempting to speculate 
that CCL18 acts as an anti inﬂ ammatory mediator in RA since its production is regu-
lated by IL-4, IL-13 and IL-10 11, 25, which places CCL18 in a Th 2 or regulatory corner. 
Th is would imply that serum CCL18 levels may lag behind of disease activity in time. 
However, these thoughts are hypothetical and have not been proved so far in expe-
rimental settings. On the other hand, CCL18 might also elicit a pro-inﬂ ammatory 
response in RA, since the inﬂ ammatory environment might direct newly attracted 
T cells by CCL18 into an undesirable state of activation, subsequently resulting in 
ongoing T cell activation. When this hypothesis is true, CCL18 might play an active 
role in the chronic phase of RA. In that case, serum CCL18 will more directly reﬂ ect 
disease activity.
Little is known on the kinetics and dynamics of CCL18 in vivo. Since in our inception 
cohort both CCL18 levels and clinical data were measured every 3 months, this relati-
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vely long time between two measurements might inﬂ uence the strength of the corre-
lation between CCL18 and DAS-28 over time. Th e fact that we observed the strongest 
correlation within the ﬁ rst two weeks aft er treatment initiation in the anti-TNF-α 
cohort may support this. However, the decrease in correlation strength over time 
may also be caused by the initiation of a new treatment regimen. Eﬀ ects of DMARDs 
on immune cells are poorly understood, but may result in altered secretion of cyto-
kines and/or chemokines. As a result, this may inﬂ uence the reﬂ ection of the disease 
course by soluble mediators such as CCL18, which might explain the decrease in cor-
relation strength over time. Next to the time between observations, another possible 
confounding factor is that elevated CCL18 levels may not only reﬂ ect disease activity 
in the joints, but also organ involvement or co-morbidity. In systemic sclerosis (SSc) 
for instance, a ﬁ rst indication for a correlation between CCL18 and pulmonary ﬁ bro-
sis has recently been described 38. Pulmonary ﬁ brosis is a clinical feature that is also 
known to occur in RA and therefore might be an additional source of CCL18 levels 
in certain patients. However, of the patients included, only 5 patients had pulmonary 
co-morbidity with no case of recorded pulmonary ﬁ brosis (data not shown).
Th e role of TNF-α in the regulation of CCL18 is still unclear. TNF-α blockade decre-
ased  CCL18 mRNA expression in vitro when administered to DC cultures during 
maturation, but administration of TNF-α to monocytes did not result in an enhanced 
secretion of CCL18 11. Aft er an initial decrease in CCL18 levels in 95% of the patients, 
accompanied with a clear correlation with DAS-28, we did not observe a signiﬁ cant 
correlation between changes in CCL18 and DAS-28 aft er 14 weeks in our anti-TNF-α 
cohort. One could speculate that the start of anti-TNF-α treatment initially results in 
a decrease in CCL18 levels due to a direct eﬀ ect of TNF-α blockade. In a later sta-
ge, the immune system has to search for a new equilibrium without the presence of 
TNF-α, which could explain why CCL18 levels do not remain low in all patients. Th e 
eﬀ ects of these changes in the immune system may overrule the eﬀ ect of the changes 
in disease activity on CCL18 levels. Th us, CCL18 levels might also be aﬀ ected by the 
type of treatment, independently of disease activity. 
We and others demonstrated that CXCL16 levels are particularly high in RA synovial 
ﬂ uid 9, 39, which is in concordance with the high expression of CXCL16 in RA syno-
vial tissue 9, 39. CXCL16 levels were not elevated in RA serum at baseline compared 
to healthy controls and we did not ﬁ nd a signiﬁ cant correlation with clinical disease 
parameters. Th is suggests that serum CXCL16 is not useful as a clinical marker in 
RA. However, this does not imply that CXCL16 does not play a role in the pathoge-
nesis of RA. In the ﬁ rst place, soluble CXCL16 does not represent the total CXCL16 
expression, since another signiﬁ cant portion is still membrane-bound. In order to 
draw conclusions with regard to a role for CXCL16 in the pathogenesis, also mem-
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brane bound CXCL16 and the levels of proteases such as ADAM-10 should be taken 
into account. Second, the data that are currently available on the role of CXCL16 
and its receptor CXCR6 in RA point towards a role in local synovial inﬂ ammation 
and are not suggestive for a role in systemic inﬂ ammation. Circulating levels of in-
ﬂ ammatory mediators do not necessarily reﬂ ect local expression in the tissues. For 
example, circulating levels of TNF-α hardly point towards a signiﬁ cant role in RA, 
which in fact is well appreciated in daily clinical practice. Given the data from the 
present study, it appears that circulating CXCL16 levels, not being elevated in RA 
and without correlation with clinical parameters, do not reﬂ ect high local levels in 
the joints. With regard to the relation between TNF-α and CXCL-16, it is interesting 
that CXCL16 levels decrease signiﬁ cantly upon treatment with anti-TNF-α, without 
a signiﬁ cant correlation with disease activity, which was diﬀ erent from our previ-
ous observations in the synovial architecture . Whether the decrease in circulating 
CXCL16 levels upon neutralization of TNF-α is a direct or indirect eﬀ ect remains to 
be elucidated. Th e exact regulation of CXCL16, which may provide more insights in 
the role of CXCL16 in RA and may help to explain this ﬁ nding is currently under our 
investigation. 
In summary, we show that elevated CCL18 levels correlate positively with disease 
activity but not joint damage in RA. Th is correlation may reﬂ ect a role in RA patho-
genesis, which might be pro- or anti-inﬂ ammatory. CXCL16 levels are not elevated 
and do not correlate with disease activity or joint damage. Both CCL18 and CXCL16 
levels decreased upon treatment with anti-TNF-α, independently of disease activity. 
Although the strength of the correlations needs to be determined in large studies, our 
data do not directly support CCL18 as a novel clinical marker in RA, as correlations 
with disease activity were lower than those of markers as ESR and CRP. More know-
ledge on the role and regulation of both CCL18 and CXCL16 is needed to value their 
role in the pathogenesis of RA, both locally and systemically.
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Letter
With great interest we read the recent paper entitled “Decreased plasma CXCL16/SR-
PSOX concentration is associated with coronary artery disease” by Sheikine et al 1. In 
this study, the authors investigated the relationship between plasma CXCL16 levels 
and coronary artery diseases (CAD) in a group of healthy individuals and patients 
with diﬀ erent types of CAD. Th ey found that patients with diﬀ erent CAD exhibit lo-
wer systemic CXCL16 levels compared with controls, while CXCL16 levels are not 
related to the degree of coronary artery stenosis or to biochemical risk indicators of 
CAD. Based on these data, the authors hypothesize that soluble CXCL16 acts as a sca-
venger for oxidized LDL (oxLDL) and therefore might have an atheroprotective role. 
CXCL16 is a trans-membrane molecule that was ﬁ rst identiﬁ ed as a scavenger recep-
tor for oxidized LDL (oxLDL) 2. It was shown to play a role in the internalization of 
oxLDL particles, leading to subsequent foam cell formation, which is a critical step 
in the development of atherosclerotic plaques. Upon cleavage by proteases, soluble 
CXCL16 exerts its eﬀ ect as a chemokine ligand for CXCR6+ cells 3, 4. Importantly, en-
hanced expression of membrane-bound CXCL16 has been found in atherosclerotic 
plaques, suggesting its role in the pathogenesis of atherogenesis 5. Th erefore, the as-
sessment of a link between CXCL16 and cardiovascular disease is justiﬁ ed. However, 
there are some concerns regarding the ﬁ ndings and interpretations of Sheikine and 
co-workers. 
First, plasma CXCL16 levels were only signiﬁ cantly decreased in patients with stable 
angina and not in patients with unstable angina, a more severe coronary syndrome 
associated with increased plaque activity (ﬁ g 1a of Sheikine et al). A high inter-per-
son variability of the CXCL16 plasma concentrations and small groups, which might 
decrease the power of analyzed data, were stated as possible explanations for this 
discrepancy. However, in an almost ten times larger group no signiﬁ cant diﬀ eren-
ces could be seen between patients with a recent myocardial infarction and healthy 
controls (ﬁ g 1b of Sheikine et al). Th erefore, the results that were obtained compa-
ring the stable angina patients with the healthy control group, on which the authors 
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based their hypothesis, become controversial. Perhaps the relation between the onset 
of CAD symptoms and the moment when CXCL16 measurements were performed 
might be of interest, since decreased levels are found aft er three days in the stable and 
unstable angina patients while this is no longer present aft er three months in patients 
with myocardial infarction. Th is however was not investigated.
Second, the interpretation of the results by the authors suggests that the soluble form 
of CXCL16 can bind oxLDL. Th is might be true since CXCL16/SR-PSOX exerts its 
scavenger role through its chemokine domain 6, which is present in both membrane 
bound and cleaved CXCL16. However, a scavenger eﬀ ect has thus far solely been 
demonstrated for membrane bound CXCL16/SR-PSOX. Th e authors oﬀ er no data 
to demonstrate the eﬀ ect of a direct interaction between soluble CXCL16 and ox-
LDL, which makes the hypothesis that less circulating CXCL16 is associated with less 
oxLDL scavenging debatable. One could propose that decreased circulating soluble 
CXCL16 levels reﬂ ects an elevated expression of membrane-bound CXCL16/SR-
PSOX, which may contribute to enhanced uptake of LDL and foam cell development. 
However, it has never been shown that enhanced cellular expression of CXCL16 is 
correlated with lower levels of soluble CXCL16. Th is would be dependent on acti-
vity of proteases such as ADAM-10, which has not been taken into account by the 
authors. Furthermore, it has never been shown that activity of ADAM-10 in terms 
of CXCL16 cleavage would be diﬀ erent in pathological conditions. In addition, the 
authors have assessed no other scavenging systems for oxLDL, which might also have 
an inﬂ uence on the development of atherosclerotic plaques.  
Despite these caveats, the study by Sheikine and colleagues suggests a potentially in-
teresting link between CXCL16 and cardiovascular risk. Th is might also be of interest 
in chronic inﬂ ammatory conditions, in which a role for CXCL16 in the pathogene-
sis has been suggested. Interestingly, patients with chronic inﬂ ammatory conditions 
have a signiﬁ cantly increased incidence of cardiovascular disease and related morbi-
dity and mortality. In fact, patients with rheumatoid arthritis have an increased risk 
for developing CAD, which is independent of disease activity 7. Intriguingly, CXCL16 
was recently found to be increased in synovial ﬂ uid and tissue of RA patients 8, 9. Th e 
present study by Sheikine et al contributes to the discussion whether CXCL16 can be 
accounted for this increased cardiovascular risk in chronic inﬂ ammation, which is 
currently under our investigation. 
Altogether, we believe the conclusions by Sheikine et al are preliminary and the rele-
vance of their data can only be valued when a role for cleaved CXCL16 in scavenging 
oxLDL is demonstrated and the current data are conﬁ rmed in larger cohorts, in par-
ticular cohorts with more patients with stable and/or unstable angina. Th e relation 
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between CXCL16 and CAD is certainly intriguing and the paper by Sheikine et al 
emphasizes the complexity of this interesting molecule and encourages thorough re-
search on its role in pathological processes.
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Abstract
CXCL16 acts as a scavenger receptor for oxLDL in its membrane-bound form and 
induces migration of activated T cells in its soluble form. Due to these properties, 
CXCL16  has been suggested to play a role in both atherosclerosis and rheumatoid 
arthritis (RA). Our aim was to evaluate the contribution of soluble CXCL16 to the 
scavenging of oxLDL and its potential as a marker for cardiovascular disease (CVD) 
in patients with RA. We found that circulating CXCL16 was not correlated with 
plasma oxLDL or ApoB and was not related to the presence of CVD in RA patients. 
Moreover, CXCL16 did not bind and scavenge oxLDL in an in vitro setting. Th ese 
data suggest that binding of oxLDL by soluble CXCL16 does not play a role in athe-
rosclerosis and, although conﬁ rmation in larger studies is needed, that circulating 
CXCL16 is not related to the presence of CVD in patients with RA. 
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Introduction
Atherosclerosis is one of the hallmarks of cardiovascular disease (CVD). Although 
the exact processes that drive atherosclerosis remain to be identiﬁ ed, there is substan-
tial evidence to support the concept that atherosclerosis is an inﬂ ammatory process 
1. Inﬁ ltration by leucocytes, such as T lymphocytes and monocytes, is one of the key 
features in the formation of atherosclerotic plaques 2. Monocytes that are attracted 
to the vessel wall diﬀ erentiate into activated macrophages, which subsequently can 
transform into cholesterol loaded foam cells 3. Oxidation of LDL and internalization 
of oxidized LDL (oxLDL) are considered to be the initiating events in this foam cell 
formation 4, 5 and are therefore critical processes in the early development of atheros-
clerosis. Circulating oxLDL has been shown to be useful as a marker for identifying 
patients with coronary vascular disease 6-10. In addition, plasma oxLDL strongly cor-
relates with other predictors of enhanced cardiovascular risk, including LDL-choles-
terol and apolipoprotein B (ApoB) 11-13. 
In order to internalize oxLDL, activated macrophages make use of scavenger recep-
tors that are situated on their surface 3. CXC Chemokine Ligand 16 (CXCL16) is a 
trans-membrane molecule that was shown to act as such a scavenger receptor for 
oxLDL 14. Besides on macrophages and dendritic cells 15, CXCL16 is expressed on the 
surface of smooth muscle cells 16, which also take part in the atherosclerotic plaque 
development process. Interestingly, enhanced expression of membrane-bound 
CXCL16 has been found in atherosclerotic plaques, substantiating its potential role 
in the pathogenesis of atherosclerosis 17. Next to its membrane-bound form, CXCL16 
can be shed from the cell surface upon proteolytic cleavage 18 to act as a chemokine 
ligand for CXCR6+ cells 19. Th is receptor is present on activated/memory type T cells, 
plasma cells and NKT cells 19-21. Recently it has been suggested that decreased circu-
lating CXCL16 levels might reﬂ ect an increased risk for CVD and may constitute a 
novel marker for the assessment of cardiovascular risk 22. 
Rheumatoid arthritis (RA) is a chronic inﬂ ammatory disease with an increased mor-
bidity and mortality due to CVD compared with the general population 23. In line 
with this increased prevalence of CVD, RA patients have an increased burden of 
cardiovascular risk factors, including an atherogenic lipid pattern with lower HDL-
cholesterol and elevated plasma oxLDL concentrations 24, altered insulin sensitivity 25
and increased plasma concentrations of pro-inﬂ ammatory markers, including CRP, 
IL-6 and TNF 26. In RA, CXCR6 is highly expressed on synovial ﬂ uid T cells 27-29. 
Furthermore, we recently described the abundant expression of CXCL16 in the sy-
novial compartment in RA, suggesting a role for CXCL16 in the pathogenesis of RA 
29, which was later conﬁ rmed by other groups 28, 30. 
Despite the evidence that supports a role for CXCL16 in atherosclerosis, the potential 
role of its soluble variant in atherosclerosis is unclear, as is the possible contribution 
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of soluble CXCL16 to the increased cardiovascular risk in RA. Th e aim of our study 
was, therefore, to investigate whether circulating CXCL16 levels reﬂ ect this increased 
risk and might compete with membrane-bound CXCL16 -mediated scavenging of 
oxLDL  by binding to oxLDL in a liquid phase.  Here, we provide data that question 
a role for soluble CXCL16 in the process of oxLDL internalization and  its use  in 
cardiovascular risk assessment.
Methods
Patients and samples
RA patients were recruited from the Nijmegen inception cohort, which is an ongoing 
cohort that continuously includes patients with early RA (disease duration <1 year 
and no prior use of disease-modifying anti-rheumatic drugs (DMARDs). For the 
present analysis, thirty consecutively enrolled patients with at least 2 years of follow-
up data were selected. During the study period, a variety of demographical data were 
recorded, including DMARD therapy and cardiovascular co-morbidities, which in 
this case were myocardial infarction, angina pectoris and primary hypertension (Ta-
ble 1). Serum samples were taken at baseline and every three months during the fol-
low-up period. OxLDL, ApoB, CXCL16 and other inﬂ ammatory markers, including 
CRP and ESR, were determined in these samples. In addition, disease activity was 
assessed at each of the above-mentioned time-points using the DAS28 score 31.
Biochemical analyses 
CXCL16 levels were measured with a sandwich Enzyme Linked Immuno Sorbent 
Assay (ELISA)  as described previously 29, 32. Th e detection limit of the ELISA is 100 
pg/ml. All samples were measured in only two separate assays. For oxLDL measu-
rements a commercially available competitive ELISA (Mercodia, Uppsala, Sweden) 
was used and performed according to the manufacturers’ instructions. Plasma ApoB 
levels were determined with ELISA using polyclonal IgG antibodies raised by our-
selves in a goat. Th e antibody is also used for immunonefelometric measurement 
of plasma apolipoprotein B and both assays showed high correlation (r=0.97, n=72; 
data not shown).
CXCL16-oxLDL co-immunoprecipitation
To test whether soluble CXCL16 can bind oxLDL in a liquid phase we performed a 
co-immunoprecipitation assay. First, cobalt beads (BD Biosciences) were washed 3x 
in PBS and transferred into tubes that were pre-coated with 1% BSA in PBS. Next, 
histidine tagged recombinant human CXCL16 (rhCXCL16-His) (R&D systems) was 
incubated with the beads for 2 hours at 4°C in four rising concentrations, all in tri-
plicate. As a negative control, beads without rhCXCL16 were taken along. Th ere-
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aft er, the beads were centrifuged and the supernatant was frozen for later CXCL16 
measurements. Aft er 3 wash steps with PBS, the beads were incubated with a ﬁ xed 
concentration of 76mU/L oxLDL (Mercodia, Uppsala, Sweden) overnight at 4°C. To 
pull down the beads, the solution was centrifuged and oxLDL still present in the su-
pernatant was determined with ELISA as described above. To test whether there was 
still rhCXCL16-His bound to the beads, the beads were washed, eluted with 10mM 
EDTA in PBS and centrifuged. Finally, eluted CXCL16 was measured in the superna-
tant of the eluted beads as described above.
Statistical analysis
Within our group of RA patients, comparisons between diﬀ erent time-points during 
the follow-up period were made using the Wilcoxon signed rank test for non-para-
metric values, while the paired Student’s t-test was use in the case the values were 
normally distributed. A Mann-Whitney test was used to make the comparisons bet-
ween RA patients with and without CVD. Correlations between CXCL16 and lipid 
markers were determined using the Spearman’s test. p-values <0.05 were considered 
signiﬁ cant. Values are expressed as mean (+ standard deviation (SD)), unless stated 
otherwise.
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Results
Patient characteristics
Patient characteristics at baseline are depicted in table 1.  Of all patients, 20% (6/30) 
had cardiovascular co-morbidity before they were enrolled in the study, which was 
either a myocardial infarction (10%, 3/30) or hypertension (10%, 3/30). Notably, all 
3 patients who previously experienced a myocardial infarction were male. During 
the follow-up period, we recorded 2 more cases of ischemic cardiac disease, being 
one angina pectoris in a patient with history of hypertension and one myocardial in-
farction. Th e therapeutic regimen of our patients during the study period comprised 
at least one DMARD in 93% of the patients, while only two patients did not receive 
DMARD treatment during this interval. Disease activity signiﬁ cantly declined from 
a DAS-28 score of 6.0 ± 1.2 at baseline to 3.9 ± 1.2 two years aft er starting anti-rheu-
matic therapy (p<0.0001).
Circulating CXCL16 levels do not correlate with CVD markers in RA patients
As mentioned above, oxLDL and ApoB are considered to be important markers of 
cardiovascular risk 11-13. To assess the possible relation between soluble CXCL16 and 
these markers, we measured circulating levels of these molecules in all patients at 
baseline (table 1) and throughout the follow-up period. Th e mean CXCL16 level was 
4669 ± 1442 pg/ml, which is comparable with results that we found in large panel of 
healthy controls and RA patients 33. In contrast to circulating CXCL16 levels, which 
remained similar to baseline, plasma concentrations of oxLDL and ApoB increased 
during the ﬁ rst two years aft er initiation of conventional anti-rheumatic therapy (data 
not shown). However, the ratio oxLDL/ApoB signiﬁ cantly decreased from 0.09 ± 
0.03 U/mg to 0.06 ± 0.01 U/mg (p<0.002) during the same interval. Soluble CXCL16 
levels neither correlated with plasma oxLDL, nor with plasma ApoB at any of the 
investigated time points (table 2). In contrast, oxLDL and ApoB levels were signiﬁ -
cantly correlated during the entire follow-up period (table 2). Furthermore, CXCL16 
levels were not diﬀ erent in patients with a history of CVD compared to non-CVD 
patients, irrespective to the time-point (table 3). Although plasma oxLDL and ApoB 
levels were not signiﬁ cantly diﬀ erent between RA patients with and without history 
of CVD, both variables were clearly higher in RA patients with CVD (table 3).
Soluble CXCL16 does not bind oxLDL in vitro
Membrane-bound CXCL16 is known to eﬀ ectively bind oxLDL 14. Th e contribution 
of soluble CXCL16 has been discussed in the literature 34, 35 but is still unclear. Th e-
refore, we questioned whether CXCL16 is able to bind oxLDL in a liquid phase. In 
ﬁ gure 1a, we show that incubation of oxLDL with increasing concentrations of rhCX-
CL16-His bound to cobalt beads did not result in a decrease in oxLDL concentrati-
ons, indicating that oxLDL does not stably bind to soluble CXCL16. To make sure 
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CXCL16 was eﬀ ectively bound to the beads, we measured CXCL16 directly aft er in-
cubation. Th is binding was highly eﬀ ective, since 97-99% of the total CXCL16 input 
was bound to the beads (ﬁ gure 1b). Importantly, also aft er incubation with oxLDL 
and several wash-steps, we could eﬀ ectively elute CXCL16 from the beads in a clear 
concentration course (ﬁ gure 1c), indicating that a signiﬁ cant amount of CXCL16 had 
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been present throughout the assay. In order to exclude that the lack of binding  could 
be explained by the temperature at which the assay was performed, we repeated the 
experiment at 37° C, which resulted in similar results (data not shown).
Discussion
In the present study, we showed that circulating CXCL16 levels do not correlate with 
oxLDL levels and are not related to the presence of CVD in patients with RA. Th e 
lack of a correlation between oxLDL and CXCL16 was further substantiated by the 
inability of CXCL16 to stably bind to oxLDL in an in vitro setting. Together, these 
data question a direct contribution of soluble CXCL16 by binding oxLDL to the pro-
cess of atherosclerotic plaque development.
Based on its potential to act as a scavenging receptor for oxLDL 14 and its enhanced 
expression in atherosclerotic plaques 17, 36, CXCL16 was suggested to play a role in 
atherosclerosis. However, there are still several major gaps in our knowledge on the 
role of CXCL16 in foam cell formation. First, the relative contribution of CXCL16 to 
the oxLDL scavenging process in vivo is uncertain, as is the exact consequence of this 
oxLDL binding. Second, the contribution of CXCR6+ T cell attraction to the athe-
rosclerotic process is insuﬃ  ciently investigated. Finally, it is unclear whether soluble 
CXCL16 might play a role in the balance of oxLDL uptake and degradation. Next 
to fractalkine (CX3CR1),  CXCL16 is one of the two known chemokines that exist 
in a trans-membrane form. It has been shown that CXCL16 binds oxLDL through 
its chemokine domain 37, which is located in the extra-cellular part of the molecule. 
One could, therefore, hypothesize that binding of oxLDL to soluble CXCL16 might 
result in a competition with cell surface scavenger receptors and subsequently in less 
oxLDL internalization and foam cell formation. Interestingly, decreased circulating 
CXCL16 levels were recently proposed to be associated with increased cardiovascular 
risk and consequently plasma CXCL16 was suggested to be atheroprotective 22. Th is 
concept, however, is not supported by the data from the present study, since we sho-
wed that CXCL16 does not correlate with oxLDL in vivo and does not bind oxLDL in
vitro. Moreover, we found no diﬀ erences in circulating CXCL16 levels between RA 
patients with and without cardiovascular co-morbidities. To draw ﬁ rm conclusions 
on this relation, this ﬁ nding should be conﬁ rmed in a larger cohort with individuals 
that do not have RA as a concomitant disease, since both RA and the small number of 
patients evaluated in the present study may inﬂ uence the relation between CXCL16 
levels and CVD. However, we and others have recently shown that serum CXCL16 
levels in RA are not signiﬁ cantly diﬀ erent from those in healthy controls 28 33. Th is 
implicates that our results cannot be explained by altered CXCL16 levels in RA that 
may bias the correlation between CXCL16 and oxLDL. Th us based on our results, 
decreased CXCL16 levels do not appear to be correlated with CVD.
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Recently, other evidence supporting an atheroprotective role for CXCL16 came from 
experiments using murine models 38. Accordingly, it was shown that CXCL16 and 
LDL receptor double knockout mice suﬀ ered from an accelerated development of 
atherosclerosis as compared with LDL receptor -/- mice.  Th is was highly intriguing, 
since macrophages from CXCL16 -/- mice internalized signiﬁ cantly less oxLDL com-
pared to wild-type macrophages, which suggests that oxLDL binding by CXCL16 
might not result in typical foam cell formation that favours atherosclerosis. Interes-
Figure 1: 
Recombinant human CXCL16 does not bind oxLDL in vitro
Panel A represents the amount of oxLDL that was recovered in the supernatants of solutions of oxLDL (76 mU/L) 
after incubation with CXCL16 coated beads and subsequent pull-down. Beads coated with increasing concentrations 
of CXCL16 were incubated with a stable concentration of oxLDL (76 mU/l). Absolute values are given on top of the 
bars. The bars represent mean and SEM of triplicates and the ﬁ gure represents one of two individual experiments. 
Panel B shows the efﬁ cacy of the binding of rhCXCL16-His to cobalt beads. The bars represent the concentration of 
CXCL16 that was measured in the supernatant of the beads solution after centrifugation and the percentage of effec-
tive binding is shown on top of the bars. The bars represent mean and SEM of one out of two experiments performed 
in triplicate. CXCL16 measurements were done in duplicate. ND = Not detectable. 
Panel C shows the concentration of CXCL16 that was eluted from the cobalt beads after incubation with oxLDL. The 
bars represent mean and SEM of one out of two experiments performed in triplicate. CXCL16 measurements were 
done in duplicate.
tingly, 80% more apoptosis was found among CXCL16   -/- macrophages compared 
to wild-type macrophages, which might be an explanation for accelerated atheros-
clerosis, but needs to be further investigated. Studies comparing CXCL16 -/- macro-
phages with macrophages deﬁ cient of other scavenger receptors may reveal whether 
processing of oxLDL via CXCL16 is atheroprotective. Another explanation for ac-
celerated atherosclerosis in CXCL16 -/-  LDL receptor -/- mice might have been the 
lack of soluble CXCL16 as a competitive binder of oxLDL. However, given the data 
from the present study, this is rather unlikely. 
In summary, our study does not advocate a role for circulating CXCL16 levels as 
a marker for the atherosclerosis and/or subsequent cardiovascular disease in RA. 
Whether the membrane-bound form of CXCL16 and its ability to internalize oxLDL 
acts pro- or anti- atherogenic remains the major question to be answered.
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chapter 8
FINAL CONSIDERATIONS

Chemokines orchestrate leukocyte migration. For this reason they play a pivotal role 
in immune responses in general and in inﬂ ammatory diseases such as RA. APC and 
T cells are two groups of leukocytes which are both crucial players in immunity and 
tolerance and hence in various auto-immune diseases. Chemokines are instrumental 
in establishing the interaction between leukocytes, including APC/T lymphocyte in-
teractions. Herein, we explored the potential role of two relatively novel chemokines 
that are secreted by APC to attract T lymphocytes: CCL18 and CXCL16. In chapter 
2 t/m 7, we provided novel data on the potential role and regulation of these chemo-
kines in general and in RA.
CCL18
Th e chemokine CCL18 is expressed and secreted by myeloid cells such as DC and 
macrophages. In chapter 3,  we showed that resting monocytes do not secrete signiﬁ -
cant amounts of CCL18 protein 1. However, when stimulated with the Th 2 cytokines 
IL-4 or IL-13, they rapidly secrete CCL18. Th erefore, it seems that CCL18 secretion 
by myeloid cells is induced by IL-4 or IL-13, although these cytokine eﬀ ects cannot 
be easily separated from their role in cell diﬀ erentiation, e.g. the generation of MoDC 
in the presence of IL-4 and GM-CSF. Based on our results from chapter 2 and 3, there 
seems to be some discrepancy between regulation on mRNA and protein level. In 
contrast to CCL18 protein secretion (chapter 3) 1, CCL18 mRNA expression is upre-
gulated upon maturation, as shown in chapter 2 2. As for DC maturation, the eﬀ ect of 
TNF-α on CCL18 expression and secretion also appear to be inconsistent. In chapter 
2, we showed that the strong increase in CCL18 mRNA upon DC maturation could 
be inhibited by neutralizing endogenous TNF-α, independently of the maturation 
state 2. However, in chapter 3 we found that stimulation of monocytes/macrophages 
with TNF-α did not sort any eﬀ ect on CCL18 protein secretion 1. Th e diﬀ erence bet-
ween CCL18 mRNA and protein might suggest that CCL18 secretion can be further 
upregulated by additional stimuli, which are yet unknown. Recent data from Auer 
and colleagues on CCL18 expression and secretion by neutrophils underscore this 
distinct regulation on mRNA and protein level 3. In this study, TNF-α also indu-
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ced CCL18 mRNA but not protein.  For protein release, an additional stimulus, e.g. 
IL-10, was needed. Interestingly, they too found evidence suggesting an additional 
CCL18 inducing factor in RA joints, in line with our data from chapter 3 1. Detailed 
studies on CCL18 mRNA vs. protein regulation would be of interest to solve this part 
of the CCL18 regulation puzzle. As DC maturation by itself did not sort any eﬀ ect 
on CCL18 secretion by MoDC, it is not surprising that we did not observe eﬀ ects 
on CCL18 secretion on protein level upon blocking TNF-α during maturation (van 
Lieshout et al, unpublished observations). Th e direct eﬀ ects of TNF-α on CCL18 
secretion in vitro therefore seem to be limited. In vivo however, we did observe a 
signiﬁ cant decrease in circulating CCL18 levels upon neutralizing TNF-α in patients 
with RA, as shown in chapter 6 4. However, it would be preliminary to conclude that 
this comprises a direct eﬀ ect of TNF-α blockade, as TNF-α is a pleitropic cytokine 
aﬀ ecting multiple direct and  indirect pathways. For instance, anti-TNF-α was re-
cently associated with the induction of a distinct population of regulatory T cell 5 and 
altered DC phenotype 6, which might have an eﬀ ect on circulating cytokine and/or 
chemokine levels. Perhaps in vivo the eﬀ ect of TNF-α on CCL18 expression is trans-
lated from mRNA to protein due to the eﬀ ect other mediators which are not present 
in vitro, leading to the apparent contrast between in vivo and in vitro regarding the 
eﬀ ect of TNF-α on CCL18 protein. Taken together, TNF-α may have its inﬂ uence 
on CCL18 through eﬀ ects on mRNA production, but pathways leading to eﬀ ects on 
protein secretion are yet to be elucidated. 
Th e anti-inﬂ ammatory cytokine IL-10 proved to be a strong inducer of CCL18 pro-
tein secretion. Interestingly, IL-10 is a well appreciated inhibitor of DC maturation 
7. Since DC maturation itself did not sort any eﬀ ect on CCL18 secretion, these data 
suggest that IL-10 acts as a direct inducer of CCL18. Moreover, IL-10 also induced 
CCL18 secretion by monocytes and not only DC. Perhaps the most intriguing ob-
servation is that IL-10 acts in strong synergy with IL-4 and IL-13. Th ese synergistic 
eﬀ ects of IL-10 on CCL18 secretion by monocytes/macrophages explain the large 
amounts of secreted CCL18 by MoDC that were stimulated with IL-10, as these cells 
were already primed with IL-4. As IL-4 and IL-13 are key players in the regulation 
of CCL18, CCL18 is well suitable as a marker for “alternative activation” of myeloid 
cells, which is now commonly accepted in literature 8-10. Although the eﬀ ects of IL-
4/IL-13 and IL-10 on CCL18 secretion are unmistakable, it would be preliminary to 
conclude that these are “THE” CCL18 inducing agents. For one, it is still unknown 
which intracellular signaling cascades drive CCL18 secretion. Elucidation of these 
cascades would help to identify novel mediators that drive CCL18 protein secretion. 
Furthermore, this might help to unravel which mediators present in RA SF cause the 
strong synergistic eﬀ ects we showed in chapter 3 1. More knowledge on CCL18 re-
gulation will ultimately lead to an increased understanding of  the physiological role 
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of this chemokine, CCL18 levels are elevated in serum (chapter 6) and synovial ﬂ uid 
of RA patients 4, 11, its mRNA expression level by MoDC is elevated in RA (chapter 
2) 2, 12 and protein expression is enhanced in RA ST (chapter 3) 1, 12. Th e most obvi-
ous explanation for elevated circulating CCL18 levels in RA would be an enhanced 
CCL18 secretion by myeloid cells. In contrast to mRNA 2, 12, we did not detect signi-
ﬁ cant diﬀ erences in CCL18 protein secretion between mature DC from RA patients 
and healthy controls in vitro. 1. Th is may indicate that an additional trigger is needed 
to induce enhanced CCL18 protein secretion in RA, as already suggested above. In 
this light, the synergistic eﬀ ects of RA SF on CCL18 (chapter 3) are intriguing 1, as 
this SF may contain such an additional factor. Th is then is likely to be a local fac-
tor in RA joints, as pre-incubation in vitro with RA SF enhanced CCL18 secretion, 
whereas freshly RA blood monocytes do not secrete more CCL18 upon stimulation 
than monocytes that have not encountered a RA environment in vivo. Intriguingly, 
this “imprinting” phenomenon in RA joints was recently also suggested as an expla-
nation for high CCL18 secretion by neutrophils isolated from RA joints 3. Another 
explanation for enhanced CCL18 expression in RA may be increased amounts of 
CCL18 secreting cells, although elevated circulating leukocyte counts are not typical 
for RA. Finally, elevated levels of IL-10, which have been reported in literature 13, or 
IL-4 or IL-13 may contribute to elevated CCL18 levels in RA. Whether a causal rela-
tion exists between levels of these cytokines and CCL18 levels however is diﬃ  cult to 
investigate in the in vivo setting. 
As discussed above, the functional role of CCL18 in humans is still largely unknown 
and novel insights in its functions in vivo are only reported sporadically. For one, 
the lack of a murine CCL18 homologue and has prevented relatively straight for-
ward murine studies on the functional role of CCL18 in vivo. Interestingly, some 
groups have investigated the eﬀ ects of human CCL18 in mice. Bruna-Romero and 
colleagues used an adenoviral vector to over-express human CCL18 in a murine ma-
laria model 14 and Pochetuhen and colleagues examined the eﬀ ects of human CCL18 
in a murine model of pulmonary ﬁ brosis 15.  Th ese experiments are all based on the 
assumption that a yet unknown receptor for CCL18 does exist in mice. Although 
these studies have claimed some eﬀ ects of CCL18, without clear evidence for the 
existence of a CCL18 receptor these data should be regarded as anecdotal. In a pilot 
study, we could not observe any chemotactic eﬀ ect of intra-articular injection of ad-
CCL18 into murine knee joints, despite the fact that signiﬁ cant amounts of CCL18 
protein could be detected in the joints (unpublished observations). Perhaps models 
using macaques could provide additional information on the role of CCL18 in vivo, 
as has been suggested previously 16. Alternatively, humanized-mouse models could 
be explored. Besides the lack of a murine variant, CCL18 research is hampered by 
the fact that a high aﬃ  nity receptor is still unknown. Identiﬁ cation of either a high 
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aﬃ  nity receptor or (multiple) low aﬃ  nity receptor(s) will lead to crucial new tools for 
CCL18 research, e.g. blocking studies to gather more precise data on its chemotactic 
properties. Moreover, detecting its target cells in vivo would help to identify the role 
of CCL18 in inﬂ ammation. Reviewing the currently available literature, the question 
whether CCL18 acts pro- or anti-inﬂ ammatory in vivo remains unanswered. In ge-
neral, CCL18 is well appreciated for its role as a chemotactic agent for Th 0 cells 17. 
In addition, it has been shown that CCL18 may also attract other T cell subsets and 
germinal centre B cells under certain circumstances 18-21. Th e ability to attract these 
leukocytes and its secretion by APC suggests that CCL18 plays a role in the initia-
tion of immune responses. Its in vivo expression in germinal centers and lymphoid 
structures is in line with this hypothesis. However, it is unknown what the exact 
contribution of CCL18 is to T cell attraction, in comparison to other Th 0 cell at-
traction chemokines such as CCL19.  In RA, strategic CCL18 expression in the ST 
and its chemotactic properties may result in attraction of Th 0 cells towards the site of 
inﬂ ammation. As the factors that drive CCL18 secretion are mostly anti-inﬂ amma-
tory, this would imply that CCL18 secretion in RA inﬂ amed RA joints is intended as 
an anti-inﬂ ammatory response. However, it is unclear whether the eventual result of 
Th 0 inﬂ uxes in RA joints is pro- or anti-inﬂ ammatory, since this is dependent on the 
diﬀ erentiation of Th 0 cells. Th 0 cells can diﬀ erentiate into Tregs or go into apoptosis 
upon contact with APC, resulting in an anti-inﬂ ammatory response. In contrast, the 
inﬂ amed RA environment, with its abundance of pro-inﬂ ammatory cytokines, may 
also result in diﬀ erentiation of Th 0 cells into activated Th 1-like cells, resulting in a 
pro- in stead of anti-inﬂ ammatory response.
Despite the uncertainty of the eventual eﬀ ect of CCL18 secretion in RA, its circula-
ting levels may correlate with clinical disease activity scores, which we demonstrated 
in chapter 6 4. Although CCL18 signiﬁ cantly correlated with disease activity, this 
correlation was rather low. Th us, CCL18 has little or no additional value as a disease 
marker over the existing ones, such as the DAS-28 and its individual constituents. 
Moreover, elevated CCL18 levels are not exclusive for RA but have now been des-
cribed in a variety of diﬀ erent auto-immune diseases 22-27, amongst others  SSc 28, 29
and SLE 30. Especially in SSc, the potential impact of CCL18 might go further than in 
RA. First, its pro-ﬁ brotic eﬀ ects 31 make this chemokine a highly interesting subject 
of investigation in SSc, a disease in which ﬁ brosis is one of the hallmarks. Second, 
CCL18 may be a downstream player in this disease in which expression of Th 2 cyto-
kines is enhanced 32. In turn, CCL18 may contribute to the disease process through 
T cell attraction. Recently, CCL18 levels were shown to be elevated in patients with 
SSc by independent groups 28, 29. Interestingly, CCL18 has indeed been suggested as 
a novel clinical marker for pulmonary ﬁ brosis in SSc 28, 29. Large prospective cohorts 
are however needed to validate the potential of CCL18 as a clinical marker for disease 
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activity in SSc and further experimental studies will have to determine the exact role 
of CCL18 in the pathogenesis of SSc, as is the case for RA. 
Taken together, the currently available data are at least suggestive for some involve-
ment of CCL18 in the complex pathogenesis of RA. However, as yet, any suggesti-
on regarding the use of CCL18 as a therapeutic target in RA would be preliminary. 
Further research on CCL18 and other chemokines is essential to determine the im-
portance of CCL18 within the “chemokine world” in general, and in  RA pathogene-
sis and treatment in particular.
CXCL16
Th e T cell attracting chemokine CXCL16 is now believed to play a role in a variety 
of inﬂ ammatory conditions. Although CXCL16 is indisputably secreted by myeloid 
cells, the triggers that induce this secretion are still largely unknown. In chapter 5 
and 6, we provided novel insights in the regulation of CXCL16 expression and secre-
tion by myeloid cells, both in general and in RA 33, 34. Interestingly, simply culturing 
monocytes proved to be the strongest trigger for CXCL16 upregulation in vitro. As 
monocytes diﬀ erentiate into macrophages or DC in vitro, this suggests that monocy-
tes may upregulate CXCL16 expression when entering the tissues to diﬀ erentiate into 
macrophages or DC. It is therefore tempting to hypothesize that CXCL16, like CC18 
35, 36, may be useful as a marker for tissue residing myeloid subsets in vivo.  Based on 
our results from chapter 4 33, TNF-α seems to act directly on CXCL16 secretion by 
day 2-3 macrophages. In chapter 5, we show that this eﬀ ect is absent in freshly isola-
ted monocytes 34. Th e explanation for this apparent inconsistency was a decrease in 
CXCL16 expression in unstimulated myeloid cells aft er 36-48 hours, which did not 
take place when cells were stimulated with TNF-α, growth factors or other cytokines 
(unpublished observations). Moreover, cells that became CXCL16 negative aft er 48 
hours died within 72 hours of culture, in contrast to CXCL16 positive cells. TNF-α 
therefore does not directly induce CXCL16 expression on monocytes/macrophages, 
but rather preserves CXCL16 expression compared to unstimulated myeloid cells in 
vitro. In chapter 6, we observed some eﬀ ect of anti-TNF-α treatment in RA patients 
on circulating CXCL16 levels, but this eﬀ ect was inconclusive 4. As for CCL18, this is 
unlikely to be a direct eﬀ ect of TNF-α neutralization.
While monocyte culture or diﬀ erentiation into DC or macrophages was the stron-
gest trigger to induce CXCL16 expression and secretion, Th 1 vs. Th 2 polarization 
also has some eﬀ ect on CXCL16 expression. In chapter 5, we demonstrated a small 
eﬀ ect of IFN-γ on CXCL16 secretion by cultured monocytes in vitro 34. Th is eﬀ ect 
was not observed on CXCL16 membrane expression at 36 hours (data not shown). 
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Recently, a positive eﬀ ect of IFN-γ on CXCL16 membrane expression was reported 
37. However, this contrast with our ﬁ ndings is diﬃ  cult to judge, as diﬀ erent controls 
were used. Omitting IgG controls may introduce a bias, especially since IFN-γ is well 
appreciated for its eﬀ ect on FcR expression. In contrast to the Th 1 cytokine IFN-γ, 
the Th 2 and anti-inﬂ ammatory cytokines IL-10, IL-4 and IL-13 inhibited CXCL16 
secretion to some extend. Th is eﬀ ect on CXCL16 secretion is interesting, the more 
since it is exactly opposite to what is observed for CCL18. In vivo studies will have 
to reveal whether CCL18 and CXCL16 play an important role in typical Th 1 or Th 2 
driven diseases, although these T helper dogma’s may lead to over-simpliﬁ cation of 
the underlying immunological process of inﬂ ammatory diseases. Given the high cir-
culating levels of both CXCL16 and CCL18 in vivo, it might be interesting to inves-
tigate whether these chemokines have opposing functional properties next to oppo-
sing regulation. In contrast to Th 2 cytokines, DC maturation had little or no eﬀ ect 
on CCL18 or CXCL16, while it is well known to induce CCL19, a chemokine that is 
important for migration of both APC and T cells towards lymph nodes. Th e fact that 
tissue resident DC and macrophages secrete large amounts of CXCL16 suggests that 
CXCL16 might be important for co-localization of these cells and T lymphocytes in 
tissues, which may induce or maintain inﬂ ammatory responses. Th e elevated local 
CXCL16 expression in a large variety of inﬂ ammatory diseases appears to be in line 
with this hypothesis. As CXCL16 attracts activated T cells in stead of Th 0 cells which 
can still diﬀ erentiate for instance Tregs, CXCL16 secretion in inﬂ ammatory diseases 
is likely to have a pro-inﬂ ammatory eﬀ ect.
Th e ﬁ rst evidence for a role for CXCL16 in RA came when its receptor CXCR6 was 
found to be highly expressed in RA joints 38. In chapter 4, we were the ﬁ rst to de-
monstrate that CXCL16 expression is enhanced in RA ST and able to attract acti-
vated T lymphocytes 33. Th is again suggests that CXCL16 might play a role in the 
pathogenesis of RA. As soluble CXCL16 is found in the circulation in large amounts, 
we hypothesized that this may reﬂ ect disease activity in RA in chapter 6. Th is ho-
wever was not the case, as CXCL16 levels did not correlate with disease activity 4. 
Based on these results, measuring circulating CXCL16 as a diagnostic or disease ac-
tivity marker for RA has no additive value. Th is however does not exclude a role for 
CXCL16 in the pathogenesis of RA. First, we found high CXCL16 expression locally 
in the ST of RA patients, suggesting that it may play a role in local inﬂ ammation. 
Second, it is debatable whether circulating levels reﬂ ect total expression, as a fraction 
of CXCL16 is membrane-bound and is not measured in serum or plasma. Perhaps 
local CXCL16 expression in the ST may reﬂ ect disease activity, which needs to be 
examined in studies using synovial biopsies, preferentially in a prospective cohort of 
RA patients with tight monitoring of clinical disease parameters. As CXCL16 may be 
an important factor for local synovial inﬂ ammation, it’s neutralization may be bene-
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ﬁ cial in RA. However, we are still in the very beginning of CXCL16 research in vivo. 
Nonetheless, the ﬁ rst study which neutralized CXCL16 in murine collagen induced 
arthritis (CIA) provided encouraging results 39. Th ese results need to be conﬁ rmed  in 
other arthritis models, including CXCL16 -/- or CXCR6 -/- mice. A potential draw-
back is that it is unknown what the eﬀ ect of CXCL16 or CXCR6 neutralization might 
be in terms of physiology. CXCL16 -/- mice are viable, but too little is known about 
their defence against micro-organisms or predisposition for malignancies. In this 
light, a local approach might be preferred. However, in clinical practise, techniques 
aiming to achieve local neutralization in the joint are still a major challenge. Per-
haps gene therapy is an interesting method to accomplish such local neutralization 
in the future.  Very recently, a promising study was published on safety and eﬃ  cacy 
of gene transfer for Leber’s congenital amaurosis, which may encourage investiga-
tors to further explore this therapeutic strategy. Next to murine knock-out or bloc-
king studies, another potentially interesting approach to study the functional role of 
CXCL16 in vivo would be to label CXCR6 positive cells to examine their homing in 
vivo in inﬂ ammatory conditions. Th is would allow us to investigate whether inﬂ uxes 
of CXCR6+ cells appear prior to clinical signs of joint inﬂ ammation, which in turn 
would plead for CXCL16 or CXCR6 neutralization as a therapeutic strategy in RA. 
Th e safety of such an experiment of course needs to be determined in in vitro and 
murine models. However, recently developed techniques such as MRI in cancer 40 are 
promising and might be worth evaluating in inﬂ ammation as well.
As mentioned above, CXCR6 expression in RA was found prior to CXCL16 expres-
sion 38. Until recently, CXCR6 expression was conﬁ ned to lymphocytes. However, 
Ruth and colleagues recently claimed CXCR6 expression by synovial macrophages 
and migration of monocytes towards CXCL16 41. Obviously, this ﬁ nding would have 
great consequences for our understanding of the role of CXCL16 and CXCR6, both 
in general and in RA. As monocytes would migrate towards CXCL16, this would 
imply that either a CXCR6 is expressed on monocytes, or another CXCL16 receptor 
exists. Moreover, it would imply that both receptor and ligand are present on the 
same cell. Th is by itself is not unique, as for instance CCL19 is secreted by mature DC 
that also express its receptor CCR7. Interestingly, the adhesive capacities of CXCL16 
42 suggest that expression of both a surface bound ligand and its receptor may play a 
role in macrophage to macrophage adhesion and subsequently in the maintenance 
of the synovial lining. However, neither on protein level (FACS), nor on mRNA le-
vel (PCR) could we detect CXCR6 expression (unpublished observations), while we 
consistently found high expression on SF lymphocytes and a stable expression on 
blood lymphocytes 33. Since migration of myeloid cells towards CXCL16 has also not 
been conﬁ rmed by others, a role for CXCL16 in attracting myeloid cells in RA ST 
is still debatable. It is of the utmost importance to conﬁ rm or reject the hypothesis 
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that  CXCL16 acts on myeloid cells. As also the role of CXCL16 in cell adhesion is 
not generally accepted one should be cautious in drawing conclusions regarding this 
topic. In conclusion, much is still to be further investigated on the role of CXCL16 
and CXCR6 in RA joints.
RA is an independent risk factor for atherosclerosis and patients with RA have been 
shown to have an accelerated atherogenesis and 43-45, a condition that is driven by 
internalization of oxLDL, subsequent foam cell formation and local inﬂ ammation 
46, 47.  Next to T cell attraction, CXCL16 has been proposed to act as a scavenger 
receptor for oxLDL 48. As  CXCL16 expression was found in atherosclerotic plaques 
49,  it was suggested to play a role in atherosclerosis. In addition, it was recently 
shown that hyperhomocysteinemia upregulates CXCL16 expression 50. However, the 
exact role of CXCL16 in atherosclerosis is unclear. As membrane-bound CXCL16 
contributes to internalization of oxLDL, it would seem likely that it enhances athe-
rosclerosis though acting in favour of foam cell formation. It is therefore remarkable 
that decreased plasma CXCL16 levels were associated with coronary artery disease 
in humans 51. In contrast, others found that elevated CXCL16 levels were correlated 
with coronary artery disease. In this study, CXCL16 was suggested to be a marker 
for atherosclerosis and acute coronary syndromes 52. In addition, a polymorphism of 
CXCL16 was found to be associated with severity of coronary artery disease 53 , which 
unfortunately has not been conﬁ rmed in a second cohort yet. Surprisingly, targeted 
disruption of CXCL16 accelerated atherosclerosis in a murine model 54, suggesting 
that CXCL16 might have an atheroprotective role. Th e mechanism behind this ef-
fect however remained unclear, as mice lacking CXCL16 expression were less capa-
ble of internalizing oxLDL. Th is in turn would suggest that oxLDL uptake through 
CXCL16 does not act in favour of atherosclerosis, which rises against the common 
opinion that oxLDL uptake is a pro-atherogenic feature.  Th e latter is supported by 
several previous studies 55-59. Th e question that rises upon these results is whether 
oxLDL uptake by CXCL16 is functionally diﬀ erent from oxLDL uptake by other 
scavenger receptors. A recent study, showing that mice deﬁ cient of the scavenger 
receptors SR-A and CD36 were not protected against atherosclerosis but even had 
accelerated atherosclerosis 60, does not support this idea and even questions the role 
of scavenger receptors as a group. Th e pro’s and contra’s regarding a causal role for 
CXCL16 in atherosclerosis were recently discussed in an elegant review by Sheikine 
and Sirsjö 61. When all currently available data on the role of CXCL16 are taken into 
account, it is highly debatable whether circulating CXCL16 levels can be related to 
atherosclerosis, which is in line with our data from chapter 7 62, 63. Although factors 
that act in favour of atherosclerosis have been described in RA 43, 64-66 and CXCL16 
might play a role in its pathogenesis, it is unlikely that soluble CXCL16 plays a role in 
this susceptibility to atherosclerosis as soluble CXCL16 does not internalize oxLDL 
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and systemic CXCL16 levels are not elevated in RA 63, regardless of disease activity. 
Moreover, we did not observe any correlations between soluble CXCL16 levels and 
circulating levels of the well appreciated marker for cardiovascular disease apoli-
poprotein B (apoB) 67-69. In general, soluble CXCL16 might still play a signiﬁ cant role 
in atherosclerosis through its ability to attract activated T cells, which may in turn be 
important for the maintenance of the local inﬂ ammatory response that is typical for 
atherosclerosis. Th erefore more in depth research on the role of CXCL16 is warran-
ted, to determine the role of both membrane-bound CXCL16 and soluble CXCL16. 
Nonetheless, the currently available data do not directly support neutralization of 
CXCL16 as a strategy to combat atherosclerosis, since it is still uncertain whether 
CXCL16 is a force to support or combat in atherosclerosis.
In summary, there is now substantial evidence supporting a role for CXCL16 and 
CXCR6 in the pathogenesis of RA. Th e exact contribution of this chemokine-recep-
tor pair to inﬂ ammation in RA needs to be determined by further studies in the 
following years. Regarding the potential role of CXCL16 in atherosclerosis, things 
are currently becoming more complex rather than more clear, which makes any pre-
diction on its potential as a therapeutic target almost impossible. 
Concluding remarks
In the present thesis, we aimed to explore the potential of CCL18 and CXCL16 as 
a therapeutic target and as a clinical marker in RA. Considering the ﬁ rst goal, it is 
critical to understand the function of a molecule in health and disease. Regarding 
CCL18, this knowledge is far from suﬃ  cient and CCL18 is still more or less a black 
box. Th e currently available data on CCL18 do not directly lead to great optimism on 
its potential as a target in RA. Perhaps chances are better in SSc, especially as it might 
play a dual role in this disease. Although serum CCL18 did correlate with disease 
activity, it seems to be safe to conclude that CCL18 is not suitable as a single marker 
for RA disease activity. For CXCL16, there is no evidence supporting the use of so-
luble CXCL16 in serum as a clinical marker for follow-up purposes in RA. Whether 
CXCL16 is useful as a marker for atherosclerosis also remains to be elucidated. Me-
anwhile, it will be interesting to follow the discussion on CXCL16 as a atherogenic 
or atheroprotective agent in atherosclerosis. Although much more is to be learned 
about the function of CXCL16 and CXCR6, intervening in their interaction might 
be useful as a tool to combat RA. Whether this potential intervention would be best 
directed against CXCL16 or CXCR6 and which tools would be best suited for this 
purpose will be a future challenge for investigators in the ﬁ eld.  Additional research 
is clearly needed to determine the potential of interfering with “traﬃ  c control” by 
means of targeting CXCL16, CCL18, or other chemokines in RA.
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chapter 9
SUMMARY

Rheumatoid arthritis (RA) is a chronic auto-immune disease which is characterized 
by joint inﬂ ammation, potentially leading to cartilage damage and bone erosions. 
As for many inﬂ ammatory diseases, a variety of leukocytes play a critical role in the 
pathogenesis of RA. T cells and antigen presenting cells (APC), such as dendritic 
cells (DC) and macrophages, are two groups of leukocytes which are believed to play 
a role in RA. Th ese APC and T cells interact in order to initiate immune responses. 
Th is APC-T cell interaction is facilitated by T cell attracting chemokines that are 
secreted by APC. In this thesis, our aim was to investigate the potential role of two 
of relatively new T cell attracting chemokines, namely CCL18 and CXCL16, in the 
pathogenesis of RA. 
In previous experiments, we started with a large panel of chemokines of which se-
veral were identiﬁ ed as potentially interesting in RA, including CCL18 and CXCL16. 
In chapter 1, we introduce CCL18 and CXCL16 as potential mediators in the pa-
thogenesis of auto-immune diseases such as RA. In chapter 2, we show that in vitro
monocyte derived DC (MoDC) from RA patients have a higher mRNA expression of 
the chemokines CCL17, CCL18, CCL19, CCL22, CCL3 and CXCL8 when compared 
with MoDC from healthy controls. Neutralization of TNF-α is now a successful the-
rapeutic strategy in patients with RA and may have an eﬀ ect on chemokine expres-
sion. Although the DC phenotype is not altered by TNF-α neutralization, MoDC 
matured in the presence of soluble TNF-α receptors secrete lower cytokine levels and 
have a lower mRNA expression of T cell attracting chemokines such as CCL18. In 
chapter 3, we show that CCL18 protein is strategically expressed in RA ST. As CCL18 
might play a role in RA, we were interested in its regulation on protein level. In chap-
ter 3, we demonstrate that CCL18 protein secretion is driven by IL-4 and IL-13, in 
strong synergy with IL-10. In contrast, stimulation with pro-inﬂ ammatory cytokines 
has no eﬀ ect on CCL18 protein secretion in vitro. Interestingly, incubation with sy-
novial ﬂ uid (SF) from RA patients signiﬁ cantly enhances the CCL18 inducing eﬀ ects 
of IL-4, IL-13 and IL-10, suggesting another yet unknown CCL18 inducing factor is 
present in RA SF.
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Th e chemokine receptor CXCR6, which is present on activated T cells,  was recently 
shown to be abundant in RA SF. Th is prompted us to investigate the expression of its 
only ligand, CXCL16, in RA. In chapter 4, we demonstrate elevated CXCL16 expres-
sion in RA ST and SF of RA patients. Furthermore, we show that CXCL16 is functio-
nally capable of attracting memory type T cells from RA SF, potentially contributing 
to T cell inﬂ uxes in RA joints. In chapter 5, we further investigated the regulation of 
CXCL16 secretion in general and in RA. In this study, we show that monocyte dif-
ferentiation by itself is the strongest inducer of CXCL16 expression and secretion in 
vitro. To a lesser extend, cytokines have a positive (IFN-γ) or negative (IL-4, IL-13, 
IL-10) eﬀ ect on CXCL16 secretion. Although local CXCL16 expression is elevated 
in RA joints, regulation of CXCL16 in myeloid cells in vitro is not altered in RA pa-
tients.
As CCL18 and CXCL16 might play a role in the pathogenesis of RA, we were in-
terested in their circulating levels and potential as clinical markers. In chapter 6, 
we show that serum CCL18 levels but not serum CXCL16 levels are elevated in RA 
patients. Moreover, we show that CCL18 levels signiﬁ cantly correlate with disease 
activity, while neither CCL18 nor CXCL16 levels correlate with joint damage. Neu-
tralization of TNF-α in vivo results in decreased serum levels of both chemokines, 
independently of disease activity. Next to its chemokine function, CXCL16 also acts 
as a scavenger receptor for oxidized LDL (oxLDL), which may be of interest in RA, as 
patients with RA have an enhanced cardiovascular morbidity. In chapter 7, we show 
that serum CXCL16 levels do not correlate with other markers of atherosclerosis in 
patients with RA. In addition, we demonstrate that CXCL16 does not bind oxLDL 
in a liquid phase, suggesting that CXCL16 does not play a role in atherosclerosis 
through scavenging oxLDL in the circulation as was previously suggested. Together, 
our ﬁ ndings suggest that CXCL16 and CCL18 may be involved in the pathogenesis 
of RA, which is discussed in chapter 8. Th e extend of this potential role in  RA and 
their potential as therapeutic targets remains to be elucidated by future studies, both 
in general and in RA.  
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Samenvatting
Reumatoïde artritis (RA) is een chronische auto-immuun ziekte die gekenmerkt 
wordt door ontsteking van de gewrichten, hetgeen kan leiden tot kraakbeen bescha-
diging en bot erosie. Zoals bij veel ontstekingziekten spelen verschillende leukocyten 
een belangrijke rol in de pathogenese van RA. T cellen and antigeen presenterende 
cellen (APC), zoals dendritische cellen (DC) en macrofagen, zijn twee soorten leu-
kocyten waarvan gedacht wordt dat ze een rol spelen in RA. Deze APC en T cellen 
communiceren met elkaar en initiëren zo een immuun respons. Deze APC-T cel 
interactie wordt mogelijk gemaakt door chemokines die worden uitgescheiden door 
APC om T cellen aan te trekken. Het doel van dit proefschrift  was de mogelijke rol 
van twee relatief nieuwe chemokines, CCL18 en CXCL16, in de pathogenese van RA 
te onderzoeken. 
Tijdens eerdere experimenten startten we met een groot chemokine panel waarvan 
enkelen potentieel interessant bleken in RA, waaronder CCL18 and CXCL16. In 
hoofdstuk 1 worden CCL18 en CXCL16 geïntroduceerd als potentiële mediatoren 
in de pathogenese van auto-immuun ziekten zoals RA. In hoofdstuk 2 tonen we aan 
dat in vitro gekweekte DC (“monocyte derived DC” (MoDC)) van RA patiënten een 
hogere mRNA expressie hebben van de chemokines CCL17, CCL18, CCL19, CCL22, 
CCL3 and CXCL8 vergeleken met MoDC van gezonde controles. Het neutraliseren 
van TNF-α is een succesvolle behandeling van RA en verloopt mogelijkerwijs via ef-
fecten op chemokine expressie. Hoewel het DC fenotype niet wordt beïnvloed door 
remming van TNF-α, produceren deze MoDC wel minder cytokines en hebben zij 
een lagere chemokine expressie, o.a. van CCL18. In hoofdstuk 3 laten we zien dat 
CCL18 op strategische plekken tot expressie komt in RA ST op eiwit niveau. Aange-
zien CCL18 een mogelijke rol speelt in RA waren wij geïnteresseerd in de regulatie 
van CCL18 op eiwit niveau. In hoofdstuk 3 tonen we aan dat CCL18 eiwit secretie 
sterk afh ankelijk is van IL-4 en IL-13, in synergie met IL-10. Stimulatie met pro-
inﬂ ammatoire cytokines daarentegen heeft  geen eﬀ ect op CCL18 eiwit secretie in 
vitro. Incubatie met synoviaal vocht (SF) van RA patiënten leidt tot een signiﬁ cante 
toename van CCL18 secretie door IL-4, IL-13 en IL-10, hetgeen suggereert dat er nog 
een onbekende CCL18 stimulerende factor aanwezig is in RA SF.
De chemokine receptor CXCR6, welke tot expressie komt op geactiveerde T cellen, 
werd recent aangetoond op lymfocyten in RA SF, met hoge expressie. Hierop raakten 
wij geïnteresseerd in de expressie van zijn enige ligand, CXCL16, in RA. In hoofdstuk 4
laten we zien dat CXCL16 expressie verhoogd is in RA ST en in SF van RA patiënten. 
Bovendien tonen we aan dat CXCL16 ook functioneel memory T cellen aantrekt uit 
het SF, hetgeen wellicht bedraagt aan T cel inﬂ uxen in RA gewrichten. In hoofdstuk 
5 bestuderen we de regulatie van CXCL16 secretie gedetailleerder, zowel in het al-
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gemeen als in RA. In deze studie laten we zien dat diﬀ erentiatie van monocyten op 
zich de sterkste stimulus is voor CXCL16 expressie en secretie in vitro. In mindere 
mate hebben cytokines een positief (IFN-γ) of negatief (IL-4, IL-13, IL-10) eﬀ ect op 
CXCL16 secretie. Hoewel locale CXCL16 expressie is verhoogd in RA gewrichten is 
de regulatie van CXCL16 in myeloide cellen in vitro niet veranderd bij RA patiënten.
Omdat CCL18 and CXCL16 een mogelijke rol spelen in de pathogenese van RA wa-
ren we geïnteresseerd in de spiegels van deze chemokines in de circulatie om zo te-
vens hun potentie als klinische markers te onderzoeken. In hoofdstuk 6 tonen we aan 
dat serum CCL18 spiegels in tegenstelling tot CXCL16 spiegels niet verhoogd zijn bij 
RA patiënten. Bovendien laten we zien dat CCL18 spiegels signiﬁ cant gecorreleerd 
zijn met ziekte activiteit, terwijl noch CCL18 noch CXCL16 spiegels correleren met 
gewrichtsschade. Het neutraliseren van TNF-α in vivo resulteert in verlaagde serum 
spiegels van beide chemokines, onafh ankelijk van  ziekte activiteit. Naast zijn rol als 
chemokine heeft  CXCL16 ook een functie als “scavenger receptor” voor geoxideerd 
LDL (oxLDL), hetgeen mogelijk interessant is in RA, aangezien patiënten met RA een 
verhoogde cardiovasculaire morbiditeit hebben. In hoofdstuk 7 laten we zien dat serum 
CXCL16 spiegels niet correleren met andere markers voor atherosclerose bij patiënten 
met RA. Verder tonen we aan dat CXCL16 niet bindt aan oxLDL in oplossing, hetgeen 
suggereert dat CXCL16 geen rol speelt in atherosclerose middels het wegvangen van 
oxLDL uit de circulatie zoals eerder werd gesuggereerd in de literatuur. Samengevat 
suggereren onze bevindingen dat CXCL16 en CCL18 mogelijk een rol spelen in de 
pathogenese van RA, hetgeen wordt bediscussieerd in hoofdstuk 8. De omvang van 
deze mogelijke rol in RA en de potentie als therapeutisch target dient verder te worden 
bestudeerd in aanvullend onderzoek, zowel in het algemeen als in RA.
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DANKWOORD

Mijn werkzaamheden zijn altijd op meerdere plekken geweest, waardoor je het voor-
recht hebt met veel verschillende mensen te mogen samenwerken. Natuurlijk was dit 
proefschrift  niet mogelijk geweest zonder jullie bijdrage, groot of klein. Het is bijna 
onmogelijk om iedereen hiervoor voldoende te bedanken, maar een aantal mensen 
waarmee ik samen heb mogen werken wil ik er graag uitlichten: Allereerst Piet; ik 
dank je voor het vertrouwen dat je als promotor in mij als onderzoeker hebt gehad. 
En natuurlijk ook de mogelijkheden die ik kreeg als beginnend arts op de polikliniek. 
Mede door jouw leiding is de afdeling reumatische ziekten een prettige plek om te 
werken en je te ontwikkelen. Ik kijk er dan ook naar uit om weer op het oude nest te-
rug te keren voor het laatste deel van mijn opleiding. Tim, het is heel simpel: Zonder 
jouw enthousiasme destijds was ik er überhaupt nooit aan begonnen. Dank je voor 
de unieke kans om mee te mogen werken aan het vormgeven van een onderzoeks-
lijn, die denk ik zeker erg succesvol zal worden de komende jaren. Ik denk dat onze 
toch verschillende manier van denken en werken uiteindelijk positief heeft  uitgepakt 
gezien het resultaat. Overigens bedenk ik me hierbij wel dat dit geintje me een stage 
(lees: reis) naar Portugal heeft  gekost, maar dat strepen we dan maar weg tegen de 
congressen. Gosse, bedankt dat ik mijn laatste jaar onder jouw supervisie op het TIL 
heb mogen doorbrengen. Ik heb in dat jaar ontzettend veel geleerd en ben erg blij dat 
je ook als mijn promotor hebt willen optreden. Ik weet zeker dat ik nog vaak ga te-
rugdenken aan onze gesprekken wanneer ik in de kliniek weer in aanraking kom met 
(fundamenteel) onderzoek. Misschien dat ik nu ook eindelijk tijd heb om je huisje in 
Frankrijk eens te testen met een goede ﬂ es wijn.
Robbert, jij was zonder twijfel mijn chemokine-partner in crime. Van jou heb ik veel 
geleerd over chemokines in het algemeen en natuurlijk vooral over CXCL16. Niet 
alleen van je kennis maar zeker ook van je kritische houding en nauwkeurige werk-
wijze; ik had geen betere “ELISA mentor” kunnen hebben. Ik zal niet vergeten hoe 
we uiteindelijk die CCL18 ELISA toch goed aan de praat hebben gekregen. Bedankt 
hierbij ook Liduine, want een analiste met 25 jaar ELISA-ervaring bleek toch onver-
vangbaar bij het opzetten van zo’n assay. Jaap, korte tijd mijn kamergenoot maar 
vooral ook mijn “epidemiologie-helpdesk”. Ik vond het altijd erg prettig hoe je toch 
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altijd het geduld op wist te brengen om mijn labwerk statistisch verantwoord te ana-
lyseren, voor zover wij statistiek daaromtrent überhaupt bijdragend acht(t)en. Veel 
onderzoekers op weinig vierkante meters leidt tot kruisbestuiving; zo kun je onze sa-
menwerking denk ik het beste beschrijven, Calin. Ik vond het erg leuk met je samen 
te werken en hoop dit in de toekomst als reumatologen op klinisch of onderzoeks ge-
bied nog zeker vaker te doen. Bedankt ook Berry en Heidi (lab interne geneeskunde) 
want zonder jullie hulp was het nooit gelukt om onze link tussen CXCL16 en oxLDL 
te leggen (danwel te ontkrachten).
Beste Mieke, 4 jaar lang AIO-frustraties over het onderzoek, gebrek aan analisten, 
doodlopende sporen, meningsverschillen over prioriteiten etc etc, tijdens onze lunch 
in de prekliniek hebben er mede voor gezorgd dat we het allebei tot een goed einde 
hebben weten te brengen. Ik kon dan ook geen betere paranimf bedenken om me bij 
te staan voor het laatste loodje. Gelukkig is vooral de gezelligheid overgebleven van 
onze tijd samen en hoop ik dat we onze eet-traditie nog lang in stand houden. Linda, 
bedankt voor je rol als hulp bij de naaldartroscopieën en je gezelligheid en inzet als 
studente in het lab. Ik denk dat je best trots mag zijn op hetgeen wat je bereikt hebt. 
Het was natuurlijk totaal geen verassing dat je nu chirurg gaat worden, maar stiekem 
vind ik het wel grappig dat je ook onderzoek gaat doen, al kan dat bij de chirurgie 
natuurlijk nooit moeilijk zijn ☺.
Als vaak enige arts op een lab ben je toch een beetje een vreemde eend in de bijt. 
Ik wil bij deze dan ook Wim, alle post-docs, AIO’s, analisten en studenten van “lab 
reuma“  bedanken voor de mogelijkheid om op jullie lab te werken en natuurlijk ook 
voor alle gezelligheid op de werkvloer (en niet te vergeten daarbuiten). Hetzelfde 
geldt natuurlijk voor Carl en alle TIL-lers, want ondanks dat een reumatoloog in spe 
bij jullie natuurlijk redelijk ver van zijn bed is, heb ik me prima thuisgevoeld en naast 
een leerzaam ook een erg leuk jaar gehad. Speciale dank aan Ilona die er zowaar in 
geslaagd is mij te leren kloneren (een niet te onderschatten prestatie) en Suzanne 
(zonde dat je mooie plaatjes niet in dit proefschrift  staan). En natuurlijk Friederike, 
mijn “oetjegenoot”. Ik was altijd blij om te zien dat er altijd nog iemand was die nog 
langere dagen maakte en na mij de lampen uit kon maken. Aan het einde van mijn 
tijd als onderzoeker op de werkvloer ben ik blij dat ik heb mogen meemaken hoe 
prettig het kan zijn om met een goede analist samen te mogen werken. Liza, bedankt 
daarvoor! 
Dit boekje gaat natuurlijk over mijn onderzoek, maar dat had ik nooit kunnen doen 
zonder steun van mensen waarmee ik mijn andere werkzaamheden deed. Dus wil ik 
ook al mijn CRU collega’s bedanken, in het bijzonder Sjoukje en Franka, voor jullie 
geduld en begrip als ik weer eens op 2 of meer plekken tegelijk moest zijn. Verder 
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wil ik alle buitenhoekers (ik was diegene met die werkplek daar die wel eens voorbij 
vloog), reumatologen (in het UMCN en de SMK), RIOs, VRCs en polimedewerkers 
bedanken voor de goede sfeer en jullie inzet wanneer ik weer eens patiënten bloed 
nodig had. In het bijzonder wil ik Frank en Madelon bedanken voor alle hulp bij mijn 
SSc werk, ook al heeft  het dit proefschrift  niet gehaald. Veel succes met het voortzet-
ten van jullie lijn! 
Buiten mijn eigen afdelingen zijn er natuurlijk ook tal van samenwerkingsverban-
den geweest met andere afdelingen binnen en buiten het UMCN, waarbij ik in ieder 
geval Gerard (Pesman) wil noemen, voor zijn uitstekende werk rondom mijn eerste 
cytokine meetingen. En zeker niet te vergeten natuurlijk alle collega’s die te dicht bij 
kwamen als ik bloed nodig had en die ik in de loop der jaren in de slachtoﬀ errol heb 
gemanoeuvreerd. Ik hoop dat het meevalt met de anaemie.  
Karin, bedankt voor je hulp bij de vormgeving van mijn boekje. Het is een ontzetten-
de understatement als ik zeg dat ik dit zelf nooit zo had kunnen doen. Bas, bedankt 
voor je optreden als tolk tussen een vorm en inhoud. Packets Sold Daily: Mooi dat 
we nog steeds muziek maken mannen. En nog mooier dat we daar nu weer meer tijd 
voor gaan krijgen. Gelukkig was ditmaal de inhoud eerder af dan de kaft  ☺. Dat we 
maar snel weer eens de studio in duiken en weer eens de planken opgaan. Voor mijn 
ouders; dit is het dan waar ik steeds mee bezig was. Toch maar goed dat ik mijn vrije 
tijd hier in heb moeten steken i.p.v. helpen met klussen aan het huis (zeker voor het 
resultaat van het klussen). Tenslotte Miran: Ik ben vooral heel blij dat ik je gewoon 
iedere dag kan zeggen wat ik hier allemaal op had kunnen schrijven.....
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Chapter 3 page 62
Figure 5
CCL18 expression in normal and RA synovial tissue.
Panel A and B depict 2 sections of control synovium, where CCL18 expression is expressed in parts of the lining and 
some perivascular regions. Panel D and E depict 2 representative synovial sections from RA where CCL18 is present 
in the lining and perivascular regions. Panel C and F represent isotype controls on RA synovium and that from healthy 
individuals  respectively.
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Chapter 4 page 78
Figure 2
Enhanced expression of CXCL16 protein within RA synovia. CXCL16 was expressed in the thin synovial lining (ar-
rowhead) of healthy synovia (A), but was much more pronounced by the hyperthrophic lining of RA synovia (B). Many 
cells present within the sub-lining of RA synovia express high levels of CXCL16 (B and C). Note that (cleaved) CXCL16 
was also associated with ﬁ laments of the extracellular matrix (B). Staining of serial sections indicated that expression 
of CXCL16 (E) correlated with the presence of CD68+ synovial Macrophages�(F). We also detected CXCL16 within 
some vessels (G). Staining serial sections for CD31 conﬁ rmed that these cells were endothelial cells (H). In addition, 
many lymphocyte aggregates contain CXCL16+ cells (I). Analysis of stained serial sections suggested that these 
CXCL16+ cells were CD68+ Macrophages (J) amidst CD45RO+ memory lymphocytes (K). Cryo-sections were stained 
for CXCL16 (A-C, E, G and I), CD68 (F and J), CD31 (H), or CD45RO (K), or matched control antibodies (D and I). 
All sections were counterstained with hematoxylin. Sections shown are representative for ST from 10 RA patients and 
5 controls. (Original magniﬁ cations x 400 in A-F, and I-L; x 630 in G and H).
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Figure 4
Reduced CXCL16 expression upon successful anti-TNF treatment of RA patients. Before anti-TNF treatment, CXCL16 
is strongly expressed within RA synovia (A and C). Expression of CXCL16 is severely reduced in clinically responding 
patients (B), but not in non-responding patients (D). Synovia were isolated before (A and C) and after (B and D) anti-
TNF treatment. All cryo-sections were stained for CXCL16 and counterstained with hematoxylin. Control stainings were 
negative. Results are representative of 3 responding and 3 non-responding patients. (Original magniﬁ cations x 100). 
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Figure 5
Enhanced expression of CXCL16 protease ADAM-10 by RA synovial macrophages. ADAM-10 negative peripheral 
blood monocytes were differentiated into Macrophages and analyzed by ﬂ ow cytometry. A: CD14+ monocytes/ Ma-
crophages were gated and stained with anti-ADAM-10 (bold lines) or isotype-matched control antibodies (thin lines). 
Dead cells were excluded by gating on propidium iodide-negative cells. Addition of RA SF to macrophages (day 3) 
increases their expression of ADAM-10 (B). After 2 days the percentage of ADAM-10+CD14+ macrophages was deter-
mined by ﬂ ow cytometry. The mean and SD percentages from 2 donors are shown. Dead cells were excluded by gating 
on propidium iodide-negative cells. * = p<0.05 versus controls. ST from controls showed expression of both CXCL16 
(C) and its protease ADAM-10 (D) in the thin synovial lining. In contrast, expression of both CXCL16 (F) and ADAM10 
(G) was highly enhanced in the hypercellular synovial lining of RA ST. Frozen sections were stained for CXCL16 (C 
and F), ADAM-10 (D and G), or a matched control antibody (E), and counterstained with hematoxylin. Representative 
stainings are shown. See ﬁ gure 1 for other deﬁ nitions (Original magniﬁ cations x 400).
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